Form990
Click to see attachment
Click to see attachment
Click to see attachment
Department of the TreasuryInternal Revenue Service
Return of Organization Exempt From Income Tax
Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except private foundations)
MediumBullet Do not enter social security numbers on this form as it may be made public.
MediumBullet Go to www.irs.gov/Form990 for instructions and the latest information.
OMB No. 1545-0047
2021
Open to Public Inspection
A For the 2021 calendar year, or tax year beginning 01-01-2021 , and ending 12-31-2021
BCheck if applicable:
CName of organization
PATH
 
 
Doing business as
 
 
Number and street (or P.O. box if mail is not delivered to street address)
2201 WESTLAKE AVENUE 200
 
Room/suite
City or town, state or province, country, and ZIP or foreign postal code
SEATTLE, WA98121
D Employer identification number

91-1157127
E Telephone number

G Gross receipts $ 398,901,838
F Name and address of principal officer:
KELLY PRIESTLEY
2201 WESTLAKE AVENUE 200
SEATTLE,WA98121
I
Tax-exempt status: (   ) LeftBullet (insert no.) or
J
Website:MediumBullet
WWW.PATH.ORG
H(a)
Is this a group return for
subordinates?
H(b)
Are all subordinates
included?
If "No," attach a list. See instructions.
H(c)
Group exemption number MediumBullet  
K Form of organization:  
L Year of formation: 1981
M State of legal domicile: WA
Part I
Summary
Activities  & Governance 1 Briefly describe the organization’s mission or most significant activities: SEE PART III, LINE 1.
2 Check this box MediumBullet
3 Number of voting members of the governing body (Part VI, line 1a) ........ 3 16
4 Number of independent voting members of the governing body (Part VI, line 1b) ..... 4 16
5 Total number of individuals employed in calendar year 2021 (Part V, line 2a) ...... 5 667
6 Total number of volunteers (estimate if necessary) ............. 6 0
7a Total unrelated business revenue from Part VIII, column (C), line 12 ........ 7a 0
b Net unrelated business taxable income from Form 990-T, Part I, line 11 ......... 7b 0
Revenues Prior Year Current Year
8 Contributions and grants (Part VIII, line 1h) ......... 287,454,383 333,068,959
9 Program service revenue (Part VIII, line 2g) ......... 0 0
10 Investment income (Part VIII, column (A), lines 3, 4, and 7d ) .... 12,502,251 9,205,357
11 Other revenue (Part VIII, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e) 1,030,112 843,270
12 Total revenue—add lines 8 through 11 (must equal Part VIII, column (A), line 12) 300,986,746 343,117,586
Expenses; 13 Grants and similar amounts paid (Part IX, column (A), lines 1–3 )... 67,994,827 75,961,955
14 Benefits paid to or for members (Part IX, column (A), line 4)..... 0 0
15 Salaries, other compensation, employee benefits (Part IX, column (A), lines 5–10) 132,096,396 135,407,327
16a Professional fundraising fees (Part IX, column (A), line 11e) ..... 0 0
b Total fundraising expenses (Part IX, column (D), line 25) MediumBullet5,667,202    
17 Other expenses (Part IX, column (A), lines 11a–11d, 11f–24e).... 92,968,260 123,975,347
18 Total expenses. Add lines 13–17 (must equal Part IX, column (A), line 25) 293,059,483 335,344,629
19 Revenue less expenses. Subtract line 18 from line 12....... 7,927,263 7,772,957
Net Assets or Fund Balances; Beginning of Current Year End of Year
20 Total assets (Part X, line 16)............. 283,556,203 307,073,332
21 Total liabilities (Part X, line 26)............. 234,982,056 253,115,813
22 Net assets or fund balances. Subtract line 21 from line 20..... 48,574,147 53,957,519
Part II
Signature Block
Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge.
Sign Here
JumboBullet
Signature of officer Date
JumboBullet
Type or print name and title
Paid Preparer Use Only
Print/Type preparer's name
Preparer's signature
Date
PTIN
Firm's name MediumBullet

Firm's EIN MediumBullet
Firm's address MediumBullet



Phone no.
May the IRS discuss this return with the preparer shown above? (see instructions) ..........
For Paperwork Reduction Act Notice, see the separate instructions.
Cat. No. 11282Y Form 990 (2021)
Form 990 (2021)
Page 2
Part III
Statement of Program Service Accomplishments
Check if Schedule O contains a response or note to any line in this Part III..............
1
Briefly describe the organization’s mission: PATH'S MISSION IS TO ADVANCE HEALTH EQUITY THROUGH INNOVATION AND PARTNERSHIPS. (CONTINUED ON SCHEDULE O)
2
Did the organization undertake any significant program services during the year which were not listed on
the prior Form 990 or 990-EZ? .....................
If "Yes," describe these new services on Schedule O.
3
Did the organization cease conducting, or make significant changes in how it conducts, any program
services? ...........................
If "Yes," describe these changes on Schedule O.
4
Describe the organization’s program service accomplishments for each of its three largest program services, as measured by expenses. Section 501(c)(3) and 501(c)(4) organizations are required to report the amount of grants and allocations to others, the total expenses, and revenue, if any, for each program service reported.
4a (Code:   ) (Expenses $ 121,408,713 including grants of $ 32,739,259 ) (Revenue $   )
THE PROGRAMS & INNOVATION DIVISION BRINGS DEEP TECHNICAL EXPERTISE AND A ROBUST, COLLABORATIVE, AND INTERDISCIPLINARY APPROACH TO SUPPORT PATH COUNTRY PROGRAMS AND PARTNERS IN ADVANCING HEALTH EQUITY. WE FOCUS ON GENERATING ANALYTICAL INSIGHTS, TRANSLATING THEM INTO ADVOCACY AND ACTION, ADVANCING INCLUSIVE AND SUSTAINABLE INNOVATION, AND STRENGTHENING WORKFORCE SKILLS AND RESOURCES THAT SUPPORT INTEGRATED AND RESILIENT HEALTH SYSTEMS. OUR WORK COVERS DIGITAL TRANSFORMATION, PRODUCT DEVELOPMENT, MARKET SHAPING, EPIDEMIC PREPAREDNESS AND RESPONSE, AND MORE.(CONTINUED ON SCHEDULE O)CENTER OF DIGITAL AND DATA EXCELLENCEPATH USES DIGITAL TECHNOLOGIES AND DATA-LED ACTION TO ADVANCE HEALTH EQUITY. IN 2021, PATH'S CENTER OF DIGITAL AND DATA EXCELLENCE CATALYZED COUNTRY-LED DIGITAL HEALTH TRANSFORMATION. FOR EXAMPLE, WORK CONTINUED ON THE DATA USE PARTNERSHIP, A BILL & MELINDA GATES FOUNDATION-FUNDED PROJECT WHERE PATH SUPPORTS THE GOVERNMENT OF TANZANIA TO IMPROVE ITS HEALTH INFORMATION SYSTEMS. THROUGH THIS PROJECT, THE GOVERNMENT ENDORSED A NEW HEALTH ENTERPRISE ARCHITECTURE, AN IMPORTANT STEP TO ENSURE ALIGNMENT OF THE COUNTRY'S DIGITAL SYSTEMS. IN ADDITION, THE PROJECT LAUNCHED AN IMPROVED E-LEARNING PLATFORM THAT STREAMLINES AND STANDARDIZES E-LEARNING MODULES TO MAKE IT EASIER TO TRACK HEALTH WORKER CREDENTIALS AND SCHOOL RECORDS.THE DATA USE ACCELERATION AND LEARNING PROJECT, ALSO FUNDED BY THE GATES FOUNDATION, CAPTURED LEARNINGS FROM FIVE COUNTRIES - BURKINA FASO, ETHIOPIA, MALAWI, SOUTH AFRICA, AND TANZANIA - TO DEVELOP A MODEL FOR DIGITAL TRANSFORMATION FOR DATA USE THAT BUILDS ON EXISTING FRAMEWORKS. THE INFORMATION WILL SUPPORT GOVERNMENTS, IMPLEMENTERS, POLICYMAKERS, AND FUNDERS AS THEY SHIFT THEIR FINANCING, GUIDANCE, AND PROGRAMMATIC APPROACHES TO IMPROVE THE USE OF DATA.BACKED BY A U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT (USAID) INVESTMENT OF UP TO $120 MILLION, DIGITAL SQUARE, A PATH-LED INITIATIVE, CONTINUED TO BRING DONORS AND PARTNERS TOGETHER TO IMPROVE HOW THE GLOBAL COMMUNITY DESIGNS, USES, AND PAYS FOR DIGITAL HEALTH TOOLS AND APPROACHES, WITH AN EMPHASIS ON COUNTRY-DRIVEN PRIORITIES.PATH, WITH U.S. CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC) FUNDING, IS LEADING THE OVERALL HEALTH INFORMATION SYSTEM SUPPORT COMPONENT OF THE U.S. PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF (PEPFAR) TECHNICAL ASSISTANCE PLATFORM THAT PARTNERS WITH COUNTRIES TO SUPPORT THEM IN BUILDING LASTING DIGITAL HEALTH CAPACITY. IN 2021, THE TEAM RECEIVED APPROVAL FOR OUR SECOND-YEAR WORK PLAN AND BUDGET, ENABLING WORK TO BEGIN ON STRENGTHENING HEALTH SYSTEMS FOR HIV AND/OR COVID-19 IN COTE D'IVOIRE, ETHIOPIA, HAITI, KENYA, NAMIBIA, NIGERIA, RWANDA, VIETNAM, AND ZAMBIA.IN 2021, PATH SUPPORTED THE LAUNCH OF THE DIGITAL HEALTH APPLIED LEADERSHIP PROGRAM, A YEAR-LONG TRAINING THAT ENHANCES PARTICIPANTS' CAPACITY TO SUCCESSFULLY LEAD AND EXECUTE DIGITAL HEALTH PROGRAMS. DESIGNED WITH A COMPREHENSIVE LEADERSHIP CURRICULUM FOR A DIVERSE COHORT OF LEARNERS, THE PROGRAM CONSISTS OF CORE ONLINE COURSES, WORKSHOPS, INSTRUCTION FROM TUTORS, AND GUIDANCE FOR PLANNING AND DELIVERING A PROJECT TO BUILD DIGITAL HEALTH CAPACITY ACROSS PARTICIPATING COUNTRIES.PATH CONTINUED TO PARTICIPATE IN HIGH-LEVEL GLOBAL COALITIONS, INCLUDING TRANSFORM HEALTH, WHICH SUPPORTS THE DEVELOPMENT OF HEALTH DATA GOVERNANCE PRINCIPLES; THE LANCET/FINANCIAL TIMES JOINT COMMISSION, WHICH RELEASED ITS REPORT ON GOVERNING HEALTH FUTURES 2030; AND THE DIGITAL CONNECTED CARE COALITION.DIAGNOSTICSPATH'S DIAGNOSTICS PROGRAM AIMS TO ADVANCE AND INCREASE ACCESS TO HIGH-QUALITY AND APPROPRIATE DIAGNOSTICS THAT IMPROVE THE HEALTH OUTCOMES OF PEOPLE AND COMMUNITIES IN LOW-RESOURCE SETTINGS.IN 2021, OUR PIONEERING WORK SUPPORTED THE ADVANCEMENT OF AFFORDABLE, RELIABLE DIAGNOSTICS, PROTEINS, ANTIBODIES, AND TOOLS BY AIDING THE DEVELOPMENT, COMMERCIALIZATION, AND PROCUREMENT OF NEW TECHNOLOGIES; SECURING REGULATORY APPROVAL; CONDUCTING PERFORMANCE EVALUATIONS AND CLINICAL STUDIES TO INFORM PATIENT CARE; AND PUBLISHING 18 PEER-REVIEWED ARTICLES.IN RESPONSE TO THE GLOBAL COVID-19 PANDEMIC, WE SUPPORTED THE DEVELOPMENT AND VALIDATION OF DIAGNOSTIC TOOLS, TECHNOLOGIES, AND SOLUTIONS SUITABLE FOR USE IN LOW- AND MIDDLE-INCOME COUNTRIES (LMICS). THIS INCLUDED DEVELOPING MULTIPLE PUBLICLY AVAILABLE INTERACTIVE COVID-19 DIAGNOSTIC DASHBOARDS TO SUPPORT DATA-DRIVEN PRODUCT SELECTION AND PROCUREMENT DECISIONS; CREATING A COVID-19 SAMPLE REPOSITORY TO SUPPORT DEVELOPERS IN ACCESSING CLINICAL SAMPLES FOR RESEARCH AND DEVELOPMENT; ENSURING THE QUALITY OF COVID-19 RAPID DIAGNOSTIC TESTS WITH A BENCHMARKING PANEL THAT ENABLES UNBIASED, COMPARATIVE EVALUATIONS BETWEEN COVID-19 TESTS; SUPPORTING THE NATIONAL RESPONSE IN BRAZIL, INDONESIA, MALAWI, NEPAL, AND PAKISTAN TO DETECT AND QUANTIFY THE PRESENCE OF SARS-COV-2 IN WASTEWATER; AND CONDUCTING CLINICAL AND OPERATIONAL STUDIES TO ENSURE THAT COVID-19 POINT-OF-CARE TESTS ARE AN EFFECTIVE MEANS OF COMBATTING COVID-19 IN SETTINGS WHERE LABORATORY RESULTS ARE DELAYED OR UNAVAILABLE.IN MAY 2021, THE SD BIOSENSOR STANDARD G6PD TEST RECEIVED REGULATORY APPROVAL FROM THE AUSTRALIAN THERAPEUTIC GOODS ADMINISTRATION (TGA). PATH HELPED GUIDE THE TEST THROUGH PRODUCT DEVELOPMENT AND CLINICAL EVIDENCE GENERATION FOR SUBMISSION TO THE TGA. THIS IS THE FIRST POINT-OF-CARE TEST FOR GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD) DEFICIENCY THAT CAN SUPPORT SAFE ACCESS TO THE CURRENTLY AVAILABLE DRUGS FOR PLASMODIUM VIVAX MALARIA.IN COLLABORATION WITH THE UNIVERSITY OF QUEENSLAND'S PROTEIN EXPRESSION FACILITY, PATH ADVANCED THE COMMERCIALIZATION OF HIGHLY SPECIFIC AND SENSITIVE MALARIA ANTIGEN REAGENTS FOR IMMUNOLOGICAL TESTS. THESE NEWLY AVAILABLE CUSTOM PROTEINS WILL FACILITATE DEVELOPMENT AND PERFORMANCE BENCHMARKING OF RAPID, ACCURATE, SPECIES-SPECIFIC MALARIA DIAGNOSTICS. THE DIAGNOSTICS TEAM CONTINUED TO MANAGE A COMMUNITY OF PRACTICE FOR G6PD OPERATIONAL RESEARCH AND HOSTED SIX INFORMATION-SHARING WEBINARS.IN COLLABORATION WITH THE U.K. NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROLS, PATH WORKED TO DEVELOP AND RELEASE 14 HIGH-QUALITY AND AFFORDABLE MONOCLONAL ANTIBODIES TO SUPPORT DEVELOPMENT OF PNEUMOCOCCAL VACCINES THAT ARE LOW-COST, SEROTYPE-SPECIFIC, AND TAILORED FOR USE BY VACCINE DEVELOPERS AND RESEARCHERS IN LMICS.MEDICAL DEVICES AND HEALTH TECHNOLOGIES THE MEDICAL DEVICES AND HEALTH TECHNOLOGIES PROGRAM IS PATH'S PRODUCT DEVELOPMENT ARM. THE PROGRAM WORKS WITH PUBLIC- AND PRIVATE-SECTOR PARTNERS AROUND THE WORLD TO DEVELOP, TEST, INTRODUCE, AND SCALE UP AFFORDABLE INNOVATIONS TO IMPROVE THE HEALTH OF PEOPLE IN LMICS. FOR EXAMPLE, IN COLLABORATION WITH LOCAL STAKEHOLDERS AND RESEARCHERS, WE DEVELOP FIT-FOR-PURPOSE HEALTH TECHNOLOGIES SUCH AS THE ELLAVI UTERINE BALLOON TAMPONADE (UBT), A LIFESAVING INTERVENTION FOR POSTPARTUM HEMORRHAGE. IN 2021, THE ELLAVI UBT'S AVAILABILITY GREW TO 16 COUNTRIES. THE CAYA DIAPHRAGM, ANOTHER PATH-DEVELOPED MEDICAL DEVICE, ACHIEVED REGULATORY APPROVAL IN 7 LATIN AMERICAN COUNTRIES, BRINGING THE GLOBAL TOTAL TO 39 COUNTRIES WHERE THE DEVICE IS NOW AVAILABLE.PATH CONTINUED TO SUPPORT INCLUSIVE INNOVATION, HIRING ADDITIONAL DESIGN AND INNOVATION SPECIALISTS IN AFRICA, WHICH ALLOWED THE LIVING LABS INITIATIVE TO CO-CREATE WITH APPROXIMATELY 1,000 FRONTLINE HEALTH WORKERS AND COMMUNITY MEMBERS. THE PATH MICROARRAY PATCH CENTER OF EXCELLENCE CONTINUED OUR CROSS-SECTOR WORK TO ADVANCE THIS NEEDLE-FREE DELIVERY TECHNOLOGY PLATFORM FOR MEASLES, RUBELLA, AND COVID-19 VACCINES.FINALLY, WE CONVENED A GLOBAL SYRINGE MANUFACTURER WORKSHOP AND PRODUCED AN AUTODISABLE SYRINGE GAP ANALYSIS MODEL TO INFORM GLOBAL STAKEHOLDERS AND U.S. DECISION-MAKERS. WE ALSO PRODUCED AND SHARED GLOBAL COLD CHAIN MODELING DATA FOR COVID-19 VACCINES ACROSS 92 ADVANCED MARKET COMMITMENT COUNTRIES. TO ADDRESS THE URGENT NEED FOR A COVID-19 VACCINE THAT IS THERMOSTABLE AND NEEDLE-FREE, THE FORMULATION TEAM SUBMITTED A PATENT APPLICATION FOR A FREEZE-DRIED FORMULATION OF AN MRNA VACCINE SUITABLE FOR ORAL AND PARENTERAL ADMINISTRATION.MARKET DYNAMICSPATH'S MARKET DYNAMICS PROGRAM WORKS TO INCREASE EQUITABLE ACCESS TO HEALTH PRODUCTS AND SERVICES BY DIAGNOSING THE ROOT CAUSES OF MARKET FAILURES, DESIGNING APPROPRIATE SOLUTIONS, AND DEVELOPING SUSTAINABLE AND INCLUSIVE HEALTH MARKETS. THIS WORK COMPLEMENTS PATH'S OTHER EFFORTS, SUCH AS PRODUCT DEVELOPMENT/INTRODUCTION AND HEALTH SYSTEMS STRENGTHENING, AND IS DONE IN CLOSE COLLABORATION WITH NATIONAL MINISTRIES OF HEALTH, GLOBAL AGENCIES, COMMERCIAL PARTNERS, AND PATH'S COUNTRY PROGRAMS. IN 2021, OUR LARGEST AREAS OF WORK WERE:
4b (Code:   ) (Expenses $ 100,080,790 including grants of $ 33,744,940 ) (Revenue $   )
ESSENTIAL MEDICINES: PATH'S ESSENTIAL MEDICINES DIVISION DEVELOPS AND DELIVERS LIFESAVING VACCINES AND DRUGS FOR WOMEN, CHILDREN, AND COMMUNITIES AROUND THE GLOBE.(CONTINUED ON SCHEDULE O)CENTER FOR VACCINE INNOVATION AND ACCESSPATH'S CENTER FOR VACCINE INNOVATION AND ACCESS ALIGNS EXPERTISE ACROSS EVERY STAGE OF VACCINE RESEARCH, DEVELOPMENT, AND INTRODUCTION TO MAKE VACCINES AVAILABLE TO MORE COMMUNITIES, PARTICULARLY IN LMICS. OUR PORTFOLIO INCLUDES MORE THAN TWO DOZEN VACCINE PRODUCTS IN DEVELOPMENT OR ALREADY IN USE, WITH AN EMPHASIS ON THE LEADING INFECTIOUS CAUSES OF CHILD DEATH AND DISEASE WORLDWIDE.IN 2021, PATH CONTINUED TO SUPPORT THE GLOBAL COVID-19 RESPONSE BY PROVIDING EXPERTISE TO THE COVAX FACILITY, SUPPORTING VACCINE SUPPLY CHAIN NETWORKS, PROVIDING TECHNICAL ASSISTANCE AND TRAINING TO VACCINE MANUFACTURERS, STRENGTHENING CLINICAL RESEARCH CENTER AND COUNTRY DELIVERY READINESS, AND TRAINING PHARMACISTS AS VACCINATORS IN GHANA. WE ALSO SUPPORTED THE MRNA VACCINE TECHNOLOGY HUB IN SOUTH AFRICA AND PROVIDED COORDINATION AND TECHNICAL ASSISTANCE FOR A CONSORTIUM DEVELOPING AN EGG-BASED COVID-19 VACCINE FOR PRODUCTION IN BRAZIL, THAILAND, VIETNAM, AND OTHER LMICS. ADDITIONALLY, PATH GUEST EDITED A SPECIAL ISSUE OF VACCINE INSIGHTS ON COVID-19.IN ONGOING EFFORTS TO FACILITATE LOCAL VACCINE PRODUCTION, PATH SUPPORTED VIETNAM-BASED MANUFACTURER POLYVAC TO ESTABLISH A SYSTEM FOR CONDUCTING POST-LICENSURE VACCINE SAFETY SURVEILLANCE AND DATA ANALYSIS. THIS NEW SYSTEM ENSURES POLYVAC'S COMPLIANCE WITH LOCAL AND GLOBAL REGULATORY REQUIREMENTS. PATH ALSO SUPPORTED CHINESE VACCINE MANUFACTURERS TO READY LOCALLY MADE VACCINES FOR THE GLOBAL MARKET, THEREBY INCREASING AVAILABLE INTERVENTIONS AND POTENTIALLY MAKING VACCINES MORE ACCESSIBLE FOR LMICS. WE HELPED LAUNCH A PHASE 3 CLINICAL STUDY IN KENYA OF A YELLOW FEVER VACCINE FROM BEIJING INSTITUTE OF BIOLOGICAL PRODUCTS. DATA FROM THE STUDY WILL SUPPORT AN APPLICATION FOR WHO PREQUALIFICATION (PQ), A KEY STEP FOR GLOBAL AVAILABILITY. WE PROVIDED TECHNICAL ASSISTANCE TO SEVERAL OTHER MANUFACTURERS PREPARING FOR WHO PQ SUBMISSION OR INSPECTION; THUS IN 2021, SINOVAC BIOTECH LTD'S COVID-19 VACCINE, CORONAVAC, RECEIVED EMERGENCY USE LISTING, AND XIAMEN INNOVAX BIOTECH'S HPV VACCINE, CECOLIN, RECEIVED WHO PQ. PATH CONTINUED TO PROVIDE TECHNICAL SUPPORT TO POLIO VACCINE MANUFACTURERS AND ADVANCE RESEARCH ON NEW INACTIVATED POLIO VACCINE AND ORAL POLIO VACCINE CANDIDATES. BASED ON THE REAL-WORLD PERFORMANCE OF A NOVEL ORAL POLIO VACCINE AGAINST TYPE 2 POLIOVIRUS (NOPV2), THE WHO STRATEGIC ADVISORY GROUP OF EXPERTS ON IMMUNIZATION (SAGE) ENDORSED WIDER USE OF NOPV2 UNDER THE EMERGENCY USE LISTING. PATH ALSO LAUNCHED A PHASE 3 STUDY OF NOPV2 AND A PHASE 1 STUDY OF NOPV1.THROUGHOUT THE YEAR, PATH AND OUR PARTNERS EXPANDED COVERAGE OF JAPANESE ENCEPHALITIS (JE) VACCINATION AND DEVELOPED AND DISSEMINATED EVIDENCE TO SUPPORT JE VACCINE DECISION-MAKING. PATH LAUNCHED A NEW STUDY ON THE COST OF ILLNESS FOR JE AND ITS LONG-TERM CONSEQUENCES IN BANGLADESH, LAOS, AND VIETNAM. WE ALSO WORKED CLOSELY WITH THE GOVERNMENT OF BANGLADESH AND LOCAL PARTNERS TO INFORM THE COUNTRY'S JE VACCINATION DECISION-MAKING, WITH AN APPLICATION TO GAVI, THE VACCINE ALLIANCE (GAVI) EXPECTED IN 2022.ALSO IN 2021, WE CONTINUED A PIVOTAL PHASE 3 STUDY OF A POLYVALENT MENINGOCOCCAL MENINGITIS CONJUGATE VACCINE. THIS VACCINE, DEVELOPED BY SERUM INSTITUTE OF INDIA PVT. LTD., BUILDS ON THE SUCCESS OF MENAFRIVAC, A GROUNDBREAKING VACCINE AGAINST SEROGROUP A MENINGOCOCCAL MENINGITIS THAT WAS DEVELOPED THROUGH AN EARLIER PATH PARTNERSHIP. THE POLYVALENT VACCINE TARGETS SEROGROUPS A, C, W, X, AND Y. AS THE FIRST VACCINE TO TARGET SEROGROUP X, THE VACCINE HAS THE POTENTIAL TO ELIMINATE MENINGOCOCCAL MENINGITIS EPIDEMICS FROM AFRICA'S "MENINGITIS BELT" REGION. WE CONTRIBUTED TECHNICAL AND STRATEGIC EXPERTISE TO THE GLOBAL DEFEATING MENINGITIS BY 2030 INITIATIVE AND SUPPORTED THE WHO CELEBRATION AND LAUNCH OF DEFEATING MENINGITIS BY 2030: A GLOBAL ROAD MAP.PATH ACCELERATED THE DEVELOPMENT AND INTRODUCTION OF A WIDE VARIETY OF MALARIA VACCINE CANDIDATES AND APPROACHES. WE CONTINUED TO WORK WITH WHO; THE MINISTRIES OF HEALTH IN GHANA, KENYA, AND MALAWI; AND OTHER PARTNERS TO INTRODUCE THE WORLD'S FIRST MALARIA VACCINE, KNOWN AS RTS,S, IN SELECTED AREAS OF THOSE COUNTRIES. IN 2021, THE VACCINE RECEIVED A RECOMMENDATION FROM WHO FOR BROAD USE TO CURB PLASMODIUM FALCIPARUM MALARIA IN CHILDREN LIVING IN MODERATE-TO-HIGH MALARIA TRANSMISSION AREAS. WE CONTINUED TO ADVANCE RESEARCH INTO WHETHER REDUCING THE DOSE LEVEL OF RTS,S AND DELAYING THE ADMINISTRATION OF DOSES HAS THE POTENTIAL TO STRETCH LIMITED VACCINE SUPPLIES. WE ALSO RESEARCHED USE OF THE VACCINE TO AVERT HIGHLY SEASONAL MALARIA ALONGSIDE SEASONAL MALARIA CHEMOPREVENTION. WE CONTINUED WORK TO IDENTIFY IMMUNE CORRELATES OF PROTECTION AND STUDY THE USE OF MONOCLONAL ANTIBODIES TO PREVENT MALARIA, AND WE CONTINUED WORK ON A FIVE-YEAR CONTRACT FROM USAID TO ADVANCE PRE-ERYTHROCYTIC, BLOOD-STAGE, AND COMBINATION MALARIA VACCINE APPROACHES.THE DEFEAT DIARRHEAL DISEASE (DEFEATDD) INITIATIVE CONTINUED ITS ROLE AS A DIGITAL HUB FOR INFORMATION ON PREVENTING AND TREATING CHILDHOOD DIARRHEAL DISEASE, THE SECOND-LEADING CAUSE OF DEATH AMONG CHILDREN IN LMICS. A MAJOR FOCUS OF 2021 WAS HIGHLIGHTING CLIMATE CHANGE AND GENDER INEQUITY AS MAJOR DRIVERS OF CHILD HEALTH OUTCOMES.TO REDUCE THE BURDEN OF ROTAVIRUS, A MAJOR CAUSE OF SEVERE DIARRHEA, PATH CONTINUED CLINICAL DEVELOPMENT OF AN INJECTABLE NONREPLICATING ROTAVIRUS VACCINE CANDIDATE WITH THE START OF A PHASE 3 EFFICACY STUDY AT THREE CLINICAL SITES IN AFRICA. PATH ALSO BEGAN A PHASE 2 STUDY WITH THIS CANDIDATE IN SOUTH AFRICA TO EXAMINE IMMUNE RESPONSES TO DIFFERENT COMBINATIONS OF ORAL AND INJECTED ROTAVIRUS VACCINES. IN ADDITION, PATH CONTINUED A CASE-CONTROL STUDY IN INDIA TO EVALUATE THE EFFECTIVENESS OF SERUM INSTITUTE OF INDIA PVT. LTD.'S LICENSED ROTAVIRUS VACCINE, ROTASIIL. PATH CONTINUED TO SUPPORT CLINICAL TRIALS AND RESEARCH ON VACCINE CANDIDATES THAT MAY PROVIDE PROTECTION AGAINST ENTEROTOXIGENIC ESCHERICHIA COLI (ETEC) AND SHIGELLA, THE LEADING BACTERIAL CAUSES OF DIARRHEAL ILLNESS. CURRENTLY, THERE ARE NO LICENSED VACCINES AGAINST EITHER PATHOGEN. WE COMPLETED FURTHER ANALYSIS OF RESULTS FROM A PHASE 2B EFFICACY STUDY OF AN ORAL ETEC VACCINE CANDIDATE (ETVAX) IN FINNISH TRAVELERS TO BENIN, WHICH SHOWED ETVAX VACCINATION REDUCED THE NEED FOR ANTIBIOTICS. IN ADDITION, WE COMPLETED IN-DEPTH EXPLORATORY IMMUNOLOGY ANALYSES OF A NOVEL, INJECTABLE SUBUNIT SHIGELLA VACCINE CANDIDATE USING SAMPLES FROM A RECENT PHASE 1 STUDY SUGGESTING EFFECTIVE IMMUNIZATION MAY BE POSSIBLE WITH A SINGLE DOSE.PATH CONTINUED TO ADVANCE PRECLINICAL DEVELOPMENT OF A VACCINE AGAINST GROUP B STREPTOCOCCUS, A LEADING CAUSE OF BACTERIAL SEPSIS AND MENINGITIS IN YOUNG INFANTS WORLDWIDE, AND AGAINST PNEUMOCOCCAL DISEASE, A TOP CAUSE OF DEADLY CHILDHOOD PNEUMONIA. WE SUPPORTED INVENTPRISE AS IT WORKS TO DEVELOP MULTIVALENT CONJUGATE VACCINES FOR BOTH DISEASES THAT WILL BE AFFORDABLE FOR LMICS.AS PART OF THE TYPHOID VACCINE ACCELERATION CONSORTIUM, PATH WORKED TO ADVANCE TYPHOID CONJUGATE VACCINE (TCV) INTRODUCTION IN GAVI-ELIGIBLE COUNTRIES: IN MALAWI AND NEPAL, WE CONTINUED TO SUPPORT EACH GOVERNMENT IN PLANNING FOR TCV INTRODUCTION; IN PAKISTAN, WE SUPPORTED THE GOVERNMENT IN PLANNING FOR THE CONCLUSION OF THE NATIONAL ROLLOUT; IN LIBERIA AND ZIMBABWE, WE WRAPPED UP OUR SUPPORT AFTER SUCCESSFUL TCV INTRODUCTION CAMPAIGNS; AND IN ADDITIONAL COUNTRIES, WE INITIATED DISCUSSIONS TO SUPPORT DECISION-MAKING. WE CONTINUED TO SHARE NEW DATA AND SERVE AS A HUB FOR TYPHOID INFORMATION, RAISING AWARENESS ON TYPHOID DISEASE AND PREVENTION THROUGH AN INTEGRATED APPROACH THAT INCLUDES VACCINES. TO PREVENT CERVICAL CANCER, PATH CONTINUED TO COORDINATE A CONSORTIUM OF NINE INDEPENDENT RESEARCH INSTITUTIONS TO COLLATE, ANALYZE, AND DISSEMINATE EVIDENCE ON SINGLE-DOSE HPV VACCINATION. THIS INCLUDED SYNTHESIZING NEWLY AVAILABLE, CRITICAL CLINICAL TRIAL DATA TO PREPARE FOR AND PRESENT EVIDENCE TO WHO'S SAGE. A SINGLE-DOSE SCHEDULE WOULD HELP ALLEVIATE COUNTRIES' FINANCIAL, LOGISTICAL, OR OTHER BARRIERS TO HPV VACCINE INTRODUCTION. PATH ALSO SPONSORED A PHASE 3 STUDY OF A LICENSED HPV VACCINE IN GHANA AND BANGLADESH TO GENERATE EVIDENCE IN LMICS AND ON EXTENDED DOSING SCHEDULES, AND CONTINUED DATA COLLECTION FOR AN HPV COST-OF-DELIVERY STUDY IN SIX COUNTRIES WITH HPV VACCINATION PROGRAMS.
4c (Code:   ) (Expenses $ 37,745,269 including grants of $ 4,420,524 ) (Revenue $   )
AFRICA REGION: PATH'S WORK IN AFRICA INTERSECTS VIRTUALLY EVERY PATH GLOBAL PROGRAM, FROM ADVOCACY AND PUBLIC POLICY TO SEXUAL AND REPRODUCTIVE HEALTH. WE HAVE COUNTRY OFFICES IN SEVEN SUB-SAHARAN NATIONS SPANNING CENTRAL, EASTERN, SOUTHERN, AND WESTERN AFRICA: THE DRC, ETHIOPIA, KENYA, SENEGAL, TANZANIA, UGANDA, AND ZAMBIA - WITH PROJECT OFFICES IN SEVEN MORE. HIGHLIGHTS FROM OUR COUNTRY OFFICES INCLUDE:(CONTINUED ON SCHEDULE O)DRCIN 2021, PATH'S ENGAGEMENT IN THE DRC FOCUSED ON HIV/AIDS, VACCINATION (COVID-19 AND POLIO), AND HEALTH SYSTEM STRENGTHENING. FOR EXAMPLE, THE USAID INTEGRATED HIV/AIDS PROJECT, WHICH PATH LEADS IN HAUT-KATANGA PROVINCE (IHAP-HK), ACHIEVED THE INTERNATIONAL GOLD STANDARD RATE OF 95% UNDETECTABLE VIRAL LOAD AMONG A COHORT OF 45,000. PATH ALSO SUPPORTED THE COVID-19 RESPONSE, INCLUDING HOSTING THE PRESIDENTIAL COVID-19 TASK FORCE IN OUR KINSHASA OFFICE, CONDUCTING THE FIRST DRC NATIONWIDE OXYGEN AVAILABILITY ASSESSMENT, AND MONITORING COVID-19 VACCINATION (THE LATTER VIA THE USAID M-RITE PROJECT). PATH SUPPORTED THE DRC PRESIDENT'S OFFICE FOR THE SECOND PRESIDENTIAL IMMUNIZATION AND POLIO ERADICATION FORUM. TO ACCELERATE TWO HIGH-PRIORITY INITIATIVES - THE DIGITAL TRANSFORMATION OF THE COUNTRY'S HEALTH SECTOR AND UNIVERSAL HEALTH COVERAGE - THE MOH, WITH SUPPORT FROM THE DIGITAL SQUARE TEAM WITHIN PATH, LAUNCHED AN INVESTMENT ROAD MAP WITH MORE THAN 60 INSTITUTIONS PARTICIPATING IN PRIORITIZING CATALYTIC INVESTMENTS.ETHIOPIAWITH FUNDING FROM GAVI THROUGH THE TARGETED COUNTRY ASSISTANCE (TCA) PROJECT, PATH SUPPORTED THE AFAR REGION TO PILOT AND IMPLEMENT CATCH-UP IMMUNIZATION IN TWO CONFLICT-AFFECTED AREAS. PATH ALSO SUPPORTED THE MOH TO IMPLEMENT A VACCINATION STRATEGY DESIGNED SPECIFICALLY FOR COVID-19 VACCINE AND HPV VACCINE, CONDUCTING AN INTEGRATED VACCINATION CAMPAIGN NATIONWIDE FOR TWO COHORTS OF ADOLESCENT GIRLS AND YOUNG WOMEN. IN CLOSE COLLABORATION WITH THE MOH, PATH DESIGNED AND WAS AWARDED A PROJECT FROM BIG WIN PHILANTHROPY TO REVAMP AND RESTORE MATERNAL AND CHILD HEALTH PROGRAMS IN CONFLICT-AFFECTED AREAS, WITH A FOCUS ON EARLY CHILDHOOD DEVELOPMENT AND CAREGIVER HEALTH.KENYAPATH'S NONCOMMUNICABLE DISEASES (NCD) TEAM PARTNERED WITH THE KENYA GOVERNMENT TO EVALUATE THE NATIONAL NCD STRATEGY 2015-2020 TO INFORM THE DESIGN AND DEVELOPMENT OF THE NCD STRATEGY 2021-2026. FOLLOWING LAUNCH OF THE STRATEGY IN JULY 2021, PATH SUPPORTED DISSEMINATION TO OUR FOCAL COUNTIES. PATH IS PRIME ON THE PEPFAR-FUNDED USAID NURU YA MTOTO PROJECT, WITH A FIVE-YEAR (2021-2026) BUDGET OF MORE THAN $44 MILLION. THROUGH THIS PROJECT, PATH LEADS A CONSORTIUM THAT PROVIDES HIV SERVICES TO YOUNG PEOPLE IN HOMA BAY, KISII, AND MIGORI COUNTIES. THROUGH THE DREAMS INITIATIVE, WE CONTINUED TO SUPPORT HIV PREVENTION FOR ADOLESCENT GIRLS AND YOUNG WOMEN. WORKING AS A SUBPARTNER, PATH ALSO SUPPORTED BORESHA JAMII, A PEPFAR-FUNDED USAID PROJECT TO INCREASE ACCESS TO AND DEMAND FOR HIGH-QUALITY TB/HIV PREVENTION, CARE, AND TREATMENT.RTS,S, THE WORLD'S FIRST MALARIA VACCINE, WAS DEVELOPED BY GSK OVER MORE THAN 30 YEARS AND IN PARTNERSHIP WITH PATH SINCE 2001. IN OCTOBER 2021, WHO RECOMMENDED EXPANDING USE OF THE VACCINE ACROSS THE AFRICAN CONTINENT. WITH PATH SUPPORT, KENYA, ONE OF THE FIRST COUNTRIES TO GAIN REGULATORY APPROVAL FOR RTS,S, EMBARKED ON A PHASED INTRODUCTION AND EVALUATION TO LEARN HOW BEST TO IMPLEMENT THE VACCINE WITHIN THE CONTEXT OF ROUTINE IMMUNIZATION.THE PATH KENYA LIVING LABS TEAM IN 2021 FINALIZED THE DESIGN AND PILOT TESTING OF A PROTOTYPE DIGITAL TOOL TO SUPPORT SCHEDULING FOR BOTH IMMUNIZATION AND PHC SERVICES. THE TOOL COMPLEMENTS AN IMMUNIZATION DASHBOARD DEVELOPED BY THE LIVING LABS TEAM TO TRACK PERFORMANCE ON KEY INDICATORS ACROSS KENYA'S COUNTIES, SUBCOUNTIES, AND FACILITIES. KENYA IS ONE OF SEVERAL COUNTRIES RECEIVING SUPPORT THROUGH THE COVID-19 RESPIRATORY CARE RESPONSE COORDINATION PROJECT, A CONSORTIUM FUNDED BY THE BILL & MELINDA GATES FOUNDATION. IN 2021, THE CONSORTIUM, LED BY PATH, PROCURED AND INSTALLED RESPIRATORY CARE EQUIPMENT AT 23 HIGH-VOLUME FACILITIES AND ENSURED THE REPAIR/INSTALLATION OF FIVE OXYGEN GENERATION PLANTS AT TERTIARY/REFERRAL HEALTH FACILITIES. ADDITIONALLY, PATH SUPPORTED KENYAN COUNTIES IN CONDUCTING CAPACITY-BUILDING AND SUPPORTIVE SUPERVISION UNDER THE M-RITE PROJECT, WHICH FOCUSES ON IMMUNIZATION.SENEGALPATH PROVIDED TECHNICAL ASSISTANCE AND LOGISTICAL SUPPORT TO THE MOH IN ROLLING OUT THE 3RD EDITION OF THE INTEGRATED DISEASE SURVEILLANCE AND RESPONSE SYSTEM, A KEY TOOL IN IDENTIFYING, MANAGING, AND MITIGATING INFECTIOUS DISEASE OUTBREAKS. RELATED, PATH PROVIDED TECHNICAL ASSISTANCE TO THE DIRECTORATE OF LABORATORIES AND THE MOH IN DEVELOPING AND VALIDATING NATIONAL STANDARD OPERATING PROCEDURES FOR DETECTION AND SURVEILLANCE OF ANTIMICROBIAL RESISTANCE (AMR).PATH SUPPORTED THE GOVERNMENT IN VARIOUS ASPECTS OF ITS COVID-19 RESPONSE, INCLUDING PROCUREMENT OF EQUIPMENT AND REAGENTS FOR DIAGNOSTIC TESTS AS WELL AS INTENSIVE CARE EQUIPMENT FOR TREATMENT OF SEVERE CASES. AT THE COMMUNITY LEVEL, PATH WORKED TO STIMULATE DEMAND FOR COVID-19 VACCINATION.IN 2021, THE TOOLS FOR INTEGRATED MANAGEMENT OF CHILDHOOD ILLNESS (TIMCI) PROJECT LAUNCHED IN SENEGAL, AND THE TRAINING, SUPERVISION, AND COMMUNITY ENGAGEMENT PHASE BEGAN WITH IMPLEMENTATION AT FOUR INTERVENTION SITES. TIMCI (WITH PATH AS LEAD PARTNER) SUPPORTED THE MOH TO REVISE THE COUNTRY'S INTEGRATED MANAGEMENT OF CHILDHOOD ILLNESS GUIDELINES WITH THE SPECIFIC OBJECTIVE OF INCLUDING PULSE OXIMETRY AND OXYGEN THERAPY INDICATIONS. AS PATH'S WESTERN AFRICA HUB, PATH SENEGAL SUPPORTED THE MOH OF GUINEA, A NEIGHBORING COUNTRY, IN INTEGRATING ALL VIRAL HEMORRHAGIC FEVERS, INCLUDING EBOLA, INTO ITS NATIONAL SURVEILLANCE EARLY WARNING SYSTEM. PATH ALSO PROVIDED TECHNICAL ASSISTANCE TO THE GOVERNMENT OF MALI IN THE DIGITALIZATION OF COVID-19 VACCINATION DATA.TANZANIAIN 2021, THE DATA USE PARTNERSHIP, A COLLABORATION BETWEEN PATH AND THE GOVERNMENT OF TANZANIA, LAUNCHED THE AFYA SUPPORTIVE SUPERVISION PLAN TO IMPLEMENT A DIGITAL SYSTEM FOR DATA COLLECTION IN HEALTH FACILITIES. THE PLAN SUPPLIED 900 TABLETS TO NATIONAL- AND REGIONAL-LEVEL USERS, WITH PATH LEVERAGING OUR EXPERTISE TO SUPPORT TRAININGS ON THE EQUIPMENT AND SOFTWARE.ALSO IN TANZANIA, THE INFECTIOUS DISEASE DETECTION AND SURVEILLANCE (IDDS) PROJECT OPERATIONALIZED A NATIONAL AMR SURVEILLANCE FRAMEWORK. HEALTH WORKERS IN THE COUNTRY CAN NOW SUBMIT HIGH-QUALITY AMR DATA PRODUCED THROUGH THIS FRAMEWORK TO THE NATIONAL DATABASE AND THE GLOBAL AMR SURVEILLANCE SYSTEM.IN COLLABORATION WITH THE MOH, PATH LAUNCHED THE TIMCI PROJECT IN THREE DISTRICTS. WORK IN 2021 INCLUDED DEVELOPING, DEPLOYING, AND SUPPORTING IMPLEMENTATION OF AN ELECTRONIC CLINICAL DECISION-SUPPORT ALGORITHM. PATH'S DIGITAL SQUARE INITIATIVE SUPPORTED THE MOH IN IMPLEMENTING A STANDARDS-BASED NATIONAL HEALTH INFORMATION EXCHANGE PLATFORM THAT BY CLOSE OF 2021 ALLOWED FOR EXCHANGE OF DATA BETWEEN 13 DISPARATE HEALTH INFORMATION SYSTEMS. THROUGH GAVI/TCA, PATH SUPPORTED THE MOH TO TRANSITION FROM A TRADITIONAL, PAPER-BASED SYSTEM FOR IMMUNIZATION TRACKING TO FULL ELECTRONIC DATA COLLECTION AND MANAGEMENT IN MORE THAN 600 PHC FACILITIES. SEPARATELY, PATH SUPPORTED THE MOH TO DEVELOP A RESPIRATORY CARE EQUIPMENT BASELINE ASSESSMENT TOOL, MEDICAL OXYGEN TRAINING MANUAL, AND SCALE-UP PLAN.IN LATE 2021, THE HEALTHY HEART AFRICA PROJECT BEGAN IN TANZANIA WITH THE SIGNING OF A MEMORANDUM OF UNDERSTANDING BETWEEN THE MOH AND ASTRAZENECA, AFTER WHICH PATH CONDUCTED A STAKEHOLDER WORKSHOP TO INTRODUCE THE PROJECT AND ENSURE GOVERNMENT COMMITMENT AND ACCOUNTABILITY. UGANDAIN 2021, PATH'S ADVOCACY AND PUBLIC POLICY TEAM IN UGANDA INFLUENCED THE INTRODUCTION OF A SUPPLEMENTARY BUDGET FOR COVID-19 VACCINATION AND ENSURED BUDGET INCREASES FROM PREVIOUS YEARS FOR ROUTINE IMMUNIZATION AND PHC WERE MAINTAINED DESPITE BUDGET SHORTFALLS AT THE NATIONAL LEVEL. PATH SUCCESSFULLY ADVOCATED FOR THE PASSAGE OF A NATIONAL HEALTH INSURANCE SCHEME AND HELPED DEVELOP A UNIVERSAL HEALTH COVERAGE ROAD MAP AND COMMUNITY HEALTH EXTENSION WORKERS STRATEGY IN PILOT DISTRICTS. OUR TEAM ADVOCATED FOR INTEGRATION OF THE ADDIS DECLARATION ON IMMUNIZATION COMMITMENTS INTO EXPANDED PROGRAM ON IMMUNIZATION WORK PLANS BY CREATING AND DISSEMINATING A SCORECARD TOOL TO SERVE AS AN ACCOUNTABILITY FRAMEWORK. PATH IN UGANDA ALSO ADVOCATED FOR PRIORITIZATION OF ROUTINE IMMUNIZATION TO PREVENT BACKSLIDING DURING COVID-19, WITH A FOCUS ON CATCH-UP CAMPAIGNS SUCH AS A NATIONAL POLIO IMMUNIZATION CAMPAIGN. PATH ALSO SUPPORTED THE MOH TO DISSEMINATE GUIDELINES ON THE CONTINUITY OF ESSENTIAL HEALTH SERVICES DURING COVID-19 AT THE SUBNATIONAL LEVEL, REACHING MORE THAN 400 CHAMPIONS AND HEALTH CARE WORKERS THROUGH TECHNICAL WORKSHOPS AND TRAININGS.
(Code:   ) (Expenses $ 41,899,328 including grants of $ 5,057,232 ) (Revenue $   )
ADVOCACY AND PUBLIC POLICYPATH'S ADVOCACY AND PUBLIC POLICY TEAM WORKS IN THE UNITED STATES, IN AFRICA (DRC, KENYA, SOUTH AFRICA, AND UGANDA), AND AT THE GLOBAL LEVEL WITH MULTILATERAL AGENCIES. WE PARTNER WITH POLICYMAKERS TO HELP THEM UNDERSTAND ISSUES AND MOTIVATE THEM TO COMMIT FUNDING, CRAFT POLICIES, AND SPONSOR INITIATIVES TO STRENGTHEN GLOBAL HEALTH. AS A 501(3)C ORGANIZATION, PATH DOES NOT INFLUENCE THE OUTCOMES OF ELECTIONS AND DOES NOT EMPLOY ANY REGISTERED LOBBYISTS. PATH PROVIDES BEHIND-THE-SCENES SUPPORT TO ADVOCACY PARTNERS IN THE PLACES WHERE WE WORK TO HELP STRENGTHEN THEIR CAPACITY TO ENGAGE WITH LOCAL DECISION-MAKERS TO IMPROVE HEALTH IN THEIR COMMUNITIES. WE FACILITATE PEER-TO-PEER LEARNINGS AMONG THESE PARTNERS TO EXCHANGE BEST PRACTICES AND LESSONS LEARNED ABOUT THE PRACTICE OF ADVOCACY, AND WE HELP ELEVATE LOCAL VOICES IN GLOBAL CONVERSATIONS AROUND HEALTH. IN 2021, PATH LED EFFORTS TO ENSURE SUPPORT AMONG OUR PARTNER POLICYMAKERS TO MAINTAIN AND STRENGTHEN PIVOTAL WORK IN GLOBAL HEALTH RESEARCH AND DEVELOPMENT, MATERNAL AND CHILD HEALTH, IMMUNIZATION, PHC, AND PANDEMIC PREPAREDNESS AND RESPONSE. SUCCESSES INCLUDED PROTECTING KEY U.S. GOVERNMENT FUNDING FOR PATH'S PRIORITY HEALTH AREAS AND HELPING DECISION-MAKERS SHAPE THE GLOBAL RESPONSE TO COVID-19.ASIA, MIDDLE EAST, AND EUROPE REGIONPATH'S LEADERSHIP IN THE ASIA, MIDDLE EAST, AND EUROPE (AMEE) REGION LEVERAGES OUR DEEP EXPERTISE ACROSS MULTIPLE HEALTH DISCIPLINES TO CHAMPION EQUITY IN ACCESS TO CARE, INTRODUCE NEW TECHNOLOGIES AND APPROACHES, AND PARTNER ACROSS SECTORS TO PROVIDE HUMAN-CENTERED CARE AND SUPPORT. PATH COORDINATES OUR WORK IN THIS REGION FROM OFFICES IN EIGHT COUNTRIES, INCLUDING OFFICES IN CHINA, INDIA, UKRAINE, AND VIETNAM THAT SERVE AS REGIONAL HUBS FOR TECHNICAL AND SCIENTIFIC INNOVATION. HIGHLIGHTS INCLUDE:IN 2021, PATH CONTINUED TO COLLABORATE CLOSELY WITH STAKEHOLDERS TO DELIVER HIGH-QUALITY HEALTH SERVICES WHILE FORGING NEW PARTNERSHIPS IN COUNTRIES SUCH AS BANGLADESH, INDONESIA, LAOS, AND NEPAL AND EXPLORING COLLABORATIONS IN NEW GEOGRAPHIES IN THE MIDDLE EAST.PATH PREPARED AND RESPONDED TO EMERGING HEALTH THREATS IN THE REGION BY PROVIDING TECHNICAL SUPPORT, ENHANCING LABORATORY CAPACITY, STRENGTHENING RESPIRATORY CARE RESPONSE, IMPROVING THE COVID-19 SURVEILLANCE SYSTEM, AND LEVERAGING OUR NETWORK OF PARTNERS TO SUPPORT PANDEMIC RESPONSE. IN ADDITION TO THE COVID-19 EMERGENCY, WE COMMITTED TO ELIMINATE LONG-NEGLECTED DISEASES SUCH AS LEISHMANIASIS AND ENSURE THAT THOSE INFECTED RECEIVE CARE.THANKS TO OUR CONTINUOUS WORK IN DEVELOPING INNOVATIVE DIGITAL HEALTH TOOLS, PATH WAS ABLE TO MAINTAIN ESSENTIAL HEALTH SERVICES FOR KEY POPULATIONS IN MYANMAR, DIGITIZE THE LACTATION MANAGEMENT SYSTEM IN INDIA, AND SUPPORT MEDICATION ADHERENCE FOR TB PATIENTS IN UKRAINE. THROUGHOUT THE YEAR, AMEE PROGRAMS FOCUSED ON INCREASING HEALTH SYSTEM CAPACITY AND RESILIENCE WITH COMMUNITY-BASED APPROACHES THAT BRING AWARENESS, AVAILABILITY, AND ACCESSIBILITY OF HEALTH SERVICES TO HARD-TO-REACH COMMUNITIES. IN VIETNAM, FOR EXAMPLE, WE IMPLEMENTED A HIGHLY SUCCESSFUL PROGRAM FOR HIV SELF-TESTING. PATH IN THE AMEE REGION ALSO CONTINUED OUR CLOSE COLLABORATION WITH WHO, UNICEF, GAVI, AND THE GLOBAL FUND ON LARGE-SCALE EFFORTS TO CONTROL AND ELIMINATE DEBILITATING DISEASES SUCH AS MALARIA AND MENINGITIS; TO IMPROVE ACCESS TO LIFESAVING VACCINES FOR CERVICAL CANCER, DIARRHEAL DISEASE, AND PNEUMOCOCCAL DISEASE IN LOW-INCOME COUNTRIES; AND TO STRENGTHEN VACCINE MANUFACTURING CAPACITY AND THE COLD CHAIN AS PART OF OUR ONGOING EFFORTS TO BRING HEALTH AND WELL-BEING TO ALL.
4d Other program services (Describe in Schedule O.)
(Expenses $ 41,899,328 including grants of $ 5,057,232 ) (Revenue $   )
4e Total program service expensesMediumBullet301,134,100
Form 990 (2021)
Form 990 (2021)
Page 3
Part IV
Checklist of Required Schedules
Yes
No
1
Is the organization described in section 501(c)(3) or 4947(a)(1) (other than a private foundation)? If "Yes," complete Schedule AClick to see attachment.....................
1
Yes
 
2
Is the organization required to complete Schedule B, Schedule of Contributors? See instructions. Click to see attachment...
2
Yes
 
3
Did the organization engage in direct or indirect political campaign activities on behalf of or in opposition to candidates for public office? If "Yes," complete Schedule C, Part IClick to see attachment.............
3
 
No
4
Section 501(c)(3) organizations. Did the organization engage in lobbying activities, or have a section 501(h) election in effect during the tax year? If "Yes," complete Schedule C, Part IIClick to see attachment.........
4
Yes
 
5
Is the organization a section 501(c)(4), 501(c)(5), or 501(c)(6) organization that receives membership dues, assessments, or similar amounts as defined in Rev. Proc. 98-19? If "Yes," complete Schedule C, Part IIIClick to see attachment..
5
 
No
6
Did the organization maintain any donor advised funds or any similar funds or accounts for which donors have the right to provide advice on the distribution or investment of amounts in such funds or accounts? If "Yes," complete Schedule D, Part IClick to see attachment.........................
6
 
No
7
Did the organization receive or hold a conservation easement, including easements to preserve open space,
the environment, historic land areas, or historic structures? If "Yes," complete Schedule D, Part IIClick to see attachment....
7
 
No
8
Did the organization maintain collections of works of art, historical treasures, or other similar assets? If "Yes,"
complete Schedule D,
Part IIIClick to see attachment..............
8
 
No
9
Did the organization report an amount in Part X, line 21 for escrow or custodial account liability; serve as a custodian for amounts not listed in Part X; or provide credit counseling, debt management, credit repair, or debt negotiation services? If "Yes," complete Schedule D, Part IVClick to see attachment..............
9
 
No
10
Did the organization, directly or through a related organization, hold assets in temporarily restricted endowments, permanent endowments, or quasi endowments? If "Yes," complete Schedule D, Part V......
10
Yes
 
11
If the organization’s answer to any of the following questions is "Yes," then complete Schedule D, Parts VI, VII, VIII, IX, or X, as applicable.
a
Did the organization report an amount for land, buildings, and equipment in Part X, line 10? If "Yes," complete
Schedule D,
Part VI. Click to see attachment...................
11a
Yes
 
b
Did the organization report an amount for investments—other securities in Part X, line 12 that is 5% or more of its total assets reported in Part X, line 16? If "Yes," complete Schedule D, Part VIIClick to see attachment.......
11b
 
No
c
Did the organization report an amount for investments—program related in Part X, line 13 that is 5% or more of its total assets reported in Part X, line 16? If "Yes," complete Schedule D, Part VIIIClick to see attachment.......
11c
 
No
d
Did the organization report an amount for other assets in Part X, line 15 that is 5% or more of its total assets reported in Part X, line 16? If "Yes," complete Schedule D, Part IXClick to see attachment............
11d
 
No
e
Did the organization report an amount for other liabilities in Part X, line 25? If "Yes," complete Schedule D, Part XClick to see attachment
11e
 
No
f
Did the organization’s separate or consolidated financial statements for the tax year include a footnote that addresses the organization’s liability for uncertain tax positions under FIN 48 (ASC 740)? If "Yes," complete Schedule D, Part XClick to see attachment
11f
 
No
12a
Did the organization obtain separate, independent audited financial statements for the tax year? If "Yes," complete
Schedule D, Parts XI and XII
Click to see attachment......................
12a
 
No
b
Was the organization included in consolidated, independent audited financial statements for the tax year? If "Yes," and if the organization answered "No" to line 12a, then completing Schedule D, Parts XI and XII is optional Click to see attachment
12b
Yes
 
13
Is the organization a school described in section 170(b)(1)(A)(ii)? If "Yes," complete Schedule E
13
 
No
14a
Did the organization maintain an office, employees, or agents outside of the United States? .....
14a
Yes
 
b
Did the organization have aggregate revenues or expenses of more than $10,000 from grantmaking, fundraising, business, investment, and program service activities outside the United States, or aggregate foreign investments valued at $100,000 or more? If "Yes," complete Schedule F, Parts I and IV.........Click to see attachment
14b
Yes
 
15
Did the organization report on Part IX, column (A), line 3, more than $5,000 of grants or other assistance to or for any foreign organization? If “Yes,” complete Schedule F, Parts II and IV.....Click to see attachment
15
Yes
 
16
Did the organization report on Part IX, column (A), line 3, more than $5,000 of aggregate grants or other assistance to or for foreign individuals? If “Yes,” complete Schedule F, Parts III and IV...Click to see attachment
16
 
No
17
Did the organization report a total of more than $15,000 of expenses for professional fundraising services on Part IX, column (A), lines 6 and 11e? If "Yes," complete Schedule G, Part I. See instructions. ....
17
 
No
18
Did the organization report more than $15,000 total of fundraising event gross income and contributions on Part VIII, lines 1c and 8a? If "Yes," complete Schedule G, Part II............
18
 
No
19
Did the organization report more than $15,000 of gross income from gaming activities on Part VIII, line 9a? If "Yes," complete Schedule G, Part III...................
19
 
No
20a
Did the organization operate one or more hospital facilities? If "Yes," complete Schedule H....
20a
 
No
b
If "Yes" to line 20a, did the organization attach a copy of its audited financial statements to this return?
20b
 
 
21
Did the organization report more than $5,000 of grants or other assistance to any domestic organization or domestic government on Part IX, column (A), line 1? If “Yes,” complete Schedule I, Parts I and II.....Click to see attachment
21
Yes
 
Form 990 (2021)
Form 990 (2021)
Page 4
Part IV
Checklist of Required Schedules (continued)
Yes
No
22
Did the organization report more than $5,000 of grants or other assistance to or for domestic individuals on Part IX, column (A), line 2? If “Yes,” complete Schedule I, Parts I and III........Click to see attachment
22
 
No
23
Did the organization answer "Yes" to Part VII, Section A, line 3, 4, or 5, about compensation of the organization’s current and former officers, directors, trustees, key employees, and highest compensated employees? If "Yes," complete Schedule J....................... Click to see attachment
23
Yes
 
24a
Did the organization have a tax-exempt bond issue with an outstanding principal amount of more than $100,000 as of the last day of the year, that was issued after December 31, 2002? If “Yes,” answer lines 24b through 24d and complete Schedule K. If “No,” go to line 25a...............
24a
 
No
b
Did the organization invest any proceeds of tax-exempt bonds beyond a temporary period exception?...
24b
 
 
c
Did the organization maintain an escrow account other than a refunding escrow at any time during the year
to defease any tax-exempt bonds? ...............
24c
 
 
d
Did the organization act as an "on behalf of" issuer for bonds outstanding at any time during the year?...
24d
 
 
25a
Section 501(c)(3), 501(c)(4), and 501(c)(29) organizations. Did the organization engage in an excess benefit transaction with a disqualified person during the year? If "Yes," complete Schedule L, Part I ....
25a
 
No
b
Is the organization aware that it engaged in an excess benefit transaction with a disqualified person in a prior year, and that the transaction has not been reported on any of the organization’s prior Forms 990 or 990-EZ? If "Yes," complete Schedule L, Part I.......................
25b
 
No
26
Did the organization report any amount on Part X, line 5 or 22 for receivables from or payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons? If "Yes," complete Schedule L, Part II...........
26
 
No
27
Did the organization provide a grant or other assistance to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or employee thereof, a grant selection committee member, or to a 35% controlled entity (including an employee thereof) or family member of any of these persons?
If "Yes," complete
Schedule L, Part III.........................
27
 
No
28
Was the organization a party to a business transaction with one of the following parties (see the Schedule L, Part IV instructions for applicable filing thresholds, conditions, and exceptions):
a
A current or former officer, director, trustee, key employee, creator or founder, or substantial contributor? If "Yes," complete Schedule L, Part IV......................
28a
 
No
b
A family member of any individual described in line 28a? If "Yes," complete Schedule L, Part IV.....
28b
 
No
c
A 35% controlled entity of one or more individuals and/or organizations described in line 28a or 28b? If "Yes," complete Schedule L, Part IV.....................
28c
 
No
29
Did the organization receive more than $25,000 in non-cash contributions? If "Yes," complete Schedule M..Click to see attachment
29
Yes
 
30
Did the organization receive contributions of art, historical treasures, or other similar assets, or qualified conservation contributions? If "Yes," complete Schedule M .................Click to see attachment
30
 
No
31
Did the organization liquidate, terminate, or dissolve and cease operations? If "Yes," complete Schedule N, Part I
31
 
No
32
Did the organization sell, exchange, dispose of, or transfer more than 25% of its net assets? If "Yes," complete Schedule N, Part II........................
32
 
No
33
Did the organization own 100% of an entity disregarded as separate from the organization under Regulations sections 301.7701-2 and 301.7701-3? If "Yes," complete Schedule R, Part I............Click to see attachment
33
 
No
34
Was the organization related to any tax-exempt or taxable entity? If "Yes," complete Schedule R, Part II, III, or IV, and Part V, line 1.........................Click to see attachment
34
Yes
 
35a
Did the organization have a controlled entity within the meaning of section 512(b)(13)?
35a
Yes
 
b
If ‘Yes’ to line 35a, did the organization receive any payment from or engage in any transaction with a controlled entity within the meaning of section 512(b)(13)? If "Yes," complete Schedule R, Part V, line 2 ...Click to see attachment
35b
Yes
 
36
Section 501(c)(3) organizations. Did the organization make any transfers to an exempt non-charitable related organization? If "Yes," complete Schedule R, Part V, line 2............. Click to see attachment
36
 
No
37
Did the organization conduct more than 5% of its activities through an entity that is not a related organization and that is treated as a partnership for federal income tax purposes? If "Yes," complete Schedule R, Part VIClick to see attachment
37
 
No
38
Did the organization complete Schedule O and provide explanations on Schedule O for Part VI, lines 11b and 19? Note. All Form 990 filers are required to complete Schedule O. ............
38
Yes
 
Part V
Statements Regarding Other IRS Filings and Tax Compliance
Check if Schedule O contains a response or note to any line in this Part V...........
Yes
No
1a
Enter the number reported in box 3 of Form 1096. Enter -0- if not applicable ..
1a
219
b
Enter the number of Forms W-2G included on line 1a. Enter -0- if not applicable .
1b
0
c
Did the organization comply with backup withholding rules for reportable payments to vendors and reportable gaming (gambling) winnings to prize winners? ..................
1c
Yes
 
Form 990 (2021)
Form 990 (2021)
Page 5
Part V
Statements Regarding Other IRS Filings and Tax Compliance (continued)
2a
Enter the number of employees reported on Form W-3, Transmittal of Wage and
Tax Statements, filed for the calendar year ending with or within the year covered by this return ..................
2a
667
b
If at least one is reported on line 2a, did the organization file all required federal employment tax returns?
Note. If the sum of lines 1a and 2a is greater than 250, you may be required to e-file. See instructions.
2b
Yes
 
3a
Did the organization have unrelated business gross income of $1,000 or more during the year?...
3a
 
No
b
If “Yes,” has it filed a Form 990-T for this year? If “No” to line 3b, provide an explanation in Schedule O...
3b
 
 
4a
At any time during the calendar year, did the organization have an interest in, or a signature or other authority over, a financial account in a foreign country (such as a bank account, securities account, or other financial account)? ..
4a
Yes
 
b
If "Yes," enter the name of the foreign country: MediumBulletBE , CH , ET , GH , IN , KE , MZ , PE , SG , SZ , TZ , UG , UK , VM , ZA , CG , MI , BM , SF , UP
See instructions for filing requirements for FinCEN Form 114, Report of Foreign Bank and Financial Accounts (FBAR).
5a
Was the organization a party to a prohibited tax shelter transaction at any time during the tax year? ..
5a
 
No
b
Did any taxable party notify the organization that it was or is a party to a prohibited tax shelter transaction?
5b
 
No
c
If "Yes," to line 5a or 5b, did the organization file Form 8886-T? ............
5c
 
 
6a
Does the organization have annual gross receipts that are normally greater than $100,000, and did the organization solicit any contributions that were not tax deductible as charitable contributions? ...
6a
 
No
b
If "Yes," did the organization include with every solicitation an express statement that such contributions or gifts were not tax deductible? ......................
6b
 
 
7
Organizations that may receive deductible contributions under section 170(c).
a
Did the organization receive a payment in excess of $75 made partly as a contribution and partly for goods and services provided to the payor? ....................
7a
 
No
b
If "Yes," did the organization notify the donor of the value of the goods or services provided? .....
7b
 
 
c
Did the organization sell, exchange, or otherwise dispose of tangible personal property for which it was required to file Form 8282? .........................
7c
 
No
d
If "Yes," indicate the number of Forms 8282 filed during the year ....
7d
 
e
Did the organization receive any funds, directly or indirectly, to pay premiums on a personal benefit contract?
7e
 
No
f
Did the organization, during the year, pay premiums, directly or indirectly, on a personal benefit contract? ..
7f
 
No
g
If the organization received a contribution of qualified intellectual property, did the organization file Form 8899 as required? ......................
7g
 
 
h
If the organization received a contribution of cars, boats, airplanes, or other vehicles, did the organization file a Form 1098-C? ..........................
7h
 
 
8
Sponsoring organizations maintaining donor advised funds. Did a donor advised fund maintained by the sponsoring organization have excess business holdings at any time during the year? ........
8
 
 
9
Sponsoring organizations maintaining donor advised funds.
a
Did the sponsoring organization make any taxable distributions under section 4966?........
9a
 
 
b
Did the sponsoring organization make a distribution to a donor, donor advisor, or related person?...
9b
 
 
10
Section 501(c)(7) organizations. Enter:
a
Initiation fees and capital contributions included on Part VIII, line 12 ...
10a
 
b
Gross receipts, included on Form 990, Part VIII, line 12, for public use of club facilities
10b
 
11
Section 501(c)(12) organizations. Enter:
a
Gross income from members or shareholders .........
11a
 
b
Gross income from other sources. (Do not net amounts due or paid to other sources against amounts due or received from them.) ..........
11b
 
12a
Section 4947(a)(1) non-exempt charitable trusts. Is the organization filing Form 990 in lieu of Form 1041?
12a
 
 
b
If "Yes," enter the amount of tax-exempt interest received or accrued during the year.
12b
 
13
Section 501(c)(29) qualified nonprofit health insurance issuers.
a
Is the organization licensed to issue qualified health plans in more than one state? .........
Note. See the instructions for additional information the organization must report on Schedule O.
13a
 
 
b
Enter the amount of reserves the organization is required to maintain by the states in which the organization is licensed to issue qualified health plans ....
13b
 
c
Enter the amount of reserves on hand ............
13c
 
14a
Did the organization receive any payments for indoor tanning services during the tax year?.....
14a
 
No
b
If "Yes," has it filed a Form 720 to report these payments? If "No," provide an explanation in Schedule O..
14b
 
 
15
Is the organization subject to the section 4960 tax on payment(s) of more than $1,000,000 in remuneration or excess parachute payment(s) during the year? ....................
If "Yes," see the instructions and file Form 4720, Schedule N.
15
 
No
16
Is the organization an educational institution subject to the section 4968 excise tax on net investment income? ..
If "Yes," complete Form 4720, Schedule O.
16
 
No
17
Section 501(c)(21) organizations. Did the trust, any disqualified person, or mine operator engage in any activities that would result in the imposition of an excise tax under section 4951, 4952, or 4953? ..
If "Yes," complete Form 6069.
17
 
 
Form 990 (2021)
Form 990 (2021)
Page 6
Part VI
Governance, Management, and Disclosure. For each "Yes" response to lines 2 through 7b below, and for a "No" response to lines 8a, 8b, or 10b below, describe the circumstances, processes, or changes in Schedule O. See instructions.
Check if Schedule O contains a response or note to any line in this Part VI..............
Section A. Governing Body and Management
Yes
No
1a
Enter the number of voting members of the governing body at the end of the tax year
1a
16
If there are material differences in voting rights among members of the governing body, or if the governing body delegated broad authority to an executive committee or similar committee, explain in Schedule O.
b
Enter the number of voting members included in line 1a, above, who are independent
1b
16
2
Did any officer, director, trustee, or key employee have a family relationship or a business relationship with any other officer, director, trustee, or key employee? .................
2
 
No
3
Did the organization delegate control over management duties customarily performed by or under the direct supervision of officers, directors or trustees, or key employees to a management company or other person? .
3
 
No
4
Did the organization make any significant changes to its governing documents since the prior Form 990 was filed? .
4
 
No
5
Did the organization become aware during the year of a significant diversion of the organization’s assets? .
5
 
No
6
Did the organization have members or stockholders? ................
6
 
No
7a
Did the organization have members, stockholders, or other persons who had the power to elect or appoint one or more members of the governing body? ....................
7a
 
No
b
Are any governance decisions of the organization reserved to (or subject to approval by) members, stockholders, or persons other than the governing body? ...................
7b
 
No
8
Did the organization contemporaneously document the meetings held or written actions undertaken during the year by the following:
a
The governing body? .......................
8a
Yes
 
b
Each committee with authority to act on behalf of the governing body? ............
8b
Yes
 
9
Is there any officer, director, trustee, or key employee listed in Part VII, Section A, who cannot be reached at the organization’s mailing address? If "Yes," provide the names and addresses in Schedule O.......
9
 
No
Section B. Policies (This Section B requests information about policies not required by the Internal Revenue Code.)
Yes
No
10a
Did the organization have local chapters, branches, or affiliates? ............
10a
 
No
b
If "Yes," did the organization have written policies and procedures governing the activities of such chapters, affiliates, and branches to ensure their operations are consistent with the organization's exempt purposes?
10b
 
 
11a
Has the organization provided a complete copy of this Form 990 to all members of its governing body before filing the form? ............................
11a
Yes
 
b
Describe on Schedule O the process, if any, used by the organization to review this Form 990. .....
12a
Did the organization have a written conflict of interest policy? If "No," go to line 13.......
12a
Yes
 
b
Were officers, directors, or trustees, and key employees required to disclose annually interests that could give rise to conflicts? ..........................
12b
Yes
 
c
Did the organization regularly and consistently monitor and enforce compliance with the policy? If "Yes," describe on Schedule O how this was done...................
12c
Yes
 
13
Did the organization have a written whistleblower policy? ...............
13
Yes
 
14
Did the organization have a written document retention and destruction policy? .........
14
Yes
 
15
Did the process for determining compensation of the following persons include a review and approval by independent persons, comparability data, and contemporaneous substantiation of the deliberation and decision?
a
The organization’s CEO, Executive Director, or top management official ...........
15a
Yes
 
b
Other officers or key employees of the organization ................
15b
Yes
 
If "Yes" to line 15a or 15b, describe the process on Schedule O. See instructions.
16a
Did the organization invest in, contribute assets to, or participate in a joint venture or similar arrangement with a taxable entity during the year? ......................
16a
 
No
b
If "Yes," did the organization follow a written policy or procedure requiring the organization to evaluate its participation in joint venture arrangements under applicable federal tax law, and take steps to safeguard the organization’s exempt status with respect to such arrangements? ............
16b
 
 
Section C. Disclosure
17
List the states with which a copy of this Form 990 is required to be filedMediumBullet
AL , AR , CA , CT , FL , IL , KS , KY , MA , MD , MI , MN , MS , NC , NH , NJ , NM , NY , OK , OR , PA , RI , SC , TN , UT , VA , WI , WV
18
Section 6104 requires an organization to make its Form 1023 (1024 or 1024-A, if applicable), 990, and 990-T (section 501(c)(3)s only) available for public inspection. Indicate how you made these available. Check all that apply.
19
Describe in Schedule O whether (and if so, how) the organization made its governing documents, conflict of interest policy, and financial statements available to the public during the tax year.
20
State the name, address, and telephone number of the person who possesses the organization's books and records:
MediumBulletKELLY PRIESTLEY CONTROLLER & PRINCIPAL FINANCIAL OFFICER2201 WESTLAKE AVE SUITE 200   SEATTLE,WA98121 (206) 285-3500
Form 990 (2021)
Form 990 (2021)
Page 7
Part VII
Compensation of Officers, Directors,Trustees, Key Employees, Highest Compensated Employees, and Independent Contractors
Check if Schedule O contains a response or note to any line in this Part VII..............
Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees
1a Complete this table for all persons required to be listed. Report compensation for the calendar year ending with or within the organization’s tax year.
RoundBullet List all of the organization’s current officers, directors, trustees (whether individuals or organizations), regardless of amount
of compensation. Enter -0- in columns (D), (E), and (F) if no compensation was paid.

RoundBullet List all of the organization’s current key employees, if any. See the instructions for definition of "key employee."
RoundBullet List the organization’s five current highest compensated employees (other than an officer, director, trustee or key employee)
who received reportable compensation (box 5 of Form W-2, Form 1099-MISC, and/or box 1 of Form 1099-NEC) of more than $100,000 from the
organization and any related organizations.

RoundBullet List all of the organization’s former officers, key employees, or highest compensated employees who received more than $100,000
of reportable compensation from the organization and any related organizations.

RoundBullet List all of the organization’s former directors or trustees that received, in the capacity as a former director or trustee of the
organization, more than $10,000 of reportable compensation from the organization and any related organizations.

See the instructions for the order in which to list the persons above.
Check this box if neither the organization nor any related organization compensated any current officer, director, or trustee.
(A)
Name and title
(B)
Average hours per week (list any hours for related organizations below dotted line)
(C)
Position (do not check more than one box, unless person is both an officer and a director/trustee)
(D)
Reportable compensation from the organization (W-2/1099-MISC/1099-NEC)
(E)
Reportable compensation from related organizations (W-2/1099-MISC/1099-NEC)
(F)
Estimated amount of other compensation from the organization and related organizations
Individual Trustee or Director; Institutional Trustee; OfficerInd; Key Employee; Highest compensated employee; FormerOfcrDirectorTrusteeInd;
(1) BETH GALETTI MBA......................................................................
CHAIR
2.00
.................
0.00
X   X       0 0 0
(2) DAVID KING JD......................................................................
VICE CHAIR
2.00
.................
0.00
X   X       0 0 0
(3) SANFORD MELZER......................................................................
SECRETARY
2.00
.................
0.00
X   X       0 0 0
(4) BRUCE MCNAMER JD MBA......................................................................
TREASURER
2.00
.................
0.00
X   X       0 0 0
(5) YEHONG ZHANG PHD MBA......................................................................
DIRECTOR
2.00
.................
0.00
X           0 0 0
(6) JO ADDY MBA MPA......................................................................
DIRECTOR
2.00
.................
0.00
X           0 0 0
(7) IREENA VITTAL......................................................................
DIRECTOR
2.00
.................
0.00
X           0 0 0
(8) DEANNA OPPENHEIMER......................................................................
DIRECTOR
2.00
.................
0.00
X           0 0 0
(9) JOHN-ARNE ROTTINGEN MD PHD......................................................................
MSC, MPA--DIRECTOR
2.00
.................
0.00
X           0 0 0
(10) JOEL HOLSINGER......................................................................
DIRECTOR
2.00
.................
0.00
X           0 0 0
(11) HELENA WAYTH MSC......................................................................
DIRECTOR
2.00
.................
0.00
X           0 0 0
(12) ABAYOMI SULE MBBS MBA......................................................................
DIRECTOR
2.00
.................
0.00
X           0 0 0
(13) LISA ANDERSON......................................................................
DIRECTOR
2.00
.................
0.00
X           0 0 0
(14) RACHEL SIBANDE MSC......................................................................
DIRECTOR
2.00
.................
0.00
X           0 0 0
(15) FREDERICK WERE......................................................................
DIRECTOR (BEGAN 3/2021)
2.00
.................
0.00
X           0 0 0
(16) LUTZ HEGEMANN MD PHD......................................................................
DIRECTOR (BEGAN 6/2021)
2.00
.................
0.00
X           0 0 0
(17) NIKOLAJ JESTED GILBERT MSC......................................................................
PRESIDENT AND CEO
39.00
.................
1.00
    X       591,896 0 43,730
Form 990 (2021)
Form 990 (2021)
Page 8
Part VII
Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees (continued)
(A)
Name and title
(B)
Average hours per week (list any hours for related organizations below dotted line)
(C)
Position (do not check more than one box, unless person is both an officer and a director/trustee)
(D)
Reportable compensation from the organization (W-2/1099-MISC/1099-NEC)
(E)
Reportable compensation from related organizations (W-2/1099-MISC/1099-NEC)
(F)
Estimated amount of other compensation from the organization and related organizations
Individual Trustee or Director; Institutional Trustee; OfficerInd; Key Employee; Highest compensated employee; FormerOfcrDirectorTrusteeInd;
(18) JERRY KUO MBA........................................................................
CHIEF OF STRGC. FIN. (UNTIL 1/4/21)
39.00
.......................1.00
    X       134,055 0 4,302
(19) PHILIPPE GUINOT MBA........................................................................
CHIEF OF BUSINESS, FIN. & OPERATIONS
1.00
.......................39.00
    X       0 316,221 25,825
(20) DAVID C KASLOW MD........................................................................
CHIEF EXECUTIVE-ESSENTIAL MEDICINES
39.00
.......................1.00
      X     408,184 0 67,963
(21) JEFFREY D BERNSON MPH MPA........................................................................
CHIEF EXECUTIVE-PROGRAM & INNOVATION
40.00
.......................0.00
      X     322,840 0 58,884
(22) DAVID W FLEMING--SENIOR VP MD........................................................................
OF PUBLIC HEALTH(UNTIL 2/11/21)
40.00
.......................0.00
      X     241,202 0 10,041
(23) CARLA ANNE COSTA SANDINE........................................................................
CHIEF OF EXTERNAL AFFAIRS
40.00
.......................0.00
      X     268,166 0 46,608
(24) MOLLI M BARNES........................................................................
CHIEF PEOPLE OFFICER
40.00
.......................0.00
      X     261,290 0 49,413
(25) ERICA JANE SESSLE MPHIL MPH........................................................................
CHIEF OF STAFF (UNTIL 10/1/21)
40.00
.......................0.00
      X     355,383 0 40,626
(26) NANTHALILE C MUGALA MD MMED........................................................................
CHIEF EXECUTIVE-AFRICA REGION
40.00
.......................0.00
      X     288,679 0 0
(27) SABRINA L POWERS JD........................................................................
GENERAL COUNSEL
40.00
.......................0.00
      X     265,189 0 44,732
(28) TRAD M HATTON MA MHS........................................................................
COUNTRY DIRECTOR
40.00
.......................0.00
        X   345,991 0 52,997
(29) KIMBERLY GREEN PHD........................................................................
DIRECTOR, PRIMARY HEALTH CARE
40.00
.......................0.00
        X   322,267 0 60,231
(30) ASHLEY J BIRKETT PHD........................................................................
GLOBAL HEAD, MALARIA VACCINES
40.00
.......................0.00
        X   330,205 0 59,071
(31) BRUCE LAMONT INNIS MD FIDSA........................................................................
GLOBAL HEAD, RESPIRATORY INFECTIONS & MATERNAL IMM
40.00
.......................0.00
        X   342,216 0 30,989
(32) JOHN O KONZ PHD........................................................................
GLOBAL HEAD, INT. PTFL. & FIN. MGMT.
40.00
.......................0.00
        X   330,414 0 64,894
(33) ELAINE L GIBBONS CFA........................................................................
FRMR VP-GLOBAL ENGMT. (LEFT 2020)
40.00
.......................0.00
          X 184,790 0 2,056
1b Sub-Total................MediumBullet
c Total from continuation sheets to Part VII, Section A....MediumBullet
d Total (add lines 1b and 1c)...........MediumBullet 4,992,767 316,221 662,362
2
Total number of individuals (including but not limited to those listed above) who received more than $100,000 of reportable compensation from the organization MediumBullet354
Yes
No
3
Did the organization list any former officer, director or trustee, key employee, or highest compensated employee on line 1a? If "Yes," complete Schedule J for such individual ..............
3
Yes
 
4
For any individual listed on line 1a, is the sum of reportable compensation and other compensation from the organization and related organizations greater than $150,000? If "Yes," complete Schedule J for such
individual
...........................
4
Yes
 
5
Did any person listed on line 1a receive or accrue compensation from any unrelated organization or individual for services rendered to the organization? If "Yes," complete Schedule J for such person ........
5
 
No
Section B. Independent Contractors
1
Complete this table for your five highest compensated independent contractors that received more than $100,000 of compensation from the organization. Report compensation for the calendar year ending with or within the organization’s tax year.
(A)
Name and business address
(B)
Description of services
(C)
Compensation
RANDSTAD INDIA PVT LTD

SUITE NO 001 002 COPIA
NEW DELHI   110025
IN
STAFFING SERVICES 1,796,178
SAFEGUARD WORLD INT'L

MOSS LANE EDWIN FODEN BUS CENTRE
SANDBACH   CW113AE
UK
GENERAL CONTRACTOR 1,322,299
UNIT4 BUSINESS SOFTWARE INC

3 BURLINGTON WOODS
BURLINGTON,MA01803
SYSTEMS CONTRACTOR 729,988
PIVOTAL CONSULTING LLC

1631 15TH AVE W 118
SEATTLE,WA98119
CONSULTING 600,556
GLOBALIZATION PARTNERS INC

175 FEDERAL ST 17TH FL
BOSTON,MA02110
STAFFING SERVICES 464,096
2
Total number of independent contractors (including but not limited to those listed above) who received more than $100,000 of compensation from the organization MediumBullet41
Form 990 (2021)
Form 990 (2021)
Page 9
Part VIII
Statement of Revenue
Check if Schedule O contains a response or note to any line in this Part VIII.............
(A)
Total revenue
(B)
Related or
exempt
function
revenue
(C)
Unrelated
business
revenue
(D)
Revenue
excluded from
tax under sections
512 - 514
Contributions, Gifts, Grants, and OtherAmt Similar Amounts 1a Federated campaigns..1a  
b Membership dues..1b  
c Fundraising events..1c  
d Related organizations1d 2,279,943
e Government grants (contributions)1e 113,800,820
f All other contributions, gifts, grants, and similar amounts not included above1f 216,988,196
g Noncash contributions included in lines 1a - 1f:$ 1g 3,097,897
h Total. Add lines 1a-1f.......MediumBullet 333,068,959
 Program Service RevenueAmt Business Code
2a
b
c
d
e
f All other program service revenue.        
g Total. Add lines 2a–2f .....MediumBullet  
 OtherAmtRevenueAmt 3 Investment income (including dividends, interest, and othersimilar amounts) ......MediumBullet 8,920,472     8,920,472
4 Income from investment of tax-exempt bond proceedsMediumBullet        
5 Royalties...........MediumBullet        
(ii) Personal (i) Real
6a Gross rents     6a
b Less: rental expenses     6b
c Rental income or (loss)     6c
d Net rental income or (loss).......MediumBullet        
(ii) Other (i) Securities
7a Gross amount from sales of assets other than inventory 22,137 56,047,000 7a
b Less: cost or other basis and sales expenses 169,653 55,614,599 7b
c Gain or (loss) -147,516 432,401 7c
d Net gain or (loss).........MediumBullet 284,885     284,885
8a Gross income from fundraising events (not including $   of contributions reported on line 1c). See Part IV, line 18 ....
8a  
b Less: direct expenses ... 8b  
c Net income or (loss) from fundraising events..MediumBullet      
9a Gross income from gaming activities.
See Part IV, line 19 ...
9a  
b Less: direct expenses ... 9b  
c Net income or (loss) from gaming activities..MediumBullet        
10a Gross sales of inventory, less
returns and allowances ..
10a  
b Less: cost of goods sold .. 10b  
c Net income or (loss) from sales of inventory..MediumBullet        
Business Code Miscellaneous Revenue
11a OTHER 900099 804,482     804,482
b REIMBURSEMENTS 900099 38,788     38,788
c            
d All other revenue ....        
e Total. Add lines 11a–11d ...... MediumBullet 843,270
12 Total revenue. See instructions.....MediumBullet 343,117,586 0 0 10,048,627
Form 990 (2021)
Form 990 (2021)
Page 10
Part IX
Statement of Functional Expenses
Section 501(c)(3) and 501(c)(4) organizations must complete all columns. All other organizations must complete column (A).Check if Schedule O contains a response or note to any line in this Part IX..............
Do not include amounts reported on lines 6b,
7b, 8b, 9b, and 10b of Part VIII.
(A)
Total expenses
(B)
Program service expenses
(C)
Management and general expenses
(D)
Fundraising
expenses
1 Grants and other assistance to domestic organizations and domestic governments. See Part IV, line 21 .... 24,971,209 24,971,209
2 Grants and other assistance to domestic individuals. See Part IV, line 22 ...........    
3 Grants and other assistance to foreign organizations, foreign governments, and foreign individuals. See Part IV, lines 15 and 16. ............. 50,990,746 50,990,746
4 Benefits paid to or for members .......    
5 Compensation of current officers, directors, trustees, and key employees ........... 3,503,184 304,810 3,198,374  
6 Compensation not included above, to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B) ......... 186,846   186,846  
7 Other salaries and wages........ 98,900,832 84,542,681 12,401,955 1,956,196
8 Pension plan accruals and contributions (include section 401(k) and 403(b) employer contributions) .... 10,846,071 9,740,836 866,213 239,022
9 Other employee benefits ....... 15,530,594 14,465,840 968,297 96,457
10 Payroll taxes ........... 6,439,800 5,787,905 592,796 59,099
11 Fees for services (non-employees):        
a Management ......        
b Legal ......... 1,361,906 689,129 669,780 2,997
c Accounting ........... 941,141 234,102 707,039  
d Lobbying ...........        
e Professional fundraising services. See Part IV, line 17    
f Investment management fees ...... 335,619   335,619  
g Other (If line 11g amount exceeds 10% of line 25, column (A) amount, list line 11g expenses on Schedule O) 21,356,638 16,798,933 4,206,724 350,981
12 Advertising and promotion .... 259,645 204,097 5,771 49,777
13 Office expenses ....... 8,500,810 8,062,238 346,509 92,063
14 Information technology ...... 7,759,274 6,314,353 1,383,166 61,755
15 Royalties .. 40,100 40,100    
16 Occupancy ........... 13,663,995 254,156 13,408,822 1,017
17 Travel ............ 8,854,734 8,756,823 97,562 349
18 Payments of travel or entertainment expenses for any federal, state, or local public officials .        
19 Conferences, conventions, and meetings .... 8,927,984 8,672,961 254,256 767
20 Interest ........... 14 14    
21 Payments to affiliates .......        
22 Depreciation, depletion, and amortization .. 2,442,094 9,302 2,432,792  
23 Insurance ... 760,860 460,013 300,847  
24 Other expenses. Itemize expenses not covered above (List miscellaneous expenses in line 24e. If line 24e amount exceeds 10% of line 25, column (A) amount, list line 24e expenses on Schedule O.)
a SUBCONTRACTORS 32,708,095 32,708,095    
b EQUIP RENT & MAINT 11,123,049 10,973,340 149,709  
c DIRECT AID TO BENEF. 986,176 986,176    
d FACILITIES ALLOC 0 13,860,521 -14,219,377 358,856
e All other expenses 3,953,213 1,305,720 249,627 2,397,866
25 Total functional expenses. Add lines 1 through 24e 335,344,629 301,134,100 28,543,327 5,667,202
26 Joint costs. Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation. Check here MediumBullet if following SOP 98-2 (ASC 958-720).        
Form 990 (2021)
Form 990 (2021)
Page 11
Part X
Balance Sheet
Check if Schedule O contains a response or note to any line in this Part IX..............
(A)
Beginning of year
(B)
End of year
Assets 1 Cash–non-interest-bearing ........ 7,194,550 1 12,911,863
2 Savings and temporary cash investments ......... 9,719,000 2 10,006,728
3 Pledges and grants receivable, net ...... 39,742,632 3 38,296,068
4 Accounts receivable, net ............. 258,036 4 555,337
5 Loans and other receivables from any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons .......
  5  
6 Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), and persons described in section 4958(c)(3)(B) ...
  6  
7 Notes and loans receivable, net ...........   7  
8 Inventories for sale or use ............   8  
9 Prepaid expenses and deferred charges ...... 7,008,112 9 7,454,031
10a Land, buildings, and equipment: cost or other basis. Complete Part VI of Schedule D 10a 37,891,859
b Less: accumulated depreciation 10b 30,772,154 8,413,303 10c 7,119,705
11 Investments—publicly traded securities . 211,220,570 11 230,729,600
12 Investments—other securities. See Part IV, line 11 .....   12  
13 Investments—program-related. See Part IV, line 11 ..   13  
14 Intangible assets ...............   14  
15 Other assets. See Part IV, line 11 ...........   15  
16 Total assets. Add lines 1 through 15 (must equal line 33)... 283,556,203 16 307,073,332
Liabilities 17 Accounts payable and accrued expenses ..... 234,982,056 17 253,115,813
18 Grants payable ...   18  
19 Deferred revenue .........   19  
20 Tax-exempt bond liabilities .........   20  
21 Escrow or custodial account liability. Complete Part IV of Schedule D   21  
22 Loans and other payables to any current or former officer, director, trustee, key employee, creator or founder, substantial contributor, or 35% controlled entity or family member of any of these persons .........
  22  
23 Secured mortgages and notes payable to unrelated third parties ..   23  
24 Unsecured notes and loans payable to unrelated third parties ..   24  
25 Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17 - 24). Complete Part X of Schedule D   25  
26 Total liabilities. Add lines 17 through 25.. 234,982,056 26 253,115,813
Net Assets or Fund Balance Organizations that follow FASB ASC 958, check here MediumBullet and complete lines 27, 28, 32, and 33.
27 Net assets without donor restrictions .......... 21,554,594 27 20,653,709
28 Net assets with donor restrictions ........... 27,019,553 28 33,303,810
Organizations that do not follow FASB ASC 958, check here MediumBullet and complete lines 29 through 33.
29 Capital stock or trust principal, or current funds .....   29  
30 Paid-in or capital surplus, or land, building or equipment fund ...   30  
31 Retained earnings, endowment, accumulated income, or other funds   31  
32 Total net assets or fund balances ........... 48,574,147 32 53,957,519
33 Total liabilities and net assets/fund balances ........ 283,556,203 33 307,073,332
Form 990 (2021)
Form 990 (2021)
Page 12
Part XI
Reconcilliation of Net Assets
Check if Schedule O contains a response or note to any line in this Part XI..............
1
Total revenue (must equal Part VIII, column (A), line 12) ............
1
343,117,586
2
Total expenses (must equal Part IX, column (A), line 25) ............
2
335,344,629
3
Revenue less expenses. Subtract line 2 from line 1 ..............
3
7,772,957
4
Net assets or fund balances at beginning of year (must equal Part X, line 32, column (A)) ..
4
48,574,147
5
Net unrealized gains (losses) on investments ...............
5
-2,389,585
6
Donated services and use of facilities .................
6
 
7
Investment expenses .....................
7
 
8
Prior period adjustments .....................
8
 
9
Other changes in net assets or fund balances (explain in Schedule O) ........
9
0
10
Net assets or fund balances at end of year. Combine lines 3 through 9 (must equal Part X, line 32, column (B))
10
53,957,519
Part XII
Financial Statements and Reporting
Check if Schedule O contains a response or note to any line in this Part XII.............
Yes
No
1
Accounting method used to prepare the Form 990:  
If the organization changed its method of accounting from a prior year or checked "Other," explain on
Schedule O.
2a
Were the organization’s financial statements compiled or reviewed by an independent accountant?
2a
 
No
If ‘Yes,’ check a box below to indicate whether the financial statements for the year were compiled or reviewed on a separate basis, consolidated basis, or both:
b
Were the organization’s financial statements audited by an independent accountant?
2b
Yes
 
If ‘Yes,’ check a box below to indicate whether the financial statements for the year were audited on a separate basis, consolidated basis, or both:
c
If "Yes," to line 2a or 2b, does the organization have a committee that assumes responsibility for oversight of the audit, review, or compilation of its financial statements and selection of an independent accountant?
2c
Yes
 
If the organization changed either its oversight process or selection process during the tax year, explain in Schedule O.
3a
As a result of a federal award, was the organization required to undergo an audit or audits as set forth in the Single Audit Act and OMB Circular A-133?
3a
Yes
 
b
If "Yes," did the organization undergo the required audit or audits? If the organization did not undergo the required audit or audits, explain why in Schedule O and describe any steps taken to undergo such audits.
3b
Yes
 
Form 990 (2021)
Form 990 (2021)
Additional Data


Software ID:  
Software Version:  
Form 990, Special Condition Description:
Special Condition Description
SCHEDULE A
(Form 990)

Department of the Treasury
Internal Revenue Service
Public Charity Status and Public Support
Complete if the organization is a section 501(c)(3) organization or a section 4947(a)(1) nonexempt charitable trust.
right arrow Attach to Form 990 or Form 990-EZ.
right arrow Go to www.irs.gov/Form990 for instructions and the latest information.
OMB No. 1545-0047
2021
Open to Public
Inspection
Name of the organization
PATH
 
Employer identification number

91-1157127
Part I
Reason for Public Charity Status (All organizations must complete this part.) See instructions.
The organization is not a private foundation because it is: (For lines 1 through 12, check only one box.)
1
2
3
4
5
6
7
8
9
10
11
12
a
b
c
d
e
f
Enter the number of supported organizations ...............................  
g
Provide the following information about the supported organization(s).
(i) Name of supported organization (ii) EIN (iii) Type of organization (described on lines 1- 10 above (see instructions)) (iv) Is the organization listed in your governing document? (v) Amount of monetary support (see instructions) (vi) Amount of other support (see instructions)
Yes No
Total
 
   
For Paperwork Reduction Act Notice, see the Instructions for
Form 990 or 990-EZ.
Cat. No. 11285F
Schedule A (Form 990) 2021

Schedule A (Form 990) 2021
Page 2
Part II
Support Schedule for Organizations Described in Sections 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)
(Complete only if you checked the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III. If the organization failed to qualify under the tests listed below, please complete Part III.)
Section A. Public Support
Calendar year (or fiscal year beginning in) right arrow (a) 2017 (b) 2018 (c) 2019 (d) 2020 (e) 2021 (f) Total
1 Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grant.") .. 347,844,394 305,316,107 286,808,545 287,454,383 333,068,959 1,560,492,388
2 Tax revenues levied for the organization's benefit and either paid to or expended on its behalf....            
3 The value of services or facilities furnished by a governmental unit to the organization without charge..            
4 Total. Add lines 1 through 3 347,844,394 305,316,107 286,808,545 287,454,383 333,068,959 1,560,492,388
5 The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f) .. 717,318,521
6 Public support. Subtract line 5 from line 4. 843,173,867
Section B. Total Support
Calendar year (or fiscal year beginning in) right arrow (a) 2017 (b) 2018 (c) 2019 (d) 2020 (e) 2021 (f) Total
7 Amounts from line 4.. 347,844,394 305,316,107 286,808,545 287,454,383 333,068,959 1,560,492,388
8 Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources... 2,050,888 2,963,587 6,310,221 12,207,084 8,920,472 32,452,252
9 Net income from unrelated business activities, whether or not the business is regularly carried on..            
10 Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.).. 5,225,302 980,560 836,870 1,030,112 843,270 8,916,114
11 Total support. Add lines 7 through 10 1,601,860,754
12
12
45,487
13
First 5 years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and stop here ........................................right arrow
Section C. Computation of Public Support Percentage
14
14
52.640 %
15
15
53.680 %
16a
b
17a
b
18
Private foundation. If the organization did not check a box on line 13, 16a, 16b, 17a, or 17b, check this box and see
instructions ..................................................... right arrow
Schedule A (Form 990) 2021

Schedule A (Form 990) 2021
Page 3
Part III
Support Schedule for Organizations Described in Section 509(a)(2)
(Complete only if you checked the box on line 10 of Part I or if the organization failed to qualify under Part II. If the organization fails to qualify under the tests listed below, please complete Part II.)
Section A. Public Support
Calendar year (or fiscal year beginning in) right arrow (a) 2017 (b) 2018 (c) 2019 (d) 2020 (e) 2021 (f) Total
1 Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .            
2 Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose            
3 Gross receipts from activities that are not an unrelated trade or business under section 513 .....            
4 Tax revenues levied for the organization's benefit and either paid to or expended on its behalf...            
5 The value of services or facilities furnished by a governmental unit to the organization without charge            
6 Total. Add lines 1 through 5            
7a Amounts included on lines 1, 2, and 3 received from disqualified persons            
b Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year.            
c Add lines 7a and 7b..            
8 Public support. (Subtract line 7c from line 6.)  
Section B. Total Support
Calendar year (or fiscal year beginning in) right arrow (a) 2017 (b) 2018 (c) 2019 (d) 2020 (e) 2021 (f) Total
9 Amounts from line 6...            
10a Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources..            
b Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975.            
c Add lines 10a and 10b.            
11 Net income from unrelated business activities not included on line 10b, whether or not the business is regularly carried on.            
12 Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI.) ..            
13 Total support. (Add lines 9, 10c, 11, and 12.)..            
14
Section C. Computation of Public Support Percentage
15
15
 
16
16
 
Section D. Computation of Investment Income Percentage
17
17
 
18
18
 
19a
b
20
Schedule A (Form 990) 2021

Schedule A (Form 990) 2021
Page 4
Part IV
Supporting Organizations
(Complete only if you checked a box on line 12 of Part I. If you checked box 12a, of Part I, complete Sections A and B. If you checked box 12b, of Part I, complete Sections A and C. If you checked box 12c, of Part I, complete Sections A, D, and E. If you checked box12d, of Part I, complete Sections A and D, and complete Part V.)
Section A. All Supporting Organizations
Yes
No
1
Are all of the organization’s supported organizations listed by name in the organization’s governing documents?
If "No," describe in Part VI how the supported organizations are designated. If designated by class or purpose,
describe the designation. If historic and continuing relationship, explain.
1
 
 
2
Did the organization have any supported organization that does not have an IRS determination of status under section 509(a)(1) or (2)? If "Yes," explain in Part VI how the organization determined that the supported organization was described in section 509(a)(1) or (2).
2
 
 
3a
Did the organization have a supported organization described in section 501(c)(4), (5), or (6)? If "Yes," answer lines 3b and 3c below.
3a
 
 
b
Did the organization confirm that each supported organization qualified under section 501(c)(4), (5), or (6) and satisfied the public support tests under section 509(a)(2)? If "Yes," describe in Part VI when and how the organization made the determination.
3b
 
 
c
Did the organization ensure that all support to such organizations was used exclusively for section 170(c)(2)(B) purposes? If "Yes," explain in Part VI what controls the organization put in place to ensure such use.
3c
 
 
4a
Was any supported organization not organized in the United States ("foreign supported organization")? If “Yes” and if you checked box 12a or 12b in Part I, answer lines 4b and 4c below.
4a
 
 
b
Did the organization have ultimate control and discretion in deciding whether to make grants to the foreign supported organization? If “Yes,” describe in Part VI how the organization had such control and discretion despite being controlled or supervised by or in connection with its supported organizations.
4b
 
 
c
Did the organization support any foreign supported organization that does not have an IRS determination under sections 501(c)(3) and 509(a)(1) or (2)? If “Yes,” explain in Part VI what controls the organization used to ensure that all support to the foreign supported organization was used exclusively for section 170(c)(2)(B) purposes.
4c
 
 
5a
Did the organization add, substitute, or remove any supported organizations during the tax year? If “Yes,” answer lines 5b and 5c below (if applicable). Also, provide detail in Part VI, including (i) the names and EIN numbers of the supported organizations added, substituted, or removed; (ii) the reasons for each such action; (iii) the authority under the organization's organizing document authorizing such action; and (iv) how the action was accomplished (such as by amendment to the organizing document).
5a
 
 
b
Type I or Type II only. Was any added or substituted supported organization part of a class already designated in the organization's organizing document?
5b
 
 
c
Substitutions only. Was the substitution the result of an event beyond the organization's control?
5c
 
 
6
Did the organization provide support (whether in the form of grants or the provision of services or facilities) to anyone other than (i) its supported organizations, (ii) individuals that are part of the charitable class benefited by one or more of its supported organizations, or (iii) other supporting organizations that also support or benefit one or more of the filing organization’s supported organizations? If “Yes,” provide detail in Part VI.
6
 
 
7
Did the organization provide a grant, loan, compensation, or other similar payment to a substantial contributor (defined in section 4958(c)(3)(C)), a family member of a substantial contributor, or a 35% controlled entity with regard to a substantial contributor? If “Yes,” complete Part I of Schedule L (Form 990) .
7
 
 
8
Did the organization make a loan to a disqualified person (as defined in section 4958) not described on line 7? If “Yes,” complete Part I of Schedule L (Form 990).
8
 
 
9a
Was the organization controlled directly or indirectly at any time during the tax year by one or more disqualified persons, as defined in section 4946 (other than foundation managers and organizations described in section 509(a)(1) or (2))? If “Yes,” provide detail in Part VI.
9a
 
 
b
Did one or more disqualified persons (as defined on line 9a) hold a controlling interest in any entity in which the supporting organization had an interest? If “Yes,” provide detail in Part VI.
9b
 
 
c
Did a disqualified person (as defined on line 9a) have an ownership interest in, or derive any personal benefit from, assets in which the supporting organization also had an interest? If “Yes,” provide detail in Part VI.
9c
 
 
10a
Was the organization subject to the excess business holdings rules of section 4943 because of section 4943(f) (regarding certain Type II supporting organizations, and all Type III non-functionally integrated supporting organizations)? If “Yes,” answer line 10b below.
10a
 
 
b
Did the organization have any excess business holdings in the tax year? (Use Schedule C, Form 4720, to determine whether the organization had excess business holdings).
10b
 
 
Schedule A (Form 990) 2021

Schedule A (Form 990) 2021
Page 5
Part IV
Supporting Organizations (continued)
Yes
No
11
Has the organization accepted a gift or contribution from any of the following persons?
a
A person who directly or indirectly controls, either alone or together with persons described on lines 11b and 11c below, the governing body of a supported organization?
11a
 
 
b
A family member of a person described on 11a above?
11b
 
 
c
A 35% controlled entity of a person described on line 11a or 11b above? If “Yes” to 11a, 11b, or 11c, provide detail in Part VI.
11c
 
 
Section B. Type I Supporting Organizations
Yes
No
1
Did the officers, directors, trustees, or membership of one or more supported organizations have the power to regularly appoint or elect at least a majority of the organization’s directors or trustees at all times during the tax year? If “No,” describe in Part VI how the supported organization(s) effectively operated, supervised, or controlled the organization’s activities. If the organization had more than one supported organization, describe how the powers to appoint and/or remove directors or trustees were allocated among the supported organizations and what conditions or restrictions, if any, applied to such powers during the tax year.
1
 
 
2
Did the organization operate for the benefit of any supported organization other than the supported organization(s) that operated, supervised, or controlled the supporting organization? If “Yes,” explain in Part VI how providing such benefit carried out the purposes of the supported organization(s) that operated, supervised or controlled the supporting organization.
2
 
 
Section C. Type II Supporting Organizations
Yes
No
1
Were a majority of the organization’s directors or trustees during the tax year also a majority of the directors or trustees of each of the organization’s supported organization(s)? If “No,” describe in Part VI how control or management of the supporting organization was vested in the same persons that controlled or managed the supported organization(s).
1
 
 
Section D. All Type III Supporting Organizations
Yes
No
1
Did the organization provide to each of its supported organizations, by the last day of the fifth month of the organization’s tax year, (i) a written notice describing the type and amount of support provided during the prior tax year, (ii) a copy of the Form 990 that was most recently filed as of the date of notification, and (iii) copies of the organization’s governing documents in effect on the date of notification, to the extent not previously provided?
1
 
 
2
Were any of the organization’s officers, directors, or trustees either (i) appointed or elected by the supported organization(s) or (ii) serving on the governing body of a supported organization? If "No," explain in Part VI how the organization maintained a close and continuous working relationship with the supported organization(s).
2
 
 
3
By reason of the relationship described in line 2 above, did the organization’s supported organizations have a significant voice in the organization’s investment policies and in directing the use of the organization’s income or assets at all times during the tax year? If "Yes," describe in Part VI the role the organization’s supported organizations played in this regard.
3
 
 
Section E. Type III Functionally-Integrated Supporting Organizations
1
Check the box next to the method that the organization used to satisfy the Integral Part Test during the year (see instructions):
a
b
c
2
Activities Test. Answer lines 2a and 2b below.
Yes
No
a
Did substantially all of the organization’s activities during the tax year directly further the exempt purposes of the supported organization(s) to which the organization was responsive? If "Yes," then in Part VI identify those supported organizations and explain how these activities directly furthered their exempt purposes, how the organization was responsive to those supported organizations, and how the organization determined that these activities constituted substantially all of its activities.
2a
 
 
b
Did the activities described on line 2a, above constitute activities that, but for the organization’s involvement, one or more of the organization’s supported organization(s) would have been engaged in? If "Yes," explain in Part VI the reasons for the organization’s position that its supported organization(s) would have engaged in these activities but for the organization’s involvement.
2b
 
 
3
Parent of Supported Organizations. Answer lines 3a and 3b below.
a
Did the organization have the power to regularly appoint or elect a majority of the officers, directors, or trustees of each of the supported organizations?If "Yes" or "No", provide details in Part VI.
3a
 
 
b
Did the organization exercise a substantial degree of direction over the policies, programs and activities of each of its supported organizations? If "Yes," describe in Part VI. the role played by the organization in this regard.
3b
 
 
Schedule A (Form 990) 2021

Schedule A (Form 990) 2021
Page 6
Part V
Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations
1
Section A - Adjusted Net Income (A) Prior Year (B) Current Year
(optional)
1 Net short-term capital gain 1    
2 Recoveries of prior-year distributions 2    
3 Other gross income (see instructions) 3    
4 Add lines 1 through 3 4    
5 Depreciation and depletion 5    
6 Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions) 6    
7 Other expenses (see instructions) 7    
8 Adjusted Net Income (subtract lines 5, 6 and 7 from line 4) 8    
Section B - Minimum Asset Amount (A) Prior Year (B) Current Year
(optional)
1 Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year): 1
a Average monthly value of securities 1a    
b Average monthly cash balances 1b    
c Fair market value of other non-exempt-use assets 1c    
d Total (add lines 1a, 1b, and 1c) 1d    
e Discount claimed for blockage or other factors
(explain in detail in Part VI):  
2 Acquisition indebtedness applicable to non-exempt use assets 2    
3 Subtract line 2 from line 1d 3    
4 Cash deemed held for exempt use. Enter 0.015 of line 3 (for greater amount, see instructions). 4    
5 Net value of non-exempt-use assets (subtract line 4 from line 3) 5    
6 Multiply line 5 by 0.035 6    
7 Recoveries of prior-year distributions 7    
8 Minimum Asset Amount (add line 7 to line 6) 8    
Section C - Distributable Amount Current Year
1 Adjusted net income for prior year (from Section A, line 8, Column A) 1  
2 Enter 85% of line 1 2  
3 Minimum asset amount for prior year (from Section B, line 8, Column A) 3  
4 Enter greater of line 2 or line 3 4  
5 Income tax imposed in prior year 5  
6 Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions) 6  
7
Schedule A (Form 990) 2021

Schedule A (Form 990) 2021
Page 7
Part V
Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations(continued)
Section D - Distributions Current Year
1 Amounts paid to supported organizations to accomplish exempt purposes 1  
2 Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in
excess of income from activity
2  
3 Administrative expenses paid to accomplish exempt purposes of supported organizations 3  
4 Amounts paid to acquire exempt-use assets 4  
5 Qualified set-aside amounts (prior IRS approval required - provide details in Part VI) 5  
6 Other distributions (describe in Part VI). See instructions 6  
7Total annual distributions. Add lines 1 through 6. 7  
8 Distributions to attentive supported organizations to which the organization is responsive (provide
details in Part VI
). See instructions
8  
9 Distributable amount for 2021 from Section C, line 6 9  
10 Line 8 amount divided by Line 9 amount 10  
Section E - Distribution Allocations (see instructions) (i)
Excess Distributions
(ii)
Underdistributions
Pre-2021
(iii)
Distributable
Amount for 2021
1 Distributable amount for 2021 from Section C, line 6  
2 Underdistributions, if any, for years prior to 2021 (reasonable cause required-- explain in Part VI).
See instructions.
 
3 Excess distributions carryover, if any, to 2021:
a From 2016.......  
b From 2017.......  
c From 2018.......  
d From 2019.......  
e From 2020.......  
fTotal of lines 3a through e  
g Applied to underdistributions of prior years  
h Applied to 2021 distributable amount  
i Carryover from 2016 not applied (see
instructions)
 
j Remainder. Subtract lines 3g, 3h, and 3i from line 3f.  
4Distributions for 2021 from Section D, line 7:
$  
a Applied to underdistributions of prior years  
b Applied to 2021 distributable amount  
c Remainder. Subtract lines 4a and 4b from line 4.  
5 Remaining underdistributions for years prior to
2021, if any. Subtract lines 3g and 4a from line 2.
If the amount is greater than zero, explain in Part VI.
See instructions.
 
6 Remaining underdistributions for 2021. Subtract
lines 3h and 4b from line 1. If the amount is greater
than zero, explain in Part VI. See instructions.
 
7 Excess distributions carryover to 2022. Add lines
3j and 4c.
 
8 Breakdown of line 7:
a Excess from 2017.....  
b Excess from 2018.....  
c Excess from 2019.....  
d Excess from 2020.....  
e Excess from 2021.....  
Schedule A (Form 990) (2021)

Schedule A (Form 990) 2021
Page 8
Part VI
Supplemental Information. Provide the explanations required by Part II, line 10; Part II, line 17a or 17b; Part III, line 12; Part IV, Section A, lines 1, 2, 3b, 3c, 4b, 4c, 5a, 6, 9a, 9b, 9c, 11a, 11b, and 11c; Part IV, Section B, lines 1 and 2; Part IV, Section C, line 1; Part IV, Section D, lines 2 and 3; Part IV, Section E, lines 1c, 2a, 2b, 3a and 3b; Part V, line 1; Part V, Section B, line 1e; Part V Section D, lines 5, 6, and 8; and Part V, Section E, lines 2, 5, and 6. Also complete this part for any additional information. (See instructions).
Facts And Circumstances Test
 
Return Reference Explanation
Schedule A (Form 990) 2021


Additional Data


Software ID:  
Software Version:  
Schedule B
(Form 990)
Department of the Treasury
Internal Revenue Service
Schedule of Contributors

Arrow Bullet Attach to Form 990, 990-EZ, or 990-PF.
Arrow Bullet Go to www.irs.gov/Form990 for the latest information.
OMB No. 1545-0047
2021
Name of the organization
PATH
 
Employer identification number

91-1157127
Organization type (check one):
Filers of:
Section:
Form 990 or 990-EZ






Form 990-PF




Check if your organization is covered by the General Rule or a Special Rule.  
Note: Only a section 501(c)(7), (8), or (10) organization can check boxes for both the General Rule and a Special Rule. See instructions.
General Rule
Special Rules
......... Arrow Bullet $  
Caution: An organization that isn't covered by the General Rule and/or the Special Rules doesn't file Schedule B (Form 990,
990-EZ, or 990-PF), but it must answer “No” on Part IV, line 2, of its Form 990; or check the box on line H of its Form 990-EZ
or on its Form 990PF, Part I, line 2, to certify that it doesn't meet the filing requirements of Schedule B (Form 990,
990-EZ, or 990-PF).
For Paperwork Reduction Act Notice, see the Instructions
for Form 990, 990-EZ, or 990-PF.
Cat. No. 30613XSchedule B (Form 990) (2021)
Schedule B (Form 990) (2021) Page 2
Name of organization
PATH
 
Employer identification number
91-1157127
Part I
Contributors
Contributors (see instructions). Use duplicate copies of Part I if additional space is needed.
(a)
No.
(b)
Name, address, and ZIP + 4
(c)
Total contributions
(d)
Type of contribution
RESTRICTED
 
 
 
 
  ,    

$ RESTRICTED


(Complete Part II for noncash contributions.)
(a)
No.
(b)
Name, address, and ZIP + 4
(c)
Total contributions
(d)
Type of contribution
 
 
 
 

$  


(Complete Part II for noncash contributions.)
(a)
No.
(b)
Name, address, and ZIP + 4
(c)
Total contributions
(d)
Type of contribution
 
 
 
 

$  


(Complete Part II for noncash contributions.)
(a)
No.
(b)
Name, address, and ZIP + 4
(c)
Total contributions
(d)
Type of contribution
 
 
 
 

$  


(Complete Part II for noncash contributions.)
(a)
No.
(b)
Name, address, and ZIP + 4
(c)
Total contributions
(d)
Type of contribution
 
 
 
 

$  


(Complete Part II for noncash contributions.)
(a)
No.
(b)
Name, address, and ZIP + 4
(c)
Total contributions
(d)
Type of contribution
 
 
 
 

$  


(Complete Part II for noncash contributions.)
Schedule B (Form 990) (2021)
Schedule B (Form 990) (2021)
Page 3
Name of organization
PATH
 
Employer identification number

91-1157127
Part II
Noncash Property (see instructions). Use duplicate copies of Part II if additional space is needed.
(a)
No. from Part I
(b)
Description of noncash property given
(c)
FMV (or estimate)
(See instructions)
(d)
Date received
 
$    
(a)
No. from Part I
(b)
Description of noncash property given
(c)
FMV (or estimate)
(See instructions)
(d)
Date received
 
$    
(a)
No. from Part I
(b)
Description of noncash property given
(c)
FMV (or estimate)
(See instructions)
(d)
Date received
 
$    
(a)
No. from Part I
(b)
Description of noncash property given
(c)
FMV (or estimate)
(See instructions)
(d)
Date received
 
$    
(a)
No. from Part I
(b)
Description of noncash property given
(c)
FMV (or estimate)
(See instructions)
(d)
Date received
 
$    
(a)
No. from Part I
(b)
Description of noncash property given
(c)
FMV (or estimate)
(See instructions)
(d)
Date received
 
$    
Schedule B (Form 990) (2021)
Schedule B (Form 990) (2021)
Page 4
Name of organization
PATH
 
Employer identification number

91-1157127
Part III
Exclusively religious, charitable, etc., contributions to organizations described in section 501(c)(7), (8), or (10) that total more than $1,000 for the year from any one contributor. Complete columns (a) through (e) and the following line entry. For organizations completing Part III, enter the total of exclusively religious, charitable, etc., contributions of $1,000 or less for the year. (Enter this information once. See instructions.) Arrow Bullet$  
Use duplicate copies of Part III if additional space is needed.
(a)
No. from Part I
(b) Purpose of gift (c) Use of gift (d) Description of how gift is held
 
(e) Transfer of gift
Transferee's name, address, and ZIP 4 Relationship of transferor to transferee
 
 
     
 
(a)
No. from Part I
(b) Purpose of gift (c) Use of gift (d) Description of how gift is held
 
(e) Transfer of gift
Transferee's name, address, and ZIP 4 Relationship of transferor to transferee
 
 
     
 
(a)
No. from Part I
(b) Purpose of gift (c) Use of gift (d) Description of how gift is held
 
(e) Transfer of gift
Transferee's name, address, and ZIP 4 Relationship of transferor to transferee
 
 
     
 
(a)
No. from Part I
(b) Purpose of gift (c) Use of gift (d) Description of how gift is held
 
(e) Transfer of gift
Transferee's name, address, and ZIP 4 Relationship of transferor to transferee
 
 
     
 
Schedule B (Form 990) (2021)
Additional Data


Software ID:  
Software Version:  
SCHEDULE C
(Form 990)

Department of the Treasury
Internal Revenue Service
Political Campaign and Lobbying Activities

For Organizations Exempt From Income Tax Under section 501(c) and section 527

SchCMd Bullet Complete if the organization is described below. SchCMd Bullet Attach to Form 990 or Form 990-EZ.
SchCMd BulletGo to www.irs.gov/Form990 for instructions and the latest information.
OMB No. 1545-0047
2021
Open to Public
Inspection
If the organization answered "Yes" on Form 990, Part IV, Line 3, or Form 990-EZ, Part V, line 46 (Political Campaign Activities), then
Round Bullet Section 501(c)(3) organizations: Complete Parts I-A and B. Do not complete Part I-C.
Round Bullet Section 501(c) (other than section 501(c)(3)) organizations: Complete Parts I-A and C below. Do not complete Part I-B.
Round Bullet Section 527 organizations: Complete Part I-A only.
If the organization answered "Yes" on Form 990, Part IV, Line 4, or Form 990-EZ, Part VI, line 47 (Lobbying Activities), then
Round Bullet Section 501(c)(3) organizations that have filed Form 5768 (election under section 501(h)): Complete Part II-A. Do not complete Part II-B.
Round Bullet Section 501(c)(3) organizations that have NOT filed Form 5768 (election under section 501(h)): Complete Part II-B. Do not complete Part II-A.
If the organization answered "Yes" on Form 990, Part IV, Line 5 (Proxy Tax) (see separate instructions) or Form 990-EZ, Part V, line 35c (Proxy Tax) (see separate instructions), then
Round Bullet Section 501(c)(4), (5), or (6) organizations: Complete Part III.
Name of the organization
PATH
 
Employer identification number

91-1157127
Part I-A
Complete if the organization is exempt under section 501(c) or is a section 527 organization.

1
Provide a description of the organization’s direct and indirect political campaign activities in Part IV. See instructions for definition of “political campaign activities."

2
Political campaign activity expenditures. See instructions ....................................................................SchCMd Bullet
$  
3
Volunteer hours for political campaign activities. See instructions ..................................................................
 

Part I-B
Complete if the organization is exempt under section 501(c)(3).
1
Enter the amount of any excise tax incurred by the organization under section 4955 ................................SchCMd Bullet
$  
2
Enter the amount of any excise tax incurred by organization managers under section 4955 .......................SchCMd Bullet
$  
3
If the organization incurred a section 4955 tax, did it file Form 4720 for this year? .........................................
4a
Was a correction made? ......................................................................................................................
b
If "Yes," describe in Part IV.
Part I-C
Complete if the organization is exempt under section 501(c), except section 501(c)(3).
1
Enter the amount directly expended by the filing organization for section 527 exempt function activities ..... SchCMd Bullet
$  
2
Enter the amount of the filing organization's funds contributed to other organizations for section 527 exempt function activities ............................................................................................................................SchCMd Bullet

$  
3
Total exempt function expenditures. Add lines 1 and 2. Enter here and on Form 1120-POL, line 17b...........SchCMd Bullet

$  
4
Did the filing organization file Form 1120-POL for this year? ...................................................................
5
Enter the names, addresses and employer identification number (EIN) of all section 527 political organizations to which the filing
organization made payments. For each organization listed, enter the amount paid from the filing organization’s funds. Also enter the amount of political contributions received that were promptly and directly delivered to a separate political organization, such as a separate segregated fund or a political action committee (PAC). If additional space is needed, provide information in Part IV.
(a) Name (b) Address (c) EIN (d) Amount paid from filing organization's funds. If none, enter -0-. (e) Amount of political contributions received and promptly and directly delivered to a separate political organization. If none, enter -0-.
1
2
3
4
5
6
For Paperwork Reduction Act Notice, see the instructions for Form 990.
Cat. No. 50084S
Schedule C (Form 990) 2021

Schedule C (Form 990) 2021
Page 2
Part II-A
Complete if the organization is exempt under section 501(c)(3) and filed Form 5768 (election under section 501(h)).
A Check SchCMd Bulletexpenses, and share of excess lobbying expenditures).
B Check SchCMd Bullet
Limits on Lobbying Expenditures
(The term "expenditures" means amounts paid or incurred.)
(a) Filing
organization's
totals
(b) Affiliated group totals
1a Total lobbying expenditures to influence public opinion (grass roots lobbying) ...................... 29,340  
b Total lobbying expenditures to influence a legislative body (direct lobbying) ........................ 177,826  
c Total lobbying expenditures (add lines 1a and 1b) ............................................................ 207,166  
d Other exempt purpose expenditures ............................................................................... 335,137,463  
e Total exempt purpose expenditures (add lines 1c and 1d) .................................................. 335,344,629  
f Lobbying nontaxable amount. Enter the amount from the following table in both
columns.
1,000,000  
If the amount on line 1e, column (a) or (b) is:The lobbying nontaxable amount is:
Not over $500,00020% of the amount on line 1e.
Over $500,000 but not over $1,000,000$100,000 plus 15% of the excess over $500,000.
Over $1,000,000 but not over $1,500,000$175,000 plus 10% of the excess over $1,000,000.
Over $1,500,000 but not over $17,000,000$225,000 plus 5% of the excess over $1,500,000.
Over $17,000,000$1,000,000.
g Grassroots nontaxable amount (enter 25% of line 1f) ................................................. 250,000  
h Subtract line 1g from line 1a. If zero or less, enter -0-. ................................................ 0  
i Subtract line 1f from line 1c. If zero or less, enter -0-. ................................................ 0  
j If there is an amount other than zero on either line 1h or line 1i, did the organization file Form 4720 reporting
section 4911 tax for this year? ...................................................................................................................

4-Year Averaging Period Under Section 501(h)
(Some organizations that made a section 501(h) election do not have to complete all of the five
columns below. See the separate instructions for lines 2a through 2f.)
Lobbying Expenditures During 4-Year Averaging Period
Calendar year (or fiscal year
beginning in)
(a) 2018 (b) 2019 (c) 2020 (d) 2021 (e) Total
2a Lobbying nontaxable amount 1,000,000 1,000,000 1,000,000 1,000,000 4,000,000
b Lobbying ceiling amount
(150% of line 2a, column(e))
6,000,000
c Total lobbying expenditures 224,944 163,912 135,193 207,166 731,215
d Grassroots nontaxable amount 250,000 250,000 250,000 250,000 1,000,000
e Grassroots ceiling amount
(150% of line 2d, column (e))
1,500,000
f Grassroots lobbying expenditures 7,856   405 29,340 37,601
Schedule C (Form 990) 2021


Schedule C (Form 990) 2021
Page 3
Part II-B
Complete if the organization is exempt under section 501(c)(3) and has NOT filed Form 5768 (election under section 501(h)).
For each "Yes" response on lines 1a through 1i below, provide in Part IV a detailed description of the lobbying activity.
(a)
Yes|No
(b)
Amount
1
During the year, did the filing organization attempt to influence foreign, national, state or local legislation, including any attempt to influence public opinion on a legislative matter or referendum, through the use of:
a
Volunteers? ...........................................................................................................
 
 
b
Paid staff or management (include compensation in expenses reported on lines 1c through 1i)? ........
 
 
c
Media advertisements? ...................................................................................................
 
 
 
d
Mailings to members, legislators, or the public? .............................................................................
 
 
 
e
Publications, or published or broadcast statements? ...........................................................
 
 
 
f
Grants to other organizations for lobbying purposes? ..........................................................
 
 
 
g
Direct contact with legislators, their staffs, government officials, or a legislative body? .......................
 
 
 
h
Rallies, demonstrations, seminars, conventions, speeches, lectures, or any similar means? ..................
 
 
 
i
Other activities? ...................................................................................................................
 
 
 
j
Total. Add lines 1c through 1i ....................................................................................................
 
2a
Did the activities in line 1 cause the organization to be not described in section 501(c)(3)? .....
 
 
b
If "Yes," enter the amount of any tax incurred under section 4912 ...........................................
 
c
If "Yes," enter the amount of any tax incurred by organization managers under section 4912 ...................
 
d
If the filing organization incurred a section 4912 tax, did it file Form 4720 for this year? ........................
 
 
Part III-A
Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6).
Yes
No
1
Were substantially all (90% or more) dues received nondeductible by members? ...............................................
1
 
 
2
Did the organization make only in-house lobbying expenditures of $2,000 or less? ............................................
2
 
 
3
Did the organization agree to carry over lobbying and political expenditures from the prior year? .................................
3
 
 
Part III-B
Complete if the organization is exempt under section 501(c)(4), section 501(c)(5), or section 501(c)(6) and if either (a) BOTH Part III-A, lines 1 and 2, are answered "No" OR (b) Part III-A, line 3, is answered “Yes."
1
Dues, assessments and similar amounts from members ......................................................................
1
 
2
Section 162(e) nondeductible lobbying and political expenditures (do not include amounts of political expenses for which the section 527(f) tax was paid).
a
Current year .............................................................................................................................
2a
 
b
Carryover from last year ............................................................................................................
2b
 
c
Total ...........................................................................................................................................
2c
 
3
Aggregate amount reported in section 6033(e)(1)(A) notices of nondeductible section 162(e) dues .
3
 
4
If notices were sent and the amount on line 2c exceeds the amount on line 3, what portion of the excess does the organization agree to carryover to the reasonable estimate of nondeductible lobbying and political expenditure next year? ......................................................................................................................
4
 
5
Taxable amount of lobbying and political expenditures. See Instructions .........................................
5
 
Part IV
Supplemental Information
Provide the descriptions required for Part l-A, line 1; Part l-B, line 4; Part l-C, line 5; Part II-A (affiliated group list); Part II-A, lines 1 and 2 (see instructions), and Part ll-B, line 1. Also, complete this part for any additional information.
Return Reference Explanation
Schedule C (Form 990) 2021


Additional Data


Software ID:  
Software Version:  

SCHEDULE D
(Form 990)
Department of the Treasury
Internal Revenue Service
Supplemental Financial Statements
SchDMd Bullet Complete if the organization answered "Yes," on Form 990,
Part IV, line 6, 7, 8, 9, 10, 11a, 11b, 11c, 11d, 11e, 11f, 12a, or 12b.
SchDMd Bullet Attach to Form 990.
SchDMd Bullet Go to www.irs.gov/Form990 for instructions and the latest information.
OMB No. 1545-0047
2021
Open to Public Inspection
Name of the organization
PATH
 
Employer identification number

91-1157127
Part I
Organizations Maintaining Donor Advised Funds or Other Similar Funds or Accounts. Complete if the organization answered "Yes" on Form 990, Part IV, line 6.
(a) Donor advised funds (b) Funds and other accounts
1 Total number at end of year .........    
2 Aggregate value of contributions to (during year)    
3 Aggregate value of grants from (during year)    
4 Aggregate value at end of year ........    
5
Did the organization inform all donors and donor advisors in writing that the assets held in donor advised funds are the organization’s property, subject to the organization’s exclusive legal control? ............
6
Did the organization inform all grantees, donors, and donor advisors in writing that grant funds can be used only for charitable purposes and not for the benefit of the donor or donor advisor, or for any other purpose conferring impermissible private benefit? ...................................
Part II
Conservation Easements.
Complete if the organization answered "Yes" on Form 990, Part IV, line 7.
1
Purpose(s) of conservation easements held by the organization (check all that apply).
2
Complete lines 2a through 2d if the organization held a qualified conservation contribution in the form of a conservation easement on the last day of the tax year.
Held at the End of the Year
a Total number of conservation easements ...................... 2a  
b Total acreage restricted by conservation easements .................... 2b  
c Number of conservation easements on a certified historic structure included in (a) ..... 2c  
d Number of conservation easements included in (c) acquired after 7/25/06, and not on a historic structure listed in the National Register ... 2d  
3
Number of conservation easements modified, transferred, released, extinguished, or terminated by the organization during the
tax year SchDMd Bullet  
4
Number of states where property subject to conservation easement is located SchDMd Bullet  
5
Does the organization have a written policy regarding the periodic monitoring, inspection, handling of violations, and enforcement of the conservation easements it holds? ............
6
Staff and volunteer hours devoted to monitoring, inspecting, handling of violations, and enforcing conservation easements during the year
SchDMd Bullet  
7
Amount of expenses incurred in monitoring, inspecting, handling of violations, and enforcing conservation easements during the year
SchDMd Bullet $  
8
Does each conservation easement reported on line 2(d) above satisfy the requirements of section 170(h)(4)(B)(i) and section 170(h)(4)(B)(ii)? .............................
9
In Part XIII, describe how the organization reports conservation easements in its revenue and expense statement, and
balance sheet, and include, if applicable, the text of the footnote to the organization’s financial statements that describes
the organization’s accounting for conservation easements.
Part III
Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets.
Complete if the organization answered "Yes" on Form 990, Part IV, line 8.
1a
If the organization elected, as permitted under FASB ASC 958, not to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide, in Part XIII, the text of the footnote to its financial statements that describes these items.
b
If the organization elected, as permitted under FASB ASC 958, to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide the following amounts relating to these items:
(i)
Revenue included on Form 990, Part VIII, line 1 .........................SchDMd Bullet $  
(ii)
Assets included in Form 990, Part X ...............................SchDMd Bullet $  
2
If the organization received or held works of art, historical treasures, or other similar assets for financial gain, provide the
following amounts required to be reported under FASB ASC 958 relating to these items:
a
Revenue included on Form 990, Part VIII, line 1 ..........................SchDMd Bullet $  
b
Assets included in Form 990, Part X ...............................SchDMd Bullet $  
For Paperwork Reduction Act Notice, see the Instructions for Form 990.
Cat. No. 52283D
Schedule D (Form 990) 2021

Schedule D (Form 990) 2021
Page 2
Part III
Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets (continued)
3
Using the organization’s acquisition, accession, and other records, check any of the following that are a significant use of its collection items (check all that apply):
a
d
b
e
 
c
4
Provide a description of the organization’s collections and explain how they further the organization’s exempt purpose in
Part XIII.
5
During the year, did the organization solicit or receive donations of art, historical treasures or other similar
assets to be sold to raise funds rather than to be maintained as part of the organization’s collection?...
Part IV
Escrow and Custodial Arrangements. Complete if the organization answered "Yes" on Form 990, Part IV, line 9, or reported an amount on Form 990, Part X, line 21.
1a
Is the organization an agent, trustee, custodian or other intermediary for contributions or other assets not
included on Form 990, Part X? ....................................
b If "Yes," explain the arrangement in Part XIII and complete the following table: Amount
c Beginning balance ............................. 1c  
d Additions during the year ............................ 1d  
e Distributions during the year .......................... 1e  
f Ending balance ................................ 1f  
2a
Did the organization include an amount on Form 990, Part X, line 21, for escrow or custodial account liability? ...
b
If "Yes," explain the arrangement in Part XIII. Check here if the explanation has been provided in Part XIII ....
Part V
Endowment Funds.
Complete if the organization answered "Yes" on Form 990, Part IV, line 10.
(a) Current year (b) Prior year (c) Two years back (d) Three years back (e) Four years back
1a Beginning of year balance .... 10,930,723 10,287,113 9,095,917 10,056,545 9,339,249
b Contributions ... 2,500 2,745 2,100 1,240 3,410
c Net investment earnings, gains, and losses 1,323,367 1,095,576 1,691,617 -494,491 1,159,282
d Grants or scholarships ...          
e Other expenditures for facilities
and programs ...
514,376 454,711 502,521 467,377 445,396
f Administrative expenses ....          
g End of year balance ...... 11,742,214 10,930,723 10,287,113 9,095,917 10,056,545
2
Provide the estimated percentage of the current year end balance (line 1g, column (a)) held as:
a
Board designated or quasi-endowment SchDMd Bullet36.000 %
b
Permanent endowment SchDMd Bullet29.000 %
c
Term endowment SchDMd Bullet35.000 %
The percentages on lines 2a, 2b, and 2c should equal 100%.
3a
Are there endowment funds not in the possession of the organization that are held and administered for the
organization by:

Yes
No
(i) Unrelated organizations .................
3a(i)
 
No
(ii) Related organizations .................
3a(ii)
 
No
b
If "Yes" on 3a(ii), are the related organizations listed as required on Schedule R? .........
3b
 
 
4
Describe in Part XIII the intended uses of the organization's endowment funds.
Part VI
Land, Buildings, and Equipment.
Complete if the organization answered "Yes" on Form 990, Part IV, line 11a. See Form 990, Part X, line 10.
Description of property (a) Cost or other basis
(investment)
(b) Cost or other basis (other) (c) Accumulated depreciation (d) Book value
1a Land .....      
b Buildings ....        
c Leasehold improvements   22,543,573 17,259,728 5,283,845
d Equipment ....   9,534,680 8,349,319 1,185,361
e Other .....   5,813,606 5,163,107 650,499
Total. Add lines 1a through 1e. (Column (d) must equal Form 990, Part X, column (B), line 10(c).)..SchDMdBullet 7,119,705
Schedule D (Form 990) 2021

Schedule D (Form 990) 2021
Page 3
Part VII
Investments - Other Securities.
Complete if the organization answered "Yes" on Form 990, Part IV, line 11b. See Form 990, Part X, line 12.
(a) Description of security or category
(including name of security)
(b) Book value (c) Method of valuation:
Cost or end-of-year market value
(1) Financial derivatives.........    
(2) Closely-held equity interests........    
(3)Other
(A)
(B)
(C)
(D)
(E)
(F)
(G)
(H)
Total. (Column (b) must equal Form 990, Part X, col. (B) line 12.)Small Bullet  
Part VIII
Investments - Program Related. Complete if the organization answered 'Yes' on Form 990, Part IV, line 11c. See Form 990, Part X, line 13.
(a) Description of investment (b) Book value (c) Method of valuation:
Cost or end-of-year market value
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
Total. (Column (b) must equal Form 990, Part X, col.(B) line 13.)Small Bullet  
Part IX
Other Assets.
Complete if the organization answered 'Yes' on Form 990, Part IV, line 11d. See Form 990, Part X, line 15.
(a) Description (b) Book value
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
Total. (Column (b) must equal Form 990, Part X, col.(B) line 15.)...........Small Bullet  
Part X
Other Liabilities.
Complete if the organization answered 'Yes' on Form 990, Part IV, line 11e or 11f. See Form 990, Part X, line 25.
1.(a) Description of liability (b) Book value
(1) Federal income taxes  
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
Total. (Column (b) must equal Form 990, Part X, col.(B) line 25.)Small Bullet  
2. Liability for uncertain tax positions. In Part XIII, provide the text of the footnote to the organization's financial statements that reports the organization's liability for uncertain tax positions under FIN 48 (ASC 740). Check here if the text of the footnote has been provided in Part XIII
Schedule D (Form 990) 2021

Schedule D (Form 990) 2021
Page 4
Part XI Reconciliation of Revenue per Audited Financial Statements With Revenue per Return. Complete if the organization answered 'Yes' on Form 990, Part IV, line 12a.
1 Total revenue, gains, and other support per audited financial statements ....... 1  
2 Amounts included on line 1 but not on Form 990, Part VIII, line 12:
a Net unrealized gains (losses) on investments .... 2a  
b Donated services and use of facilities ......... 2b  
c Recoveries of prior year grants ........... 2c  
d Other (Describe in Part XIII.) ............ 2d  
e Add lines 2a through 2d ..................... 2e  
3 Subtract line 2e from line 1.................. 3  
4 Amounts included on Form 990, Part VIII, line 12, but not on line 1:
a Investment expenses not included on Form 990, Part VIII, line 7b . 4a  
b Other (Describe in Part XIII.) ........... 4b  
c Add lines 4a and 4b.................... 4c  
5 Total revenue. Add lines 3 and 4c. (This must equal Form 990, Part I, line 12.) ...... 5  
Part XII Reconciliation of Expenses per Audited Financial Statements With Expenses per Return. Complete if the organization answered 'Yes' on Form 990, Part IV, line 12a.
1 Total expenses and losses per audited financial statements ........... 1  
2 Amounts included on line 1 but not on Form 990, Part IX, line 25:
a Donated services and use of facilities ......... 2a  
b Prior year adjustments ............ 2b  
c Other losses ................ 2c  
d Other (Describe in Part XIII.) ............ 2d  
e Add lines 2a through 2d.................... 2e  
3 Subtract line 2e from line 1................... 3  
4 Amounts included on Form 990, Part IX, line 25, but not on line 1:
a Investment expenses not included on Form 990, Part VIII, line 7b .. 4a  
b Other (Describe in Part XIII.) ............ 4b  
c Add lines 4a and 4b..................... 4c  
5 Total expenses. Add lines 3 and 4c. (This must equal Form 990, Part I, line 18.) ...... 5  
Part XIII
Supplemental Information
Provide the descriptions required for Part II, lines 3, 5, and 9; Part III, lines 1a and 4; Part lV, lines 1b and 2b; Part V, line 4; Part X, line 2; Part XI, lines 2d and 4b; and Part XII, lines 2d and 4b. Also complete this part to provide any additional information.
Return Reference Explanation
PART V, LINE 4: PATH UTILIZES THE INVESTED INTEREST EARNINGS FROM THE ENDOWMENT AS AN IMPORTANT FUNDING SOURCE TO FUND NEW OPPORTUNITIES TO EXPAND ITS REACH AND IMPACT AS AN ORGANIZATION IN THE FIELD OF GLOBAL HEALTH, IN ACCORDANCE WITH PATH'S ENDOWMENT SPENDING POLICY.
Schedule D (Form 990) 2021


Additional Data


Software ID:  
Software Version:  




SCHEDULE F(Form 990)
Department of the Treasury
Internal Revenue Service
Statement of Activities Outside the United States
Right pointing arrow large image Complete if the organization answered "Yes" to Form 990, Part IV, line 14b, 15, or 16.Right pointing arrow large image Attach to Form 990.Right pointing arrow large image Go to www.irs.gov/Form990 for instructions and the latest information.
OMB No. 1545-0047
2021
Open to Public Inspection
Name of the organization
PATH
 
Employer identification number

91-1157127
Part I
General Information on Activities Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 14b.
1
For grantmakers. Does the organization maintain records to substantiate the amount of its grants and
other assistance, the grantees’ eligibility for the grants or assistance, and the selection criteria used
to award the grants or assistance? . . . . . . . . . . . . . . . . . . . . . . . . .
2
For grantmakers. Describe in Part V the organization’s procedures for monitoring the use of its grants and other assistance outside the United States.
3
Activites per Region. (The following Part I, line 3 table can be duplicated if additional space is needed.)
(a) Region (b) Number of offices in the region (c) Number of employees, agents, and independent contractors in the region (d) Activities conducted in region (by type) (such as, fundraising, program services, investments, grants to recipients located in the region) (e) If activity listed in (d) is a program service, describe specific type of
service(s) in the region
(f) Total expenditures
for and investments
in the region
CENTRAL AMERICA AND THE CARIBBEAN 0 0 PROGRAM SERVICES AFRICA 217,383
CENTRAL AMERICA AND THE CARIBBEAN 0 0 PROGRAM SERVICES AMEE 165,240
CENTRAL AMERICA AND THE CARIBBEAN 0 0 BID & PROPOSAL BID & PROPOSAL 33,612
CENTRAL AMERICA AND THE CARIBBEAN 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 1,261,725
CENTRAL AMERICA AND THE CARIBBEAN 0 0 FUNDRAISING FUNDRAISING 109,157
CENTRAL AMERICA AND THE CARIBBEAN 0 0 MANAGEMENT & GENERAL MANAGEMENT & GENERAL 1,777,579
CENTRAL AMERICA AND THE CARIBBEAN 0 0 PROGRAM SERVICES OTHER 62,676
CENTRAL AMERICA AND THE CARIBBEAN 0 0 PROGRAM SERVICES PROGRAM INNOVATION 920,872
CENTRAL AMERICA AND THE CARIBBEAN 0 0 GRANTMAKING   929,969
EAST ASIA AND THE PACIFIC 5 118 PROGRAM SERVICES AMEE 6,547,799
EAST ASIA AND THE PACIFIC 0 0 BID & PROPOSAL BID & PROPOSAL 82,678
EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 7,846,097
EAST ASIA AND THE PACIFIC 0 0 FUNDRAISING FUNDRAISING 2,700
EAST ASIA AND THE PACIFIC 0 0 MANAGEMENT & GENERAL MANAGEMENT & GENERAL 1,576,557
EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES OTHER 54,699
EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES PROGRAM INNOVATION 2,386,560
EAST ASIA AND THE PACIFIC 0 0 GRANTMAKING   9,766,636
EUROPE 1 5 PROGRAM SERVICES AFRICA 132,045
EUROPE 0 0 PROGRAM SERVICES AMEE 682,847
EUROPE 0 0 BID & PROPOSAL BID & PROPOSAL 10,044
EUROPE 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 17,261,790
EUROPE 0 0 MANAGEMENT & GENERAL MANAGEMENT & GENERAL 2,419,101
EUROPE 0 0 PROGRAM SERVICES OTHER 51,211
EUROPE 0 0 PROGRAM SERVICES PROGRAM INNOVATION 11,174,147
EUROPE 0 0 GRANTMAKING   20,410,132
MIDDLE EAST AND NORTH AFRICA 0 0 PROGRAM SERVICES PROGRAM INNOVATION 18,176
MIDDLE EAST AND NORTH AFRICA 0 0 GRANTMAKING   10,000
NORTH AMERICA 0 0 PROGRAM SERVICES AFRICA 9,600
NORTH AMERICA 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 616,112
NORTH AMERICA 0 0 FUNDRAISING FUNDRAISING 4,995
NORTH AMERICA 0 0 MANAGEMENT & GENERAL MANAGEMENT & GENERAL 88,345
NORTH AMERICA 0 0 PROGRAM SERVICES OTHER 23,285
NORTH AMERICA 0 0 PROGRAM SERVICES PROGRAM INNOVATION 699,541
NORTH AMERICA 0 0 GRANTMAKING   706,919
RUSSIA AND NEIGHBORING STATES 1 25 PROGRAM SERVICES AMEE 3,464,908
RUSSIA AND NEIGHBORING STATES 0 0 BID & PROPOSAL BID & PROPOSAL 19,196
RUSSIA AND NEIGHBORING STATES 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 399
RUSSIA AND NEIGHBORING STATES 0 0 MANAGEMENT & GENERAL MANAGEMENT & GENERAL 653,450
RUSSIA AND NEIGHBORING STATES 0 0 PROGRAM SERVICES PROGRAM INNOVATION 128,590
RUSSIA AND NEIGHBORING STATES 0 0 GRANTMAKING   1,829,202
SOUTH AMERICA 1 5 BID & PROPOSAL BID & PROPOSAL 610
SOUTH AMERICA 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 593,454
SOUTH AMERICA 0 0 MANAGEMENT & GENERAL MANAGEMENT & GENERAL 33,701
SOUTH AMERICA 0 0 PROGRAM SERVICES OTHER 1,080
SOUTH AMERICA 0 0 PROGRAM SERVICES PROGRAM INNOVATION 847,838
SOUTH AMERICA 0 0 GRANTMAKING   1,068,327
SOUTH ASIA 5 173 PROGRAM SERVICES AFRICA 14,620
SOUTH ASIA 0 0 PROGRAM SERVICES AMEE 14,176,008
SOUTH ASIA 0 0 BID & PROPOSAL BID & PROPOSAL 48,403
SOUTH ASIA 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 3,906,531
SOUTH ASIA 0 0 MANAGEMENT & GENERAL MANAGEMENT & GENERAL 2,581,026
SOUTH ASIA 0 0 PROGRAM SERVICES OTHER 14,339
SOUTH ASIA 0 0 PROGRAM SERVICES PROGRAM INNOVATION 1,444,393
SOUTH ASIA 0 0 GRANTMAKING   2,589,327
SUB-SAHARAN AFRICA 41 723 PROGRAM SERVICES AFRICA 26,446,647
SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES AMEE 13,792
SUB-SAHARAN AFRICA 0 0 BID & PROPOSAL BID & PROPOSAL 196,707
SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 9,523,251
SUB-SAHARAN AFRICA 0 0 FUNDRAISING FUNDRAISING 815
SUB-SAHARAN AFRICA 0 0 MANAGEMENT & GENERAL MANAGEMENT & GENERAL 10,904,369
SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES OTHER 2,666,469
SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES PROGRAM INNOVATION 26,394,347
SUB-SAHARAN AFRICA 0 0 GRANTMAKING   13,680,233
3a Sub-total .... 0 0 4,548,244
b Total from continuation sheets to Part I ... 54 1,049 206,754,017
c Totals (add lines 3a and 3b) 54 1,049 211,302,261
For Paperwork Reduction Act Notice, see the Instructions for Form 990.Cat. No. 50082W Schedule F (Form 990) 2021
Schedule F (Form 990) 2021
Page 2
Part II
Grants and Other Assistance to Organizations or Entities Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 15, for any recipient who received more than $5,000. Part II can be duplicated if additional space is needed.
1 (a) Name of organization (b) IRS code section
and EIN (if applicable)
(c) Region (d) Purpose of
grant
(e) Amount of
cash grant
(f) Manner of
cash
disbursement
(g) Amount
of noncash
assistance
(h) Description
of noncash
assistance
(i) Method of
valuation
(book, FMV,
appraisal, other)
CENTRAL AMERICA AND THE CARIBBEAN ESSENTIAL MEDICINE 227,985 CHECK/WIRE 0    
CENTRAL AMERICA AND THE CARIBBEAN ESSENTIAL MEDICINE 15,000 CHECK/WIRE 0    
CENTRAL AMERICA AND THE CARIBBEAN PROGRAM INNOVATION 10,524 CHECK/WIRE 0    
CENTRAL AMERICA AND THE CARIBBEAN ESSENTIAL MEDICINE 215,408 CHECK/WIRE 0    
CENTRAL AMERICA AND THE CARIBBEAN ESSENTIAL MEDICINE 361,052 CHECK/WIRE 0    
CENTRAL AMERICA AND THE CARIBBEAN PROGRAM INNOVATION 30,000 CHECK/WIRE 0    
CENTRAL AMERICA AND THE CARIBBEAN PROGRAM INNOVATION 70,000 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC AMEE 71,479 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC PROGRAM INNOVATION 79,069 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC PROGRAM INNOVATION 25,000 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC PROGRAM INNOVATION 24,100 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC AMEE 31,654 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC ESSENTIAL MEDICINE 1,059,500 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC AMEE 71,326 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC PROGRAM INNOVATION 57,821 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC AMEE 166,913 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC AMEE 24,313 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC AMEE 91,383 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC AMEE 42,330 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC PROGRAM INNOVATION 126,213 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC AMEE 10,524 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC AMEE 72,828 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC AMEE 49,919 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC AMEE 7,010 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC ESSENTIAL MEDICINE 271,548 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC AMEE 129,349 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC PROGRAM INNOVATION 94,424 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC ESSENTIAL MEDICINE 218,743 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC PROGRAM INNOVATION 33,437 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC PROGRAM INNOVATION 13,508 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC ESSENTIAL MEDICINE & PROGRAM INNOVATION 1,721,642 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC AMEE 66,193 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC AMEE 243,955 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC AMEE 17,769 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC ESSENTIAL MEDICINE 3,664,864 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC AMEE 18,921 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC ESSENTIAL MEDICINE 150,000 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC PROGRAM INNOVATION 49,988 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC ESSENTIAL MEDICINE 222,394 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC AMEE 117,367 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC AMEE 288,175 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC PROGRAM INNOVATION 67,463 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC ESSENTIAL MEDICINE 23,575 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC PROGRAM INNOVATION 49,441 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC ESSENTIAL MEDICINE 29,242 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC AMEE 83,315 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC AMEE 11,074 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC AMEE 34,649 CHECK/WIRE 0    
EAST ASIA AND THE PACIFIC PROGRAM INNOVATION 130,168 CHECK/WIRE 0    
EUROPE PROGRAM INNOVATION 464,778 CHECK/WIRE 0    
EUROPE PROGRAM INNOVATION 38,183 CHECK/WIRE 0    
EUROPE ESSENTIAL MEDICINE 224,974 CHECK/WIRE 0    
EUROPE AFRICA 102,374 CHECK/WIRE 0    
EUROPE AMEE 212,829 CHECK/WIRE 0    
EUROPE ESSENTIAL MEDICINE 1,743,618 CHECK/WIRE 0    
EUROPE ESSENTIAL MEDICINE & PROGRAM INNOVATION 92,712 CHECK/WIRE 0    
EUROPE PROGRAM INNOVATION 29,960 CHECK/WIRE 0    
EUROPE PROGRAM INNOVATION 6,000 CHECK/WIRE 0    
EUROPE ESSENTIAL MEDICINE 600,613 CHECK/WIRE 0    
EUROPE ESSENTIAL MEDICINE & PROGRAM INNOVATION 2,712,511 CHECK/WIRE 0    
EUROPE PROGRAM INNOVATION 49,500 CHECK/WIRE 0    
EUROPE PROGRAM INNOVATION 10,296 CHECK/WIRE 0    
EUROPE PROGRAM INNOVATION 1,026,135 CHECK/WIRE 0    
EUROPE PROGRAM INNOVATION 28,400 CHECK/WIRE 0    
EUROPE ESSENTIAL MEDICINE 279,243 CHECK/WIRE 0    
EUROPE PROGRAM INNOVATION 507,807 CHECK/WIRE 0    
EUROPE ESSENTIAL MEDICINE 853,035 CHECK/WIRE 0    
EUROPE PROGRAM INNOVATION 45,185 CHECK/WIRE 0    
EUROPE ESSENTIAL MEDICINE 124,000 CHECK/WIRE 0    
EUROPE ESSENTIAL MEDICINE 50,000 CHECK/WIRE 0    
EUROPE PROGRAM INNOVATION 88,970 CHECK/WIRE 0    
EUROPE PROGRAM INNOVATION 1,279,135 CHECK/WIRE 0    
EUROPE AMEE 164,921 CHECK/WIRE 0    
EUROPE ESSENTIAL MEDICINE 231,168 CHECK/WIRE 0    
EUROPE ESSENTIAL MEDICINE 881,326 CHECK/WIRE 0    
EUROPE ESSENTIAL MEDICINE 225,000 CHECK/WIRE 0    
EUROPE PROGRAM INNOVATION 1,767,625 CHECK/WIRE 0    
EUROPE ESSENTIAL MEDICINE & PROGRAM INNOVATION 607,577 CHECK/WIRE 0    
EUROPE PROGRAM INNOVATION 40,000 CHECK/WIRE 0    
EUROPE PROGRAM INNOVATION 45,000 CHECK/WIRE 0    
EUROPE PROGRAM INNOVATION 12,461 CHECK/WIRE 0    
EUROPE PROGRAM INNOVATION 75,000 CHECK/WIRE 0    
EUROPE AFRICA, AMEE, ESSENTIAL MEDICINE, & PROGRAM INNOVATION 5,789,794 CHECK/WIRE 0    
MIDDLE EAST & NORTH AFRICA PROGRAM INNOVATION 10,000 CHECK/WIRE 0    
NORTH AMERICA ESSENTIAL MEDICINE 124,774 CHECK/WIRE 0    
NORTH AMERICA PROGRAM INNOVATION 100,000 CHECK/WIRE 0    
NORTH AMERICA PROGRAM INNOVATION 422,975 CHECK/WIRE 0    
NORTH AMERICA ESSENTIAL MEDICINE 59,170 CHECK/WIRE 0    
RUSSIA AND NEIGHBORING STATES AMEE 13,366 CHECK/WIRE 0    
RUSSIA AND NEIGHBORING STATES AMEE 85,308 CHECK/WIRE 0    
RUSSIA AND NEIGHBORING STATES AMEE 45,891 CHECK/WIRE 0    
RUSSIA AND NEIGHBORING STATES AMEE 45,746 CHECK/WIRE 0    
RUSSIA AND NEIGHBORING STATES AMEE 17,675 CHECK/WIRE 0    
RUSSIA AND NEIGHBORING STATES AMEE 82,462 CHECK/WIRE 0    
RUSSIA AND NEIGHBORING STATES AMEE 29,707 CHECK/WIRE 0    
RUSSIA AND NEIGHBORING STATES AMEE 25,138 CHECK/WIRE 0    
RUSSIA AND NEIGHBORING STATES AMEE 14,255 CHECK/WIRE 0    
RUSSIA AND NEIGHBORING STATES AMEE 176,629 CHECK/WIRE 0    
RUSSIA AND NEIGHBORING STATES AMEE 18,457 CHECK/WIRE 0    
RUSSIA AND NEIGHBORING STATES AMEE 449,620 CHECK/WIRE 0    
RUSSIA AND NEIGHBORING STATES AMEE 39,901 CHECK/WIRE 0    
RUSSIA AND NEIGHBORING STATES AMEE 17,227 CHECK/WIRE 0    
RUSSIA AND NEIGHBORING STATES AMEE 32,985 CHECK/WIRE 0    
RUSSIA AND NEIGHBORING STATES AMEE 67,892 CHECK/WIRE 0    
RUSSIA AND NEIGHBORING STATES AMEE 17,698 CHECK/WIRE 0    
RUSSIA AND NEIGHBORING STATES AMEE 19,542 CHECK/WIRE 0    
RUSSIA AND NEIGHBORING STATES AMEE 41,708 CHECK/WIRE 0    
RUSSIA AND NEIGHBORING STATES PROGRAM INNOVATION 209,012 CHECK/WIRE 0    
RUSSIA AND NEIGHBORING STATES AMEE 37,400 CHECK/WIRE 0    
RUSSIA AND NEIGHBORING STATES AMEE 47,434 CHECK/WIRE 0    
RUSSIA AND NEIGHBORING STATES AMEE 38,192 CHECK/WIRE 0    
RUSSIA AND NEIGHBORING STATES AMEE 62,796 CHECK/WIRE 0    
RUSSIA AND NEIGHBORING STATES AMEE 84,569 CHECK/WIRE 0    
RUSSIA AND NEIGHBORING STATES AMEE 30,998 CHECK/WIRE 0    
RUSSIA AND NEIGHBORING STATES AMEE 36,033 CHECK/WIRE 0    
RUSSIA AND NEIGHBORING STATES AMEE 41,560 CHECK/WIRE 0    
SOUTH AMERICA PROGRAM INNOVATION 168,199 CHECK/WIRE 0    
SOUTH AMERICA PROGRAM INNOVATION 20,007 CHECK/WIRE 0    
SOUTH AMERICA ESSENTIAL MEDICINE 362,750 CHECK/WIRE 0    
SOUTH AMERICA ESSENTIAL MEDICINE 74,798 CHECK/WIRE 0    
SOUTH AMERICA PROGRAM INNOVATION 15,000 CHECK/WIRE 0    
SOUTH AMERICA PROGRAM INNOVATION 176,616 CHECK/WIRE 0    
SOUTH AMERICA ESSENTIAL MEDICINE 56,253 CHECK/WIRE 0    
SOUTH AMERICA ESSENTIAL MEDICINE 87,883 CHECK/WIRE 0    
SOUTH AMERICA PROGRAM INNOVATION 106,821 CHECK/WIRE 0    
SOUTH ASIA AMEE & PROGRAM INNOVATION 46,814 CHECK/WIRE 0    
SOUTH ASIA ESSENTIAL MEDICINE & PROGRAM INNOVATION 30,872 CHECK/WIRE 0    
SOUTH ASIA AMEE 142,895 CHECK/WIRE 0    
SOUTH ASIA AMEE 11,937 CHECK/WIRE 0    
SOUTH ASIA ESSENTIAL MEDICINE 35,629 CHECK/WIRE 0    
SOUTH ASIA ESSENTIAL MEDICINE 633,973 CHECK/WIRE 0    
SOUTH ASIA PROGRAM INNOVATION 150,000 CHECK/WIRE 0    
SOUTH ASIA PROGRAM INNOVATION 268,084 CHECK/WIRE 0    
SOUTH ASIA AMEE 10,192 CHECK/WIRE 0    
SOUTH ASIA AMEE 69,757 CHECK/WIRE 0    
SOUTH ASIA AMEE 8,375 CHECK/WIRE 0    
SOUTH ASIA ESSENTIAL MEDICINE 55,000 CHECK/WIRE 0    
SOUTH ASIA AMEE 35,613 CHECK/WIRE 0    
SOUTH ASIA ESSENTIAL MEDICINE 684,743 CHECK/WIRE 0    
SOUTH ASIA AMEE 22,878 CHECK/WIRE 0    
SOUTH ASIA AMEE 11,754 CHECK/WIRE 0    
SOUTH ASIA AMEE 7,440 CHECK/WIRE 0    
SOUTH ASIA AMEE & PROGRAM INNOVATION 187,263 CHECK/WIRE 0    
SOUTH ASIA ESSENTIAL MEDICINE 20,970 CHECK/WIRE 0    
SOUTH ASIA ESSENTIAL MEDICINE 33,198 CHECK/WIRE 0    
SOUTH ASIA AMEE & PROGRAM INNOVATION 118,896 CHECK/WIRE 0    
SUB-SAHARAN AFRICA AFRICA 13,424 CHECK/WIRE 0    
SUB-SAHARAN AFRICA PROGRAM INNOVATION 15,000 CHECK/WIRE 0    
SUB-SAHARAN AFRICA PROGRAM INNOVATION 21,000 CHECK/WIRE 0    
SUB-SAHARAN AFRICA AFRICA 6,270 CHECK/WIRE 0    
SUB-SAHARAN AFRICA AFRICA 62,011 CHECK/WIRE 0    
SUB-SAHARAN AFRICA AFRICA 99,480 CHECK/WIRE 0    
SUB-SAHARAN AFRICA PROGRAM INNOVATION 41,055 CHECK/WIRE 0    
SUB-SAHARAN AFRICA PROGRAM INNOVATION 227,642 CHECK/WIRE 0    
SUB-SAHARAN AFRICA PROGRAM INNOVATION 12,129 CHECK/WIRE 0    
SUB-SAHARAN AFRICA AFRICA 12,152 CHECK/WIRE 0    
SUB-SAHARAN AFRICA PROGRAM INNOVATION 35,635 CHECK/WIRE 0    
SUB-SAHARAN AFRICA PROGRAM INNOVATION 157,401 CHECK/WIRE 0    
SUB-SAHARAN AFRICA AFRICA 162,805 CHECK/WIRE 0    
SUB-SAHARAN AFRICA AFRICA 6,515 CHECK/WIRE 0    
SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 1,000,000 CHECK/WIRE 0    
SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 428,863 CHECK/WIRE 0    
SUB-SAHARAN AFRICA PROGRAM INNOVATION 245,842 CHECK/WIRE 0    
SUB-SAHARAN AFRICA PROGRAM INNOVATION 527,263 CHECK/WIRE 0    
SUB-SAHARAN AFRICA PROGRAM INNOVATION 28,851 CHECK/WIRE 0    
SUB-SAHARAN AFRICA AFRICA 8,509 CHECK/WIRE 0    
SUB-SAHARAN AFRICA AFRICA 106,638 CHECK/WIRE 0    
SUB-SAHARAN AFRICA AFRICA 37,800 CHECK/WIRE 0    
SUB-SAHARAN AFRICA PROGRAM INNOVATION 44,460 CHECK/WIRE 0    
SUB-SAHARAN AFRICA AFRICA 10,846 CHECK/WIRE 0    
SUB-SAHARAN AFRICA OTHER & PROGRAM INNOVATION 115,300 CHECK/WIRE 0    
SUB-SAHARAN AFRICA AFRICA 60,018 CHECK/WIRE 0    
SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 104,684 CHECK/WIRE 0    
SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 7,683 CHECK/WIRE 0    
SUB-SAHARAN AFRICA PROGRAM INNOVATION 12,611 CHECK/WIRE 0    
SUB-SAHARAN AFRICA AFRICA 10,682 CHECK/WIRE 0    
SUB-SAHARAN AFRICA OTHER 8,669 CHECK/WIRE 0    
SUB-SAHARAN AFRICA PROGRAM INNOVATION 537,043 CHECK/WIRE 0    
SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 539,937 CHECK/WIRE 0    
SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 399,962 CHECK/WIRE 0    
SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 246,615 CHECK/WIRE 0    
SUB-SAHARAN AFRICA PROGRAM INNOVATION 247,713 CHECK/WIRE 0    
SUB-SAHARAN AFRICA AFRICA 491,789 CHECK/WIRE 0    
SUB-SAHARAN AFRICA AFRICA 58,630 CHECK/WIRE 0    
SUB-SAHARAN AFRICA PROGRAM INNOVATION 475,324 CHECK/WIRE 0    
SUB-SAHARAN AFRICA PROGRAM INNOVATION 26,950 CHECK/WIRE 0    
SUB-SAHARAN AFRICA AFRICA 124,276 CHECK/WIRE 0    
SUB-SAHARAN AFRICA OTHER & PROGRAM INNOVATION 38,832 CHECK/WIRE 0    
SUB-SAHARAN AFRICA PROGRAM INNOVATION 167,358 CHECK/WIRE 0    
SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 456,000 CHECK/WIRE 0    
SUB-SAHARAN AFRICA OTHER & PROGRAM INNOVATION 24,589 CHECK/WIRE 0    
SUB-SAHARAN AFRICA PROGRAM INNOVATION 14,876 CHECK/WIRE 0    
SUB-SAHARAN AFRICA PROGRAM INNOVATION 115,516 CHECK/WIRE 0    
SUB-SAHARAN AFRICA AFRICA 5,385 CHECK/WIRE 0    
SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 12,299 CHECK/WIRE 0    
SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 1,242,616 CHECK/WIRE 0    
SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 7,690 CHECK/WIRE 0    
SUB-SAHARAN AFRICA AFRICA 87,022 CHECK/WIRE 0    
SUB-SAHARAN AFRICA PROGRAM INNOVATION 688,202 CHECK/WIRE 0    
SUB-SAHARAN AFRICA AFRICA 7,828 CHECK/WIRE 0    
SUB-SAHARAN AFRICA PROGRAM INNOVATION 275,719 CHECK/WIRE 0    
SUB-SAHARAN AFRICA PROGRAM INNOVATION 439,041 CHECK/WIRE 0    
SUB-SAHARAN AFRICA AFRICA 7,372 CHECK/WIRE 0    
SUB-SAHARAN AFRICA PROGRAM INNOVATION 15,000 CHECK/WIRE 0    
SUB-SAHARAN AFRICA PROGRAM INNOVATION 110,443 CHECK/WIRE 0    
SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 65,000 CHECK/WIRE 0    
SUB-SAHARAN AFRICA PROGRAM INNOVATION 200,000 CHECK/WIRE 0    
SUB-SAHARAN AFRICA AFRICA, ESSENTIAL MEDICINE, & PROGRAM INNOVATION 599,874 CHECK/WIRE 0    
SUB-SAHARAN AFRICA PROGRAM INNOVATION 241,692 CHECK/WIRE 0    
SUB-SAHARAN AFRICA AFRICA 1,167,548 CHECK/WIRE 0    
SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 701,521 CHECK/WIRE 0    
SUB-SAHARAN AFRICA AFRICA 73,356 CHECK/WIRE 0    
SUB-SAHARAN AFRICA AFRICA 14,584 CHECK/WIRE 0    
SUB-SAHARAN AFRICA AFRICA 75,234 CHECK/WIRE 0    
SUB-SAHARAN AFRICA AFRICA 7,831 CHECK/WIRE 0    
SUB-SAHARAN AFRICA PROGRAM INNOVATION 12,000 CHECK/WIRE 0    
2 Enter total number of recipient organizations listed above that are recognized as charities by the foreign country, recognized as tax-exempt by the IRS, or for which the grantee or counsel has provided a section 501(c)(3) equivalency letter .......MediumBullet
166
3 Enter total number of other organizations or entities .......................MediumBullet
50
Schedule F (Form 990) 2021
Schedule F (Form 990) 2021Page 3
Part III
Grants and Other Assistance to Individuals Outside the United States. Complete if the organization answered "Yes" on Form 990, Part IV, line 16.
Part III can be duplicated if additional space is needed.
(a) Type of grant or assistance (b) Region (c) Number of recipients (d) Amount of
cash grant
(e) Manner of cash
disbursement
(f) Amount of
noncash
assistance
(g) Description
of noncash
assistance
(h) Method of
valuation
(book, FMV,
appraisal, other)
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
               
Schedule F (Form 990) 2021
Schedule F (Form 990) 2021
Page 4
Part IV
Foreign Forms
1 Was the organization a U.S. transferor of property to a foreign corporation during the tax year? If "Yes," the organization may be required to file Form 926, Return by a U.S. Transferor of Property to a Foreign Corporation (see Instructions for Form 926). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2 Did the organization have an interest in a foreign trust during the tax year? If "Yes," the organization may be required to separately file Form 3520, Annual Return to Report Transactions with Foreign Trusts and Receipt of Certain Foreign Gifts, and/or Form 3520-A, Annual Information Return of Foreign Trust With a U.S. Owner (see Instructions for Forms 3520 and 3520-A; don't file with Form 990). . . . . . . . . . . . . . . . . . . . . . . .
3 Did the organization have an ownership interest in a foreign corporation during the tax year? If "Yes," the organization may be required to file Form 5471, Information Return of U.S. Persons with Respect to Certain Foreign Corporations. (see Instructions for Form 5471). . . . . . . . . . . . . . . . . . . . . . . . . . . .
4 Was the organization a direct or indirect shareholder of a passive foreign investment company or a qualified electing fund during the tax year? If “Yes,” the organization may be required to file Form 8621, Information Return by a Shareholder of a Passive Foreign Investment Company or Qualified Electing Fund. (see Instructions for Form 8621) .
5 Did the organization have an ownership interest in a foreign partnership during the tax year? If "Yes," the organization may be required to file Form 8865, Return of U.S. Persons with Respect to Certain Foreign Partnerships (see Instructions for Form 8865). . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
6 Did the organization have any operations in or related to any boycotting countries during the tax year? If "Yes," the organization may be required to separately file Form 5713, International Boycott Report (see Instructions for Form 5713; don't file with Form 990).. . . . . . . . . . . . . . . . . . . . . . . . . . . .
Schedule F (Form 990) 2021
Schedule F (Form 990) 2021
Page 5
Part V
Supplemental Information
Provide the information required by Part I, line 2 (monitoring of funds); Part I, line 3, column (f) (accounting method; amounts of investments vs. expenditures per region); Part II, line 1 (accounting method); Part III (accounting method); and Part III, column (c) (estimated number of recipients), as applicable. Also complete this part to provide any additional information. See instructions.
ReturnReference Explanation
PART I, LINE 2: PATH HAS A SUBRECIPIENT POLICY AND PROCEDURES IN PLACE TO GUIDE THE WAY OUR PROJECT TEAMS MONITOR SUBRECIPIENTS. THIS INCLUDES BOTH FINANCIAL AND TECHNICAL MONITORING. PATH USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, AND OTHER MEANS TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD PROJECT STEWARDSHIP. THESE ACTIVITIES ALSO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS, AND THAT THE SUBRECIPIENT ACHIEVES PERFORMANCE GOALS. PATH HAS ESTABLISHED COMPREHENSIVE POLICIES AND PROCEDURES TO PROMOTE BEST BUSINESS PRACTICES AND ENSURE EFFICIENT AND EFFECTIVE INTERNAL CONTROL. THESE ARE COMBINED WITH AN INTERNAL AUDIT FUNCTION THROUGH WHICH PATH CONDUCTS AUDITS ON GRANT-FUNDED PROGRAMS TO ENSURE COMPLIANCE WITH REGULATORY REQUIREMENTS.
PART III ACCOUNTING METHOD:  
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
Schedule F (Form 990) 2021
Additional Data


Software ID:  
Software Version:  




Note: To capture the full content of this document, please select landscape mode (11" x 8.5") when printing.

Schedule I
(Form 990)
Department of the Treasury
Internal Revenue Service
Grants and Other Assistance to Organizations,
Governments and Individuals in the United States
Complete if the organization answered "Yes," on Form 990, Part IV, line 21 or 22.
lBullet Attach to Form 990.
lBullet Go to www.irs.gov/Form990 for the latest information.
OMB No. 1545-0047
2021
Open to Public
Inspection
Name of the organization
PATH
 
Employer identification number
91-1157127
Part I
General Information on Grants and Assistance
1
Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and
the selection criteria used to award the grants or assistance? ........................
2
Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States.
Part II
Grants and Other Assistance to Domestic Organizations and Domestic Governments. Complete if the organization answered "Yes" on Form 990, Part IV, line 21, for any recipient
that received more than $5,000. Part II can be duplicated if additional space is needed.
(a) Name and address of organization
or government
(b) EIN (c) IRC section
(if applicable)
(d) Amount of cash grant (e) Amount of non-cash
assistance
(f) Method of valuation
(book, FMV, appraisal,
other)
(g) Description of
noncash assistance
(h) Purpose of grant
or assistance
(1) ABT ASSOCIATES INC
6130 EXECUTIVE BLVD
ROCKVILLE,MD20852
04-2347643 OTHER 9,708 0     PROGRAM INNOVATION
(2) ADARA DEVELOPMENT (USA)
300 ADMIRAL WY SUITE 106
EDMONDS,WA98020
98-0634789 501(C)(3) 93,108 0     PROGRAM INNOVATION
(3) AJINOMOTO ALTHEA INC (DBA AJINOMOTO BIO-PHARMA SERVICES)
11040 ROSELLE STREET
SAN DIEGO,CA92121
33-0788907 OTHER 11,430 0     ESSENTIAL MEDICINES
(4) AKROS INC
PO BOX 457
LARAMIE,WY82073
OTHER 75,197 0     PROGRAM INNOVATION
(5) BAGAMIAN SCIENTIFIC CONSULTING
222 NW 3RD AVE
GAINESVILLE,FL32601
82-1347380 501(C)(3) 149,150 0     ESSENTIAL MEDICINES
(6) BENEVOLENT HEALTHCARE FOUNDATION DBA PROJECT CURE
10377 E GEDDES AVENUE SUITE 200
CENTENNIAL,CO80112
84-1568566 501(C)(3) 25,153 0     AFRICA
(7) CENTERS FOR DISEASE CONTROL AND PREVENTION
1600 CLIFTON ROAD
ATLANTA,GA30333
58-6051157 GOV 71,634 0     ESSENTIAL MEDICINES
(8) CHILDREN'S HOSPITAL BOSTON
RESEARCH FINANCE PO BOX 414413
BOSTON,MA022414413
04-2774441 501(C)(3) 377,756 0     ESSENTIAL MEDICINES
(9) CINCINNATI CHILDREN'S HOSPITAL
MEDICAL CENTER 3333 BURNET AVE ML
6014
CINCINNATI,OH452293039
31-0833936 501(C)(3) 230,000 0     ESSENTIAL MEDICINES
(10) CLINTON HEALTH ACCESS INITIATIVE
383 DORCHESTER AVE SUITE 400
BOSTON,MA02127
27-1414646 501(C)(3) 1,821,638 0     PROGRAM INNOVATION
(11) COOPERSMITH
4206 RIVER RD NW
WASHINGTON,DC20016
47-2387850 OTHER 188,947 0     PROGRAM INNOVATION
(12) DARTMOUTH-HITCHCOCK CLINIC
ONE MEDICAL CENTER DR
LEBANON,NH03756
22-2715483 501(C)(3) 199,968 0     ESSENTIAL MEDICINES
(13) DIMAGI INC
585 MASSACHUSETTS AVE SUITE 4
CAMBRIDGE,MA02139
83-0343298 501(C)(3) 287,935 0     PROGRAM INNOVATION
(14) FOOD AND DRUG ADMINISTRATION
5600 FISHERS LNHFA-140 RM 11-40
ROCKVILLE,MD20857
53-0196965 GOV 75,000 0     ESSENTIAL MEDICINES
(15) G&L SCIENTIFIC INC
25 INDEPENDENCE BLVD SUITE 404
WARREN,NJ07059
81-1114075 OTHER 12,360 0     PROGRAM INNOVATION
(16) GLOBAL CONNECT DEVELOPMENT GROUP LLC
480 BEACH ST
BOSTON,MA02131
82-3433604 OTHER 398,175 0     PROGRAM INNOVATION
(17) GLOBAL HEALTH STRATEGIES LLC
27 WEST 24TH STREET SUITE 900
NEW YORK,NY10010
27-2494697 501(C)(3) 264,021 0     PROGRAM INNOVATION
(18) GUARALDI SYSTEMS LLC
97 ALGER BROOK RD
SOUTH STAFFORD,VT05070
85-1148274 OTHER 276,640 0     PROGRAM INNOVATION
(19) HARVARD SCHOOL OF PUBLIC HEALTH
677 HUNTINGTON AVENUE
BOSTON,MA02215
04-2103580 501(C)(3) 1,415,739 0     ESSENTIAL MEDICINES
(20) HARVARD UNIVERSITY
1033 MASSACHUSETTS AVE 2ND FLOOR
CAMBRIDGE,MA02115
04-2103580 501(C)(3) 157,819 0     ESSENTIAL MEDICINES & PROGRAM INNOVATION
(21) HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE INC
6720-A ROCKLEDGE DRIVE STE 100
BETHESDA,MD20817
52-1317896 501(C)(3) 10,663 0     ESSENTIAL MEDICINES
(22) HISP US LLC
31 ANCONA AVE
OCEAN PARK,ME04063
85-0894858 OTHER 310,352 0     PROGRAM INNOVATION
(23) HJF MEDICAL RESEARCH INTERNATIONAL INC
6720A ROCKLEDGE DRIVE SUITE 100
BETHESDA,MD20817
52-2322791 501(C)(3) 63,260 0     ESSENTIAL MEDICINES
(24) ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
1 GUSTAVE L LEVY PLACE
NEW YORK,NY10029
13-6171197 501(C)(3) 535,000 0     ESSENTIAL MEDICINES
(25) ICF MACRO INC
9300 LEE HIGHWAY
FAIRFAX,VA22031
22-3661438 OTHER 2,049,999 0     PROGRAM INNOVATION
(26) INDIANA UNIVERSITY
107 S INDIAN AVE
BLOOMINGTON,IN47405
35-6001673 GOV 148,623 0     PROGRAM INNOVATION
(27) INTERNATIONAL FOOD POLICY RESEARCH INSTITUTE (IFPRI)
1201 EYE STREET NW
WASHINGTON,DC20005
52-1041632 501(C)(3) 16,666 0     PROGRAM INNOVATION
(28) INTRAHEALTH INTERNATIONAL INC
6340 QUADRANGLE DRIVE SUITE 200
CHAPEL HILL,NC27517
55-0825466 501(C)(3) 824,333 0     AFRICA & PROGRAM INNOVATION
(29) IPAS
300 MARKET ST 200
CHAPEL HILL,NC27516
56-1071085 501(C)(3) 63,941 0     PROGRAM INNOVATION
(30) JHPIEGO
1615 THAMES STREET SUITE 200
BALTIMORE,MD212313447
23-7424444 501(C)(3) 437,778 0     AFRICA & AMEE
(31) JOHNS HOPKINS UNIVERSITY
BLOOMBERG SCHL OF PUB HLTH 615 N
WOLFE STREET
BALTIMORE,MD21205
52-0595110 501(C)(3) 10,566 0     ESSENTIAL MEDICINES
(32) JSI RESEARCH AND TRAINING INSTITUTE INC
1616 NORTH FORT MYER DR 16TH FLOOR
ARLINGTON,VA222093100
04-2679824 501(C)(3) 1,138,899 0     PROGRAM INNOVATION
(33) KINDEVA DRUG DELIVERY LP
11200 HUDSON RD
WOODBURY,MN55129
OTHER 146,960 0     PROGRAM INNOVATION
(34) LEIDOS BIOMEDICAL RESEARCH INC
1050 BOYLES ST
FREDERICK,MD21702
33-0653185 OTHER 148,511 0     ESSENTIAL MEDICINES
(35) LINKSBRIDGE SPC
101 TAYLOR AVE N 105
SEATTLE,WA98109
26-3067893 OTHER 27,849 0     ESSENTIAL MEDICINES
(36) MAGEE-WOMENS RESEARCH INSTITUTE AND FOUNDATION (MWRI)
3339 WARD ST
PITTSBURGH,PA15213
25-1462312 501(C)(3) 35,761 0     PROGRAM INNOVATION
(37) MANAGEMENT SCIENCES FOR HEALTH INC
200 RIVERS EDGE DRIVE SUITE 320
MEDFORD,MA02155
04-2482188 501(C)(3) 111,280 0     PROGRAM INNOVATION
(38) MASSACHUSETTS GENERAL HOSPITAL
DEPT OF EMERGENCY MEDICINE ZERO
EMERSON PL 104
BOSTON,MA02114
04-1564655 501(C)(3) 22,298 0     ESSENTIAL MEDICINES
(39) MEDIC MOBILE INC
3254 19TH STREET FLOOR 2
SAN FRANCISCO,CA94110
27-5104203 501(C)(3) 100,439 0     PROGRAM INNOVATION
(40) MICHIGAN STATE UNIVERSITY
3900 COLLINS RD SUITE 1044
LANSING,MI48910
38-6005984 501(C)(3) 148,595 0     PROGRAM INNOVATION
(41) NATIONAL FOUNDATION FOR THE CDC
55 PARK PLACE SUITE 400
ATLANTA,GA30303
58-2106707 501(C)(3) 51,394 0     ESSENTIAL MEDICINES
(42) NAT'L INST OF ALLERGY & INFECTIOUS DISEASES (NIAID)
6610 ROCKLEDGE DR ROOM 2800
BETHESDA,MD208926606
52-0858115 GOV 260,000 0     ESSENTIAL MEDICINES
(43) NICHOLAS INST FOR ENVIRONMENTAL POLICY SOLUTIONS AT DUKE UNIVERSITY
2117 CAMPUS DR PO BOX 90335
DURHAM,NC27708
56-0532129 501(C)(3) 15,333 0     PROGRAM INNOVATION
(44) ONA SYSTEMS INC
126 E 12TH ST SUITE 4A
NEW YORK,NY100035320
38-3940780 OTHER 256,923 0     PROGRAM INNOVATION
(45) OPEN FUNCTION GROUP LLC
66 EUCLID AVE
HASTINGS ON HUDSON,NY10706
OTHER 62,200 0     PROGRAM INNOVATION
(46) OPENMRS INC
10425 COMMERCE DR STE 110
CARMEL,IN460327643
45-5316647 501(C)(3) 129,443 0     PROGRAM INNOVATION
(47) PARTNERS IN HEALTH A NONPROFIT CORPORATION
800 BOYLSTON ST SUITE 300
BOSTON,MA02199
04-3567502 501(C)(3) 24,608 0     PROGRAM INNOVATION
(48) PATHFINDER INTERNATIONAL
9 GALEN STREET SUITE 217
WATERTOWN,MA02472
53-0235320 501(C)(3) 104,629 0     PROGRAM INNOVATION
(49) PHARMARON CPC INC
800 W BALTIMORE STREET 5TH FLOOR
BALTIMORE,MD21201
20-8419781 OTHER 76,832 0     ESSENTIAL MEDICINES
(50) POPULATION COUNCIL
ONE DAG HAMMERKJOLD PLAZA
NEW YORK,NY10017
13-1687001 501(C)(3) 113,568 0     PROGRAM INNOVATION
(51) POPULATION SERVICES INTERNATIONAL INC
1120 19TH ST NW STE 600
WASHINGTON,DC20036
56-0942853 501(C)(3) 640,025 0     AMEE & PROGRAM INNOVATION
(52) REGENSTRIEF INSTITUTE INC
1101 W 10TH ST
INDIANAPOLIS,IN46202
30-0007730 501(C)(3) 1,245,318 0     PROGRAM INNOVATION
(53) ROSTROPOVICH-VISHNEVSKAYA FOUNDATION
1776 K STREET NW SUITE 700
WASHINGTON,DC20006
52-1752473 501(C)(3) 69,530 0     ESSENTIAL MEDICINES
(54) RTI INTERNATIONAL
PO BOX 12106
DURHAM,NC277092106
56-0686338 501(C)(3) 167,169 0     PROGRAM INNOVATION
(55) SOLAR ELECTRIC LIGHT FUND
1612 K STREET NW SUITE 300
WASHINGTON,DC20006
52-1701564 501(C)(3) 32,052 0     PROGRAM INNOVATION
(56) SYSTEMONE LLC
5 BRIDGE STREET
SHELBURNE FALLS,MA01370
46-1066795 OTHER 178,199 0     AMEE
(57) TECHCHANGE INC
2001 13TH ST NW 2ND FLOOR
WASHINGTON,DC20009
27-3358772 OTHER 401,650 0     PROGRAM INNOVATION
(58) TECHNICAL RESOURCES INTERNATIONAL INC (TRI)
6500 ROCK SPRING DR SUITE 650
BETHESDA,MD20817
52-1122901 OTHER 14,582 0     ESSENTIAL MEDICINES
(59) THE NATURE CONSERVANCY
4245 FAIRFAX DRIVE
ARLINGTON,VA22203
53-0242652 501(C)(3) 28,818 0     PROGRAM INNOVATION
(60) THE RECTOR AND VISITORS OF THE UNIVERSITY OF VIRGINIA (UVA)
1001 N EMMET ST
CHARLOTTESVILLE,VA22903
54-6001796 501(C)(3) 66,037 0     ESSENTIAL MEDICINES
(61) THE REGENTS OF THE UNIVERSITY OF CA SF
UCSF OFFICE OF SPONSORED RES 3333
CALIFORNIA ST STE 315
SAN FRANCISCO,CA94118
94-6036493 501(C)(3) 199,937 0     PROGRAM INNOVATION
(62) THE STATE UNIVERSITY OF NEW YORK
35 STATE STREET
ALBANY,NY122072826
14-1368361 501(C)(3) 41,040 0     ESSENTIAL MEDICINES
(63) TULANE UNIVERSITY
6823 ST CHARLES AVE
NEW ORLEANS,LA70112
72-0423889 501(C)(3) 535,028 0     ESSENTIAL MEDICINES & PROGRAM INNOVATION
(64) UNITED NATIONS FOUNDATION INC
1750 PENNSYLVANIA AVE NW STE 300
WASHINGTON,DC20006
58-2368165 501(C)(3) 178,680 0     PROGRAM INNOVATION
(65) UNIVERSITY OF CALIFORNIA LOS ANGELES (UCLA)
10889 WILSHIRE BLVD SUITE 700
LOS ANGELES,CA90095
95-6006143 GOV 276,086 0     AFRICA
(66) UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC
310 E CAMPUS RD
ATHENS,GA30602
58-1353149 501(C)(3) 71,437 0     ESSENTIAL MEDICINES
(67) UNIVERSITY OF MARYLAND BALTIMORE
BALTIMORE PO BOX 41428
BALTIMORE,MD212036428
52-6002033 GOV 91,228 0     ESSENTIAL MEDICINES
(68) UNIVERSITY OF MASSACHUSETTS
MEDICAL SCHOOL 55 LAKE AVE NORTH
WORCESTER,MA01655
04-3167352 GOV 198,235 0     PROGRAM INNOVATION
(69) UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
CENTER FOR INFECTIOUS DISEASES
CHAPEL HILL,NC275993368
56-6001393 501(C)(3) 618,814 0     ESSENTIAL MEDICINES & PROGRAM INNOVATION
(70) UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE
85 SOUTH PROSPECT STREET
BURLINGTON,VT05405
03-0179440 501(C)(3) 313,359 0     ESSENTIAL MEDICINES
(71) UNIVERSITY OF WASHINGTON (UW)
GRANT CONTRACT ACCOUNTING 12455
COLLECTIONS DRIVE
CHICAGO,IL60693
91-6001537 501(C)(3) 1,500,176 0     ESSENTIAL MEDICINES & PROGRAM INNOVATION
(72) VILLAGEREACH
2900 EASTLAKE AVE E SUITE 230
SEATTLE,WA981023012
91-2088484 501(C)(3) 283,330 0     AFRICA & PROGRAM INNOVATION
(73) VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY
300 TURNER ST NW SUITE 4200
BLACKSBURG,VA24061
54-6001805 GOV 76,922 0     ESSENTIAL MEDICINES
(74) VITAL STRATEGIES INC
100 BROADWAY 4TH FLOOR
NEW YORK,NY10005
22-3419667 501(C)(3) 218,104 0     PROGRAM INNOVATION
(75) VITAL WAVE INC
555 BRYANT STREET 226
PALO ALTO,CA94301
20-3208079 OTHER 813,825 0     PROGRAM INNOVATION
(76) WALTER REED ARMY INSTITUTE OF RESEARCH
US TREASURY 503 ROBERT GRANT AVE
SILVER SPRING,MD20910
52-0664528 GOV 2,812,443 0     ESSENTIAL MEDICINES
(77) WASHINGTON STATE UNIVERSITY
901 5TH AVE SUITE 2900
SEATTLE,WA98164
91-6001108 GOV 310,104 0     AFRICA
2
Enter total number of section 501(c)(3) and government organizations listed in the line 1 table ................. Bullet Image
58
3
Enter total number of other organizations listed in the line 1 table ........................ . Bullet Image
20
For Paperwork Reduction Act Notice, see the Instructions for Form 990.
Cat. No. 50055P
Schedule I (Form 990) 2021

Schedule I (Form 990) 2021
Page 2
Part III
Grants and Other Assistance to Domestic Individuals. Complete if the organization answered "Yes" on Form 990, Part IV, line 22.
Part III can be duplicated if additional space is needed.
(a) Type of grant or assistance (b) Number of
recipients
(c) Amount of
cash grant
(d) Amount of
noncash assistance
(e) Method of valuation (book,
FMV, appraisal, other)
(f) Description of noncash assistance
(1)
(2)
(3)
(4)
(5)
(6)
(7)
Part IV
Supplemental Information. Provide the information required in Part I, line 2; Part III, column (b); and any other additional information.
Return Reference Explanation
PART I, LINE 2: PATH HAS A SUBRECIPIENT POLICY AND PROCEDURES IN PLACE TO GUIDE THE WAY OUR PROJECT TEAMS MONITOR SUBRECIPIENTS. THIS INCLUDES BOTH FINANCIAL AND TECHNICAL MONITORING. PATH USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, AND OTHER MEANS TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD PROJECT STEWARDSHIP. THESE ACTIVITIES ALSO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS, AND THAT THE SUBRECIPIENT ACHIEVES PERFORMANCE GOALS. PATH HAS ESTABLISHED COMPREHENSIVE POLICIES AND PROCEDURES TO PROMOTE BEST BUSINESS PRACTICES AND ENSURE EFFICIENT AND EFFECTIVE INTERNAL CONTROL. THESE ARE COMBINED WITH AN INTERNAL AUDIT FUNCTION THROUGH WHICH PATH CONDUCTS AUDITS ON GRANT-FUNDED PROGRAMS TO ENSURE COMPLIANCE WITH REGULATORY REQUIREMENTS.
Schedule I (Form 990) 2021



Additional Data


Software ID:  
Software Version:  


Schedule J
(Form 990)
Department of the Treasury
Internal Revenue Service
Compensation Information
For certain Officers, Directors, Trustees, Key Employees, and Highest
Compensated Employees
SchJMediumBullet Complete if the organization answered "Yes" on Form 990, Part IV, line 23.
SchJMediumBullet Attach to Form 990.
SchJMediumBullet Go to www.irs.gov/Form990 for instructions and the latest information.
OMB No. 1545-0047
2021
Open to Public Inspection
Name of the organization
PATH
 
Employer identification number

91-1157127
Part I
Questions Regarding Compensation
Yes
No
1a
Check the appropiate box(es) if the organization provided any of the following to or for a person listed on Form
990, Part VII, Section A, line 1a. Complete Part III to provide any relevant information regarding these items.
b
If any of the boxes on Line 1a are checked, did the organization follow a written policy regarding payment or reimbursement or provision of all of the expenses described above? If "No," complete Part III to explain .....
1b
Yes
 
2
Did the organization require substantiation prior to reimbursing or allowing expenses incurred by all
directors, trustees, officers, including the CEO/Executive Director, regarding the items checked on Line 1a? ....
2
Yes
 
3
Indicate which, if any, of the following the filing organization used to establish the compensation of the
organization's CEO/Executive Director. Check all that apply. Do not check any boxes for methods
used by a related organization to establish compensation of the CEO/Executive Director, but explain in Part III.
4
During the year, did any person listed on Form 990, Part VII, Section A, line 1a, with respect to the filing organization or a related organization:
a
Receive a severance payment or change-of-control payment? .............
4a
Yes
 
b
Participate in, or receive payment from, a supplemental nonqualified retirement plan? .........
4b
 
No
c
Participate in, or receive payment from, an equity-based compensation arrangement? .........
4c
 
No
If "Yes" to any of lines 4a-c, list the persons and provide the applicable amounts for each item in Part III.
Only 501(c)(3), 501(c)(4), and 501(c)(29) organizations must complete lines 5-9.
5
For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the revenues of:
a
The organization? ....................
5a
 
No
b
Any related organization? .......................
5b
 
No
If "Yes," on line 5a or 5b, describe in Part III.
6
For persons listed on Form 990, Part VII, Section A, line 1a, did the organization pay or accrue any
compensation contingent on the net earnings of:
a
The organization? ..................
6a
 
No
b
Any related organization? ......................
6b
 
No
If "Yes," on line 6a or 6b, describe in Part III.
7
For persons listed on Form 990, Part VII, Section A, line 1a, did the organization provide any nonfixed
payments not described in lines 5 and 6? If "Yes," describe in Part III ............
7
Yes
 
8
Were any amounts reported on Form 990, Part VII, paid or accured pursuant to a contract that was
subject to the initial contract exception described in Regulations section 53.4958-4(a)(3)? If "Yes," describe
in Part III ..........................
8
 
No
9
If "Yes" on line 8, did the organization also follow the rebuttable presumption procedure described in Regulations section 53.4958-6(c)? .........................
9
 
 
For Paperwork Reduction Act Notice, see the Instructions for Form 990.
Cat. No. 50053T
Schedule J (Form 990) 2021

Schedule J (Form 990) 2021
Page 2
Part II
Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees. Use duplicate copies if additional space is needed.
For each individual whose compensation must be reported on Schedule J, report compensation from the organization on row (i) and from related organizations, described in the
instructions, on row (ii). Do not list any individuals that are not listed on Form 990, Part VII.
Note. The sum of columns (B)(i)-(iii) for each listed individual must equal the total amount of Form 990, Part VII, Section A, line 1a, applicable column (D) and (E) amounts for that individual.
(A) Name and Title (B) Breakdown of W-2, 1099-MISC compensation, and/or 1099-NEC (C) Retirement and other deferred compensation (D) Nontaxable
benefits
(E) Total of columns
(B)(i)-(D)
(F) Compensation in column (B) reported as deferred on prior Form 990
(i) Base
compensation
(ii) Bonus & incentive
compensation
(iii) Other reportable compensation
1NIKOLAJ JESTED GILBERT MSC
PRESIDENT AND CEO
(i)

(ii)
455,096
-------------
0
135,000
-------------
0
1,800
-------------
0
34,200
-------------
0
9,530
-------------
0
635,626
-------------
0
0
-------------
0
2DAVID C KASLOW MD
CHIEF EXECUTIVE-ESSENTIAL MEDICINES
(i)

(ii)
406,234
-------------
0
0
-------------
0
1,950
-------------
0
34,200
-------------
0
33,763
-------------
0
476,147
-------------
0
0
-------------
0
3TRAD M HATTON MA MHS
COUNTRY DIRECTOR
(i)

(ii)
145,889
-------------
0
0
-------------
0
200,102
-------------
0
17,613
-------------
0
35,384
-------------
0
398,988
-------------
0
0
-------------
0
4ERICA JANE SESSLE MPHIL MPH
CHIEF OF STAFF (UNTIL 10/1/21)
(i)

(ii)
166,386
-------------
0
0
-------------
0
188,997
-------------
0
21,156
-------------
0
19,470
-------------
0
396,009
-------------
0
0
-------------
0
5JOHN O KONZ PHD
GLOBAL HEAD, INT. PTFL. & FIN. MGMT.
(i)

(ii)
329,574
-------------
0
0
-------------
0
840
-------------
0
32,831
-------------
0
32,063
-------------
0
395,308
-------------
0
0
-------------
0
6ASHLEY J BIRKETT PHD
GLOBAL HEAD, MALARIA VACCINES
(i)

(ii)
329,140
-------------
0
0
-------------
0
1,065
-------------
0
29,551
-------------
0
29,520
-------------
0
389,276
-------------
0
0
-------------
0
7KIMBERLY GREEN PHD
DIRECTOR, PRIMARY HEALTH CARE
(i)

(ii)
270,667
-------------
0
0
-------------
0
51,600
-------------
0
24,087
-------------
0
36,144
-------------
0
382,498
-------------
0
0
-------------
0
8JEFFREY D BERNSON MPH MPA
CHIEF EXECUTIVE-PROGRAM & INNOVATION
(i)

(ii)
322,840
-------------
0
0
-------------
0
0
-------------
0
32,628
-------------
0
26,256
-------------
0
381,724
-------------
0
0
-------------
0
9BRUCE LAMONT INNIS MD FIDSA
GLOBAL HEAD, RESPIRATORY INFECTIONS
(i)

(ii)
341,376
-------------
0
0
-------------
0
840
-------------
0
32,831
-------------
0
-1,842
-------------
0
373,205
-------------
0
0
-------------
0
10PHILIPPE GUINOT MBA
CHIEF OF BUSINESS, FIN. & OPERATIONS
(i)

(ii)
0
-------------
309,985
0
-------------
0
0
-------------
6,236
0
-------------
24,840
0
-------------
985
0
-------------
342,046
0
-------------
0
11CARLA ANNE COSTA SANDINE
CHIEF OF EXTERNAL AFFAIRS
(i)

(ii)
267,566
-------------
0
0
-------------
0
600
-------------
0
29,684
-------------
0
16,924
-------------
0
314,774
-------------
0
0
-------------
0
12MOLLI M BARNES
CHIEF PEOPLE OFFICER
(i)

(ii)
261,290
-------------
0
0
-------------
0
0
-------------
0
26,317
-------------
0
23,096
-------------
0
310,703
-------------
0
0
-------------
0
13SABRINA L POWERS JD
GENERAL COUNSEL
(i)

(ii)
263,164
-------------
0
0
-------------
0
2,025
-------------
0
31,728
-------------
0
13,004
-------------
0
309,921
-------------
0
0
-------------
0
14NANTHALILE C MUGALA MD MMED
CHIEF EXECUTIVE-AFRICA REGION
(i)

(ii)
208,499
-------------
0
0
-------------
0
80,180
-------------
0
0
-------------
0
0
-------------
0
288,679
-------------
0
0
-------------
0
15DAVID W FLEMING--SENIOR VP MD
OF PUBLIC HEALTH(UNTIL 2/11/21)
(i)

(ii)
42,434
-------------
0
0
-------------
0
198,768
-------------
0
8,176
-------------
0
1,865
-------------
0
251,243
-------------
0
0
-------------
0
16ELAINE L GIBBONS CFA
FRMR VP-GLOBAL ENGMT. (LEFT 2020)
(i)

(ii)
0
-------------
0
0
-------------
0
184,790
-------------
0
2,056
-------------
0
0
-------------
0
186,846
-------------
0
0
-------------
0
Schedule J (Form 990) 2021

Schedule J (Form 990) 2021
Page 3
Part III
Supplemental Information
Provide the information, explanation, or descriptions required for Part I, lines 1a, 1b, 3, 4a, 4b, 4c, 5a, 5b, 6a, 6b, 7, and 8, and for Part II. Also complete this part for any additional information.
Return Reference Explanation
PART I, LINE 1A HOUSING ALLOWANCES & TAX INDEMNIFICATIONS ARE ONLY PROVIDED TO THOSE INDIVIDUALS WHO ARE EXPATRIATE EMPLOYEES. ALL BENEFIT PAYMENTS ARE MADE ACCORDING TO OUR EXPATRIATE POLICY. PART I, LINE 3: PATH ENGAGES WITH A CONSULTING FIRM TO REVIEW THE COMPENSATION FOR EACH OF THE SENIOR MANAGEMENT POSITIONS. PATH PROVIDES AN ANNUAL SALARY ADJUSTMENT EACH JANUARY BASED ON THE OVERALL LABOR MARKET MOVEMENT.
PART I, LINE 4A LIST OF PERSONS IN FORM 990, PART VII, SECTION A WHO RECEIVED SEVERANCE PAYMENTS IN 2021: - DAVID W. FLEMING $172,266 - ELAINE L. GIBBONS $143,508 - JERRY KUO $99,570 - ERICA JANE SESSLE $170,055
PART I, LINE 7 BONUS COMPENSATION HAS BEEN REFLECTED IN PART II, COLUMN (B)(II).
Schedule J (Form 990) 2021

Additional Data


Software ID:  
Software Version:  
SCHEDULE M
(Form 990)


Department of the Treasury
Internal Revenue Service
Noncash Contributions
Right pointing arrow large imageComplete if the organizations answered "Yes" on Form 990, Part IV, lines 29 or 30.
Right pointing arrow large image Attach to Form 990.
Right pointing arrow large imageGo to www.irs.gov/Form990 for the latest information.
OMB No. 1545-0047
2021
Open to Public Inspection
Name of the organization
PATH
 
Employer identification number

91-1157127
Part I
Types of Property
(a)
Check if applicable
(b)
Number of contributions or items contributed
(c)
Noncash contribution amounts reported on
Form 990, Part VIII, line 1g
(d)
Method of determining
noncash contribution amounts
1 Art—Works of art ....        
2 Art—Historical treasures .        
3 Art—Fractional interests ..        
4 Books and publications ..      
5 Clothing and household
goods .......
     
6 Cars and other vehicles ..        
7 Boats and planes ....        
8 Intellectual property ...        
9 Securities—Publicly traded . X 14 9,567 FMV
10 Securities—Closely held stock .        
11 Securities—Partnership, LLC,
or trust interests ....
       
12 Securities—Miscellaneous ..        
13 Qualified conservation
contribution—Historic
structures .....
       
14 Qualified conservation
contribution—Other ...
       
15 Real estate—Residential .        
16 Real estate—Commercial ..        
17 Real estate—Other ...        
18 Collectibles .....        
19 Food inventory ...        
20 Drugs and medical supplies .        
21 Taxidermy ......        
22 Historical artifacts ....        
23 Scientific specimens ..        
24 Archeological artifacts ...        
25 Other Right pointing arrow large image ( SOFTWARE/SUPP. ) X 5 3,088,330 COST
26 Other Right pointing arrow large image ( )
27 Other Right pointing arrow large image ( )
28 Other Right pointing arrow large image ( )
29
Number of Forms 8283 received by the organization during the tax year for contributions
for which the organization completed Form 8283, Part IV, Donee Acknowledgement
29
0
Yes
No
30a
During the year, did the organization receive by contribution any property reported in Part I, lines 1 through 28, that it must hold for at least three years from the date of the initial contribution, and which isn't required to be used for exempt purposes for the entire holding period? ...................
30a
 
No
b
If "Yes," describe the arrangement in Part II.
31
Does the organization have a gift acceptance policy that requires the review of any nonstandard contributions?
31
Yes
 
32a
Does the organization hire or use third parties or related organizations to solicit, process, or sell noncash
contributions? ..........................
32a
 
No
b
If "Yes," describe in Part II.
33
If the organization didn't report an amount in column (c) for a type of property for which column (a) is checked,
describe in Part II.
For Paperwork Reduction Act Notice, see the Instructions for Form 990.
Cat. No. 51227J
Schedule M (Form 990) (2021)
Schedule M (Form 990) (2021)
Page 2
Part IISupplemental Information. Provide the information required by Part I, lines 30b, 32b, and 33, and whether the organization is reporting in Part I, column (b), the number of contributions, the number of items received, or a combination of both. Also complete this part for any additional information.
Return Reference Explanation
PART I, COLUMN (B): THIS COLUMN REFLECTS THE NUMBER OF CONTRIBUTIONS.
Schedule M (Form 990) (2021)

Additional Data


Software ID:  
Software Version:  
SCHEDULE O
(Form 990)

Department of the Treasury
Internal Revenue Service
Supplemental Information to Form 990 or 990-EZ

Complete to provide information for responses to specific questions on
Form 990 or 990-EZ or to provide any additional information.
MediumBullet Attach to Form 990 or 990-EZ.
MediumBullet Go to www.irs.gov/Form990 for the latest information.
OMB No. 1545-0047
2021
Open to Public
Inspection
Name of the organization
PATH
 
Employer identification number

91-1157127
Return Reference Explanation
FORM 990, PART III, LINE 1, DESCRIPTION OF ORGANIZATION MISSION: PATH IS A GLOBAL NONPROFIT DEDICATED TO ACHIEVING HEALTH EQUITY. WITH MORE THAN 40 YEARS OF EXPERIENCE FORGING MULTISECTOR PARTNERSHIPS, AND WITH EXPERTISE IN SCIENCE, ECONOMICS, TECHNOLOGY, ADVOCACY, AND DOZENS OF OTHER SPECIALTIES, PATH DEVELOPS AND SCALES UP INNOVATIVE SOLUTIONS TO THE WORLD'S MOST PRESSING HEALTH CHALLENGES.
FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE: (1) IMPROVING ACCESS TO MEDICAL OXYGEN AND RELATED RESPIRATORY CARE PRODUCTS IN LMICS. AS PART OF THAT WORK, WE SUPPORTED OUR GOVERNMENT PARTNERS IN THE DEVELOPMENT AND EXECUTION OF COMPREHENSIVE RESPIRATORY CARE PLANS TO MEET THE DEMANDS OF COVID-19. BEYOND THE PANDEMIC RESPONSE, WE ALSO HELPED PRIORITIZE AND IMPROVE ACCESS TO OXYGEN THERAPY AND OTHER ESSENTIAL RESPIRATORY CARE EQUIPMENT AS AN INTEGRAL PART OF NATIONAL AND GLOBAL HEALTH SYSTEMS STRENGTHENING. IN INDIA, KENYA, SENEGAL, AND TANZANIA, WE ADVANCED ACCESS TO AFFORDABLE AND APPROPRIATE TOOLS SUCH AS PULSE OXIMETRY AND ELECTRONIC CLINICAL DECISION-SUPPORT ALGORITHMS TO HELP HEALTH CARE WORKERS IDENTIFY CRITICALLY ILL CHILDREN AND REFER THEM FOR TREATMENT WITHOUT DELAY. (2) SUPPORTING INTRODUCTION AND SCALE-UP OF MALARIA HEALTH PRODUCTS. THROUGH OUR ROLE IN THE PARTNERSHIP FOR VIVAX ELIMINATION, WE CONTINUED TO FOSTER ACCESS TO CRITICAL MALARIA DRUGS AND DIAGNOSTICS FOR ADULTS AND CHILDREN ACROSS 15 MALARIA-ENDEMIC COUNTRIES. EPIDEMIC PREPAREDNESS AND RESPONSE PATH'S EPIDEMIC PREPAREDNESS AND RESPONSE TEAM CONTINUED TO INNOVATE FOR THE PREVENTION, DETECTION, AND CONTROL OF INFECTIOUS DISEASE OUTBREAKS. UNDER THE USAID DISCOVERY & EXPLORATION OF EMERGING PATHOGENS - VIRAL ZOONOSES PROJECT, THE TEAM SUPPORTED GLOBAL DATA MANAGEMENT AND SHARING AND LED PROJECT START-UP IN SENEGAL AND VIETNAM. THE TEAM WORKED AS A MAJOR SUBGRANTEE ON THE USAID INFECTIOUS DISEASE DETECTION AND SURVEILLANCE (IDDS) PROJECT AND LED IN SENEGAL, TANZANIA, UGANDA, AND VIETNAM. IN THESE COUNTRIES, OUR CROSS-ORGANIZATIONAL IMPACT TEAM ALSO SUPPORTED COVID-19 OUTBREAK RESPONSE ACTIVITIES, WHILE REMAINING AT THE FOREFRONT OF ANTIMICROBIAL RESISTANCE AND GENOMIC SURVEILLANCE IN VIETNAM, IN PARTICULAR. WITH SUPPORT FROM THE U.S. CDC, PATH WORKED WITH NATIONAL LEADERS IN MYANMAR, SENEGAL, TANZANIA, AND VIETNAM TO BUILD CAPACITY FOR EPIDEMIC PREPAREDNESS AND RESPONSE. OTHER EFFORTS INCLUDED STRENGTHENING ELECTRONIC HEALTH INFORMATION SYSTEMS, ADVANCING DIAGNOSTIC NETWORK CAPABILITIES, AND LINKING THIS WORK WITH THE DEVELOPMENT OF NEW DIAGNOSTICS, VACCINES, AND DATA TOOLS. MALARIA AND NEGLECTED TROPICAL DISEASES PATH PARTNERS WITH GOVERNMENTS, THE PRIVATE SECTOR, AND FUNDERS AROUND THE GLOBE TO BRING THE WORLD CLOSER TO MALARIA ERADICATION. OUR MALARIA AND NEGLECTED TROPICAL DISEASES PROGRAM INCLUDES MORE THAN 100 PATH STAFF MEMBERS IN TEN COUNTRIES. OUR STRATEGY INCLUDES OPTIMIZING THE DELIVERY OF CURRENT TOOLS AND APPROACHES TO ENSURE THEY REACH THE PEOPLE WHO NEED THEM, DESIGNING NEW STRATEGIES AND DEVELOPING NEXT-GENERATION TOOLS TO OVERCOME EMERGING CHALLENGES, AND CREATING INNOVATIVE PARTNERSHIPS AND FUNDING MODELS TO ENSURE OUR PROGRAMS ARE SUSTAINABLE AND EFFECTIVE. IN 2021, OUR MALARIA CONTROL AND ELIMINATION PARTNERSHIP IN AFRICA (MACEPA) PROGRAM CONTINUED TO SUPPORT THE GOVERNMENTS OF ETHIOPIA, SENEGAL, AND ZAMBIA TOWARD THEIR MALARIA ELIMINATION GOALS. FOR INSTANCE, MACEPA PROVIDED MATHEMATICAL MODELING AND DATA ANALYTICS SUPPORT, INCLUDING ESTIMATING THE CATCHMENT POPULATION OF EACH HEALTH FACILITY IN ZAMBIA AND USING HUMAN MIGRATION DATA TO CAPTURE POPULATION FLOW AT THE DISTRICT LEVEL IN ETHIOPIA. MACEPA ALSO CONDUCTED EXPLORATORY ACTIVITIES IN THE DEMOCRATIC REPUBLIC OF THE CONGO (DRC) AND NIGERIA (E.G., ANALYSES OF CURRENT MALARIA SURVEILLANCE SYSTEMS) TO INFORM TECHNICAL ASSISTANCE NEEDS AND RECOMMENDATIONS FOR THOSE GEOGRAPHIES. THE PAMO PLUS PROJECT, FUNDED BY THE U.S. PRESIDENT'S MALARIA INITIATIVE (PMI), PROVIDED TECHNICAL AND MATERIAL ASSISTANCE TO THE ZAMBIA MINISTRY OF HEALTH (MOH) IN MALARIA CASE MANAGEMENT, MALARIA IN PREGNANCY, SOCIAL BEHAVIOR CHANGE, DISEASE SURVEILLANCE, AND DATA MANAGEMENT AND USE. WORK IN 2021 INVOLVED MENTORING HEALTH WORKERS IN THE PROJECT'S FOUR FOCUS PROVINCES ON ADHERENCE TO MALARIA CASE MANAGEMENT STANDARDS AS WELL AS TRAINING, DEPLOYING, AND SUPPORTING COMMUNITY HEALTH WORKERS WHO TEST AND TREAT MALARIA AT THE COMMUNITY LEVEL. ADDITIONALLY, PAMO PLUS WORKED WITH THE ZAMBIA NURSING AND MIDWIFERY COUNCIL TO INTEGRATE MALARIA IN PREGNANCY TRAINING INTO THE NURSING COLLEGE CURRICULUM, AND TRAINED ANTENATAL CARE PROVIDERS AND SAFE MOTHERHOOD ACTION GROUP MEMBERS ON THE MALARIA IN PREGNANCY GUIDELINES. PAMO PLUS SUPPORTED THE DEVELOPMENT OF COMMUNITY ENGAGEMENT PLANS, ORIENTED COMMUNITY CHANGE AGENTS, CONDUCTED DATA QUALITY AUDITS, AND TRAINED MOH STAFF IN DATA MANAGEMENT AND MENTORSHIP. PAMO PLUS CONTINUED IMPLEMENTING A MALARIA PRE-ELIMINATION PROGRAM, CONDUCTING RESEARCH IN LOW-BURDEN DISTRICTS OF EASTERN PROVINCE, ZAMBIA. IN 2021, PATH CONTINUED TO EVALUATE NEW VECTOR CONTROL TOOLS WITH OUR PARTNERS UNDER PMI VECTORLINK, USAID'S FLAGSHIP MALARIA VECTOR CONTROL PROJECT. SIMILARLY, UNDER THE NEW NETS PROJECT FUNDED BY UNITAID AND THE GLOBAL FUND TO FIGHT AIDS, TUBERCULOSIS AND MALARIA (THE GLOBAL FUND), WE HELPED GENERATE EVIDENCE FOR THE ADOPTION OF BEDNETS EFFECTIVE AGAINST PYRETHROID-RESISTANT MOSQUITOES. IN ZAMBIA, PATH LED THE DESIGN AND IMPLEMENTATION OF LABORATORY AND FIELD ACTIVITIES TO TEST ANOTHER NEW TOOL FOR MALARIA VECTOR CONTROL, THE ATTRACTIVE TARGETED SUGAR BAIT (ATSB). WE COORDINATED PARTNERS WORKING ON ATSB RESEARCH IN KENYA, MALI, AND ZAMBIA, TOGETHER WITH ISRAEL-BASED MANUFACTURER WESTHAM LTD. AND U.K.-BASED FUNDER INNOVATIVE VECTOR CONTROL CONSORTIUM. PATH ALSO LED A USAID INITIATIVE TO SUPPORT MALARIA OPERATIONAL RESEARCH AND PROGRAM EVALUATION. UNDER THE PMI INSIGHTS PROJECT, PATH COORDINATED THE WORK OF SEVERAL PARTNERS TO STRENGTHEN NATIONAL POLICIES, STRATEGIES, AND GUIDELINES FOR MALARIA CONTROL AND ELIMINATION. IN SENEGAL AND THE GAMBIA, PATH CONTINUED TO INTEGRATE MALARIA INTO THE SCOPE OF NATIONAL EMERGENCY OPERATIONS CENTERS (EOCS). IN SENEGAL, WE SUPPORTED THE MOH TO CREATE AND RESOURCE REGIONAL EOC-MALARIA UNITS. WITH A REGIONAL PRESENCE, THE EOC CAN MORE RAPIDLY RESPOND TO POTENTIAL PUBLIC HEALTH THREATS. THIS WORK HAS STRENGTHENED CROSS-BORDER COLLABORATION BETWEEN THE GAMBIA AND SENEGAL ON EMERGENCY PREPAREDNESS AND RESPONSE AND MALARIA INTERVENTIONS. PATH'S LABORATORY TEAM AT THE NATIONAL MALARIA ELIMINATION CENTER IN LUSAKA, ZAMBIA - A TEAM TASKED WITH GENOTYPING PLASMODIUM PARASITES TO LOOK FOR MARKERS OF RESISTANCE TO COMMON MALARIA TREATMENTS - ALSO APPLIED THEIR EXPERTISE TO SARS-COV-2. IN 2021, THEY WORKED WITH THE UNIVERSITY OF ZAMBIA'S SCHOOL OF VETERINARY MEDICINE TO SEQUENCE INFECTIONS AND MAP THE RISE AND FALL OF DIFFERENT COVID-19 VARIANTS. THE TEAM RECEIVED FUNDING TO EXPAND THEIR FOCUS FROM GENERATING DATA TO STRENGTHENING THE SEQUENCING SKILLS WITHIN THE ZAMBIAN GOVERNMENT. THE VIVACTION PROJECT WORKS TO CATALYZE ADOPTION AND EVENTUAL SCALE-UP OF PLASMODIUM VIVAX TOOLS. IN ETHIOPIA, PATH IS STUDYING WHETHER IT IS OPERATIONALLY FEASIBLE TO PROVIDE OPTIMIZED RADICAL CURE TREATMENT TO P. VIVAX PATIENTS WHO ARE ELIGIBLE BASED ON TREATMENT GUIDELINES. IN 2021, PATH HELD MEETINGS WITH LOCAL PARTNER ARMAUER HANSEN RESEARCH INSTITUTE TO DISCUSS PROJECT ACTIVITIES. IN INDIA, PATH CONTINUED TO PROVIDE STRATEGIC TECHNICAL ASSISTANCE IN THE STATE OF UTTAR PRADESH, SUPPORTING THE NATIONAL VECTOR BORNE DISEASE CONTROL PROGRAM TO ADDRESS DENGUE AND MALARIA THROUGH SKILLS STRENGTHENING, OUTBREAK INVESTIGATION, AND DATA MANAGEMENT. PATH PROVIDED TECHNICAL SUPPORT FOR SAFE AND SUCCESSFUL MASS DRUG ADMINISTRATION CAMPAIGNS AS WELL AS MORBIDITY MANAGEMENT AND DISABILITY PREVENTION SERVICES ACROSS 50 LYMPHATIC FILARIASIS-ENDEMIC DISTRICTS. IN THE STATE OF BIHAR, PATH SUPPORTED IMPLEMENTATION OF A JAPANESE ENCEPHALITIS VACCINATION CAMPAIGN. EARLY CHILDHOOD DEVELOPMENT ACTION NETWORK IN 2021, THE EARLY CHILDHOOD DEVELOPMENT ACTION NETWORK (ECDAN), HOSTED BY PATH, CONTINUED TO ADVOCATE FOR YOUNG CHILDREN AND THEIR CAREGIVERS. ECDAN SUPPORTED AND FACILITATED SEVERAL COLLABORATIVE INITIATIVES, INCLUDING LAUNCH OF THE GLOBAL CHILDCARE CAMPAIGN AND - WITH OUR PARTNERS, THE WORLD HEALTH ORGANIZATION (WHO), UNICEF, PARTNERSHIP FOR LIFELONG HEALTH, AND GLOBAL PARTNERSHIP TO END VIOLENCE AGAINST CHILDREN - LAUNCH OF THE GLOBAL INITIATIVE TO SUPPORT PARENTS. ECDAN CONNECTED AND ALIGNED THE GLOBAL COMMUNITY THROUGH CALLS TO ACTION, JOINT STATEMENTS, AND COMMUNITIES OF PRACTICE AND ACCELERATED LEARNING AND KNOWLEDGE EXCHANGE THROUGH WEBINARS AND TWO PLATFORMS: ECD CONNECT AND ECD KNOWLEDGE GATEWAY. ECDAN FINALIZED THREE COUNTRY PILOTS TO TEST THE "COST OF INACTION" METHODOLOGY WITH UNICEF IN BULGARIA AND MADAGASCAR AND WITH THE UNIVERSITY OF SAO PAULO IN BRAZIL. ECDAN ALSO WELCOMED OUR FIRST COHORT OF KNOWLEDGE FELLOWS. FIVE FELLOWS (FROM COLOMBIA, THE PHILIPPINES, SPAIN, UNITED STATES, AND ZAMBIA) COMPLETED THE PROGRAM, WORKING WITH A MENTOR TO DESIGN AND FINALIZE A KNOWLEDGE PRODUCT.
FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE: PRIMARY HEALTH CARE PATH'S PRIMARY HEALTH CARE (PHC) DEPARTMENT EMPLOYS A COMPREHENSIVE, ONE HEALTH, PEOPLE- AND COMMUNITY-CENTERED PHC MODEL THAT ADDRESSES BROADER DETERMINANTS OF HEALTH (E.G., SOCIAL, ECONOMIC, ENVIRONMENTAL). WE FOCUS ON INNOVATIVE, EVIDENCE-BASED TOOLS AND APPROACHES TO MEET PEOPLE'S NEEDS AND PREFERENCES ACROSS THEIR LIFETIME. PHC AT PATH IS COMPOSED OF SIX TEAMS, DESCRIBED BELOW. MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION TOGETHER WITH PARTNERS AROUND THE WORLD, PATH'S MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION (MNCHN) TEAM DEVELOPS, ADAPTS, AND SCALES UP TECHNOLOGIES AND SYSTEMS TO REDUCE ILLNESS AND DEATH AMONG MOTHERS AND CHILDREN AND GIVE CHILDREN THE BEST POSSIBLE START IN LIFE. TO ENSURE THAT ALL INFANTS HAVE ACCESS TO HUMAN MILK, PATH FOCUSES ON BREASTFEEDING PROMOTION, PROVISION OF SPECIALIZED LACTATION SUPPORT FOR MOTHERS OF SMALL AND SICK NEWBORNS, AVAILABILITY OF SAFE DONOR MILK THROUGH LOCAL HUMAN MILK BANKS, AND UPTAKE AND USE OF GLOBAL STANDARDS FOR HUMAN MILK BANKING. USING HUMAN-CENTERED DESIGN, WE CONTINUED CREATING A DIGITAL ADAPTATION KIT FOR OPTIMAL NEWBORN FEEDING AND THE PROVISION OF LACTATION SUPPORT, WHICH IS BEING DEVELOPED IN KENYA AS A GLOBAL GOOD FOR ALL SETTINGS. PATH CONTINUED SUPPORTING ARIADNE LABS AS A SUBJECT MATTER EXPERT AND PERFORMED A FEASIBILITY ASSESSMENT IN INDIA, MALAWI, AND TANZANIA ON THE USE OF DONOR HUMAN MILK FOR LOW-BIRTHWEIGHT INFANTS. THESE FINDINGS ARE BEING DISSEMINATED GLOBALLY AND THROUGH MULTIPLE PEER-REVIEWED PUBLICATIONS. IN GHANA, PATH IS LEADING A FOUR-YEAR EFFORT, ADVANCED NEWBORN CARE IN GHANA: BEYOND MAKING EVERY BABY COUNT INITIATIVE (MEBCI 2.0), TO REDUCE PERINATAL MORTALITY IN FOUR HIGH-VOLUME REFERRAL HOSPITALS. IN 2021, MEBCI 2.0 ENGAGED WITH THE GHANA HEALTH SERVICE TO OPERATIONALIZE ITS NEWBORN ACTION PLAN, MOBILIZE REGIONAL STAKEHOLDERS AND RESOURCES, AND DRIVE ADVOCACY AND POLICY ACTION. THROUGH THE NEOLENS PROJECT, PATH DOCUMENTED COUNTRY-LEVEL JOURNEYS IN ESTABLISHING IN-PATIENT CARE FOR SMALL AND SICK NEWBORNS IN LOW-RESOURCE SETTINGS. TO SHOWCASE LESSONS LEARNED IN ETHIOPIA, INDIA, MALAWI, AND RWANDA, WE CREATED CASE STUDIES FOR EACH COUNTRY AND PARTNERED WITH MASS DESIGN GROUP TO DEVELOP AN INTERACTIVE, VIRTUAL EXPERIENCE. FOLLOWING A PATH PROJECT THAT DOCUMENTED UPTAKE OF 14 KEY MNCHN ASSETS IN 81 COUNTDOWN TO 2030 COUNTRIES, IN 2021 PATH CONDUCTED A SUBNATIONAL INQUIRY IN FIVE FOCUS COUNTRIES ON THE INHERENT BARRIERS AND ENABLERS TO SCALE-UP OF THESE COMMODITIES. WE DEVELOPED COMPLEMENTARY INTERACTIVE DASHBOARDS TO PROVIDE THE DATA IN A USER-FRIENDLY INTERFACE. IN COLLABORATION WITH THE GHANA HEALTH SERVICE AND WITH FUNDING FROM THE PFIZER FOUNDATION, PATH INITIATED THE INTEGRATED ANTENATAL CARE PROJECT IN THE BONO EAST REGION OF GHANA. THE PROJECT AIMS TO AVERT INFECTIOUS DISEASE MORTALITY AND MORBIDITY IN NEONATES AND MOTHERS BY IMPLEMENTING AN IMPROVED, COMPREHENSIVE INFECTIOUS DISEASE SCREENING PROGRAM DURING PREGNANCY. ALSO IN 2021, MNCHN STAFF SERVED GLOBALLY IN LEADERSHIP ROLES RELATED TO COVID-19 AND THE PROTECTION OF WOMEN AND CHILDREN. WE PARTICIPATED IN GLOBAL TECHNICAL WORKING GROUPS, PRESENTED (MOSTLY VIRTUALLY) AT KEY GLOBAL AND NATIONAL MEETINGS, AND AUTHORED AND CONTRIBUTED TO HIGH-PROFILE PEER-REVIEWED JOURNAL ARTICLES, BOOK CHAPTERS, GLOBAL REPORTS, AND SYSTEMATIC REVIEWS. THESE EFFORTS ADVANCED THINKING ON BROAD, EFFECTIVE SOLUTIONS TO THE MOST PRESSING CHALLENGES IN MNCHN. RECOGNIZING THAT NUTRITION IS AFFECTED BY A VARIETY OF ECONOMIC AND ENVIRONMENTAL FACTORS, PATH'S NUTRITION TEAM DRIVES NOVEL APPROACHES TO ADDRESS THE MASSIVE BURDEN OF MALNUTRITION IN COMMUNITIES AROUND THE WORLD. TOGETHER WITH PATH'S CLIMATE CHANGE COMMUNITY OF PRACTICE, PATH'S NUTRITION TEAM CONTINUED TO ADVOCATE FOR SUSTAINABLE CLIMATE-FRIENDLY ALTERNATIVES, SUCH AS CULTURED PROTEINS AND EDIBLE INSECTS. AS A REFLECTION OF OUR EXPERTISE, PATH LEADS THE BIOMARKER COLLECTION AND ANALYSIS COMPONENTS OF THE DEMOGRAPHIC HEALTH SURVEY CONDUCTED IN COUNTRIES AROUND THE WORLD. FINALLY, PATH CONTINUED OUR WORK ON THE BRIDGE COLLABORATIVE, A TRAILBLAZING, CROSS-DISCIPLINARY EFFORT OF MORE THAN 150 LEADING TECHNICAL EXPERTS FROM THE HEALTH, DEVELOPMENT, AND ENVIRONMENTAL SECTORS TO ADDRESS HUMAN AND PLANETARY HEALTH. EARLY CHILDHOOD DEVELOPMENT IN 2021, PATH CONTINUED TO EXPAND OUR GLOBAL AND NATIONAL LEADERSHIP IN EARLY CHILDHOOD DEVELOPMENT (ECD). FOR EXAMPLE, WITH PATH SUPPORT, THE GOVERNMENTS OF ETHIOPIA, KENYA, AND MOZAMBIQUE CONTINUED TO SCALE UP ECD SERVICE PROVISION AS AN ESSENTIAL COMPONENT OF BASIC HEALTH CARE AND INTRODUCED INTEGRATED ECD SERVICE DELIVERY INTO ADDITIONAL SUBNATIONAL GEOGRAPHIES. THIS PIONEERING WORK CENTERS AROUND BUILDING AN ENABLING LEADERSHIP AND POLICY ENVIRONMENT WHILE STRENGTHENING THE CAPACITY OF HEALTH SYSTEMS AND HEALTH SERVICE PROVIDERS. WITH A CONSTELLATION OF PARTNERS, PATH FACILITATED COLLECTIVE ACTION ACROSS MULTIPLE SECTORS AT NATIONAL AND SUBNATIONAL LEVELS TO PROMOTE ECD THROUGH ENHANCED PLANNING, COORDINATION, AND RESOURCING. HEALTH SYSTEMS THE HEALTH SYSTEMS TEAM SERVES AS AN ORGANIZING MECHANISM FOR PATH'S PROJECTS AND INITIATIVES THAT STRENGTHEN HEALTH SYSTEMS. BOTH WITHIN PATH AND IN COLLABORATION WITH EXTERNAL PARTNERS, THE TEAM LEADS COMPLEX EVALUATIONS OF HEALTH PROGRAMS, ENGAGES IN IMPLEMENTATION SCIENCE RESEARCH, FACILITATES INTERVENTION SCALE-UP, AND IMPROVES DATA QUALITY AND USE FOR DECISION-MAKING. IN 2021, MAJOR ACTIVITIES INCLUDED (1) COMPLETION OF A FOUR-YEAR PROSPECTIVE EVALUATION OF THE GLOBAL FUND'S INVESTMENTS IN THE DRC, GUATEMALA, SENEGAL, AND UGANDA; (2) LEADING MONITORING, EVALUATION, AND LEARNING WITHIN USAID'S MOMENTUM ROUTINE IMMUNIZATION TRANSFORMATION AND EQUITY (M-RITE) PORTFOLIO ACROSS SEVERAL COUNTRIES IN AFRICA AND SOUTHEAST ASIA; AND (3) EVALUATION OF AN INNOVATION TO INCREASE HIV PRE-EXPOSURE PROPHYLAXIS UPTAKE AMONG ADOLESCENT GIRLS AND YOUNG WOMEN IN ZIMBABWE. HIV, TUBERCULOSIS, AND VIRAL HEPATITIS AS COVID-19 CONTINUED TO DISRUPT ACCESS TO ESSENTIAL HEALTH SERVICES, PATH'S HIV, TUBERCULOSIS (TB), AND VIRAL HEPATITIS TEAM FOCUSED ON ADVANCING PERSON-CENTERED HEALTH CARE ACROSS AFRICA, CENTRAL ASIA, AND SOUTHEAST ASIA FOR GENERAL, KEY, AND PRIORITY POPULATIONS. METHODS INCLUDED PROMOTING INTEGRATED SERVICE DELIVERY MODELS, ACCELERATING SELF-CARE INITIATIVES, AND LEVERAGING DIGITAL HEALTH TOOLS TO ENSURE EQUITABLE AND HIGH-QUALITY ACCESS TO HEALTH SERVICES. PATH, WITH FUNDING FROM UNITAID THROUGH THE STAR-III PROJECT, CONTINUED TO ACCELERATE ACCESS TO HIV SELF-TESTING (HIVST) IN INDIA, INDONESIA, AND UGANDA BY CONDUCTING ASSESSMENTS TO INFORM DEVELOPMENT OF NEW HIVST DISTRIBUTION MODELS AND NATIONAL POLICIES AND GUIDELINES. IN 2021, THE PROJECT SUPPORTED THE DISTRIBUTION OF MORE THAN 150,000 HIVST KITS AND TRAINED MORE THAN 750 PROVIDERS ON HIVST SERVICES. PATH ALSO RECEIVED FUNDING TO ADVANCE SELF-TESTING FOR HEPATITIS C IN INDIA AND VIETNAM AND SELF-TESTING FOR COVID-19 IN BRAZIL, INDIA, SOUTH AFRICA, AND UGANDA, WITH THIS YEAR'S EFFORTS FOCUSED ON ORIENTING STAKEHOLDERS AND PREPARING FOR IMPLEMENTATION. AS A PARTNER ON THE UNITAID-FUNDED ADHERENCE SUPPORT COALITION TO END TB PROJECT, PATH WORKED TO ESTABLISH A GLOBAL MARKET FOR DIGITAL ADHERENCE TECHNOLOGIES (DATS). WE IMPLEMENTED RESEARCH IN UKRAINE ON THE USE OF DATS AND SUCCESSFULLY ADVOCATED WITH THE UKRAINIAN GOVERNMENT FOR SCALE-UP OF DATS DURING WAR AND AMONG DISPLACED PERSONS. IN PARTNERSHIP WITH THE TB ALLIANCE, PATH WORKED TO ADVANCE A SHORTER TREATMENT (BEDAQUILINE, PRETOMANID, AND LINEZOLID, KNOWN AS BPAL) FOR MULTIDRUG-RESISTANT TB, DEVELOPING A ROAD MAP TO INTRODUCE BPAL IN PERU AND UKRAINE AS WELL AS FACILITATING A COSTING STUDY OF BPAL IN UKRAINE. IN THE DRC, UNDER THE USAID-FUNDED INTEGRATED HIV/AIDS PROJECT IN HAUT-KATANGA (IHAP-HK), PATH TESTED AND EXPANDED PERSON-CENTERED APPROACHES FOR ENHANCED CARE, TREATMENT SUPPORT, AND VIRAL LOAD MONITORING. THE PROJECT CO-CREATED AN ELECTRONIC CLIENT FEEDBACK SYSTEM WITH FACILITY PROVIDERS AND ASSOCIATIONS OF PEOPLE LIVING WITH HIV (PLHIV) AND THEN TESTED THE SYSTEM AT SIX FACILITIES. IMPLEMENTATIONS BASED ON THE FEEDBACK RESULTED IN SHORTER WAIT TIMES FOR CLIENTS AND FEWER INSTANCES OF STIGMA AND DISCRIMINATION. IHAP-HK ALSO CO-ADAPTED, WITH ADOLESCENTS AND YOUNG PEOPLE, KENYA'S OPERATION TRIPLE ZERO APPROACH FOR THE DRC CONTEXT. THIS LED TO THE CREATION OF ADDITIONAL COMMUNITY SUPPORT GROUPS FOR CHILDREN, ADOLESCENTS, AND YOUNG PEOPLE FOCUSED ON PROMOTING ADHERENCE TO TREATMENT AND CLINICAL APPOINTMENTS, WITH THE GOAL OF VIRAL SUPPRESSION. THE PROJECT ALSO TESTED COLLABORATIVE CASE MANAGEMENT AMONG HEALTH WORKERS, PEER EDUCATORS, AND CASE MANAGERS FOR CHILDREN LIVING WITH HIV TO PROVIDE ENHANCED ADHERENCE SUPPORT SERVICES, AGAIN TO HELP ACHIEVE VIRAL SUPPRESSION.
FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE: IN WESTERN KENYA, PATH SUCCESSFULLY CLOSED OUT THE PEPFAR-FUNDED AFYA ZIWANI PROJECT. OVER THE PROJECT LIFETIME, 1,586,802 PEOPLE WERE TESTED FOR HIV, OF WHICH 25,569 WERE DIAGNOSED WITH HIV AND LINKED TO CARE AND TREATMENT. IN MID-2021, PATH TRANSITIONED THE PROGRAMMING TO TWO NEW INITIATIVES: (1) A COMPREHENSIVE PACKAGE OF HEALTH, SOCIAL, AND ECONOMIC STRENGTHENING SERVICES FOR CHILDREN, ADOLESCENTS, AND YOUNG PEOPLE THROUGH THE PEPFAR-FUNDED NURU YA MTOTO PROJECT, FOR WHICH PATH IS PRIME; AND (2) HIGH-QUALITY CLINICAL HIV AND TB/HIV SERVICES FOR PEOPLE LIVING WITH OR AT RISK OF HIV THROUGH THE PEPFAR-FUNDED BORESHA JAMII PROJECT, FOR WHICH PATH IS A KEY SUBPARTNER LEADING THE CLINICAL WORK. PATH ALSO LED THE CHAK A CHAKA PROJECT, WHICH STRENGTHENS ECONOMIC SKILLS AMONG YOUNG WOMEN IN KISUMU, HOMA BAY, AND MIGORI COUNTIES TO REDUCE HIV RISK AND VULNERABILITY. IN 2021, PATH HELPED 1,225 YOUNG WOMEN BUILD SAVINGS AND ENTREPRENEURIAL SKILLS THROUGH ACCESS TO BUSINESS DEVELOPMENT TRAININGS AND INSURANCE FUNDS. IN INDIA, THROUGH THE U.S. CDC-FUNDED STRENGTHENING STRATEGIC INFORMATION MANAGEMENT SYSTEMS PROJECT, PATH CONTINUED TO SUPPORT THE NATIONAL AIDS CONTROL PROGRAM AT THE STATE AND DISTRICT LEVEL IN MUMBAI AND ANDHRA PRADESH AS WELL AS NATIONALLY TO FURTHER STREAMLINE DATA REPORTING SYSTEMS AND ENHANCE DATA USE FOR PROGRAM IMPROVEMENT AND PLANNING. AMONG OTHER ACTIVITIES, WE CREATED SITE-LEVEL SYSTEMS TO IMPROVE FOLLOW-UP WITH CLIENTS, DEPLOYED A MONTHLY DISTRICT-LEVEL PLANNING PROCESS IN ANDHRA PRADESH TO IMPROVE HIV TESTING AND LINKAGES TO SERVICE, AND CREATED NATIONAL-LEVEL DASHBOARDS TO BETTER MONITOR HIV PROGRAM PERFORMANCE AGAINST EPIDEMIC CONTROL INDICATORS. IN SUPPORT OF TB PROGRAMMING IN INDIA, PATH INTRODUCED ARTIFICIAL INTELLIGENCE TO STREAMLINE CHEST X-RAY READINGS, ENABLING QUICKER DIAGNOSIS AND INITIATION ON TREATMENT. WITH SUPPORT FROM USAID, PATH FACILITATED A NEEDS ASSESSMENT FOR TECHNICAL SUPPORT UNITS TO FOSTER LOCAL PRIVATE-SECTOR ENGAGEMENT ACROSS FIVE INDIAN STATES. PATH ALSO SUPPORTED REVISIONS AND UPDATES TO TB CONTROL STANDARDS IN PARTNERSHIP WITH WHO AND THE NATIONAL TB PROGRAM. IN ZAMBIA, PATH CONTINUED TO IMPLEMENT THE USAID-FUNDED ERADICATE TB PROJECT, WHICH SCREENED 1,967,914 INDIVIDUALS FOR SYMPTOMS OF TB, AMONG WHOM 223,337 (11%) WERE PRESUMED TO HAVE TB. SAMPLES FROM 200,899 (90%) OF THOSE WERE THEN TESTED IN THE LABORATORY, RESULTING IN 9,872 (5%) CONFIRMED TB CASES. OF THESE, 9,521 (96%) WERE SUCCESSFULLY INITIATED ON TREATMENT. THE PROJECT ALSO STRENGTHENED THE LABORATORY NETWORK TO MORE EFFICIENTLY AND EFFECTIVELY DIAGNOSE AND MONITOR PEOPLE WITH TB. AN EXTERNAL QUALITY ASSESSMENT SHOWED THAT 90% OF HEALTH FACILITY LABORATORIES ACHIEVED 95% CORRECT RESULTS. THE PROJECT CONTINUED TO TRAIN FRONTLINE HEALTH CARE WORKERS IN THE SIX SUPPORTED PROVINCES ON CHILDHOOD TB DETECTION AND DRUG-RESISTANT TB CASE MANAGEMENT. IN TANZANIA, THE USAID-FUNDED IDDS PROJECT SUPPORTED KEY FUNCTIONS AT THE CENTRAL TB REFERENCE LABORATORY, FACILITATED REPORTING FROM SITES USING THE GENEXPERT PLATFORM, COMPLETED AN ASSESSMENT OF THE TB DIAGNOSTIC NETWORK, AND PREPARED FOR INTRODUCTION OF NEW DIAGNOSTIC METHODS. THROUGH THIS PROJECT IN VIETNAM, PATH CONTINUED TO SUPPORT THE NATIONAL TB PROGRAM BY ASSESSING PROGRESS ON THE "DOUBLE X" STRATEGY (CHEST X-RAY AND GENEXPERT TEST), SUPPORTING THE APPLICATION OF ARTIFICIAL INTELLIGENCE FOR READING CHEST X-RAYS, AND PERFORMING ANALYSES TO IMPROVE SPECIMEN TRANSPORT SYSTEMS AND DIAGNOSTIC ACCESS. ALSO IN VIETNAM, THE USAID/PATH HEALTHY MARKETS PROJECT INTRODUCED NEW HIV PRODUCTS TO OPTIMIZE CHOICE FOR CLIENTS, SUPPORTED THE DEVELOPMENT OF CRITICAL NEW POLICIES (INCLUDING A FIRST-EVER HIV PRIVATE-SECTOR ENGAGEMENT PLAN), AND RAPIDLY PIVOTED KEY POPULATION PLATFORMS TO DELIVER LIFESAVING COVID-19 AND HIV CARE DURING VIETNAM'S SEVERE FOURTH SURGE OF COVID-19. IN DECEMBER, THE TEAM TRANSITIONED THE PROJECT TO USAID/PATH STEPS, A FIVE-YEAR PEPFAR-FUNDED INITIATIVE THAT BUILDS ON THE ACHIEVEMENTS OF HEALTHY MARKETS. IN PARTNERSHIP WITH THE HEPATITIS FUND, PATH LAUNCHED INTEGRATED AND COMMUNITY-BASED HIV AND VIRAL HEPATITIS SCREENING AT 27 HEALTH FACILITIES IN VIETNAM, TESTING MORE THAN 11,000 PEOPLE FOR HEPATITIS B AND C AND ENROLLING MORE THAN 500 ON TREATMENT. WE ALSO PARTNERED WITH THE MOH TO PROTOTYPE A DIGITALIZED VIRAL HEPATITIS HEALTH INFORMATION AND TRACKING SYSTEM. IN TAJIKISTAN, KAZAKHSTAN, AND UZBEKISTAN, PATH PROVIDED CLINICAL EXPERTISE TO CREATE AND REVISE NATIONAL GUIDELINES AND PROTOCOLS FOR DRUG-SENSITIVE AND DRUG-RESISTANT TB, DEVELOPED PLANS FOR A CLINICAL AUDIT, AND SUPPORTED OPERATIONS RESEARCH AND SCALE-UP PLANNING FOR NEW TB REGIMENS UNDER THE USAID ELIMINATING TB IN CENTRAL ASIA PROJECT. IN UKRAINE, PATH CONTINUED TO LEAD THE USAID-FUNDED SERVING LIFE PROJECT, WHICH REDUCES TB, HIV, AND HEPATITIS C TRANSMISSION IN THE PENAL SYSTEM AND COMMUNITIES ACROSS 12 REGIONS. WE PILOTED INNOVATIVE INTERVENTIONS THAT WILL ULTIMATELY BE TRANSITIONED TO GOVERNMENT LEADERSHIP, INCLUDING MEDICATION-ASSISTED THERAPY, PROVISION OF PSYCHOSOCIAL AND HIV SERVICES FOR PRE-TRIAL DETAINEES, AND INDEX CASE TESTING FOR CONTACTS OF DETAINEES NEWLY DIAGNOSED WITH HIV. PATH CONTINUED TO IMPLEMENT THE USAID-FUNDED SUPPORT TB CONTROL EFFORTS IN UKRAINE (STBCEU) PROJECT, WHICH FOCUSES ON PREVENTION, DETECTION, AND TREATMENT OF TB, DRUG-RESISTANT TB, AND TB/HIV. IN 2021, STBCEU SUCCESSFULLY ADVOCATED FOR THE INTRODUCTION OF STOOL TESTING AS THE PREFERRED METHOD OF TB DIAGNOSIS AMONG CHILDREN, PILOTED MOBILE X-RAY SCREENINGS, IMPROVED ALGORITHMS FOR ACTIVE CASE FINDING AMONG POPULATIONS AT RISK FOR TB, AND PROVIDED TB EDUCATION THROUGH NATIONAL NEWS PROGRAMS. NONCOMMUNICABLE DISEASES PATH IS AT THE FOREFRONT OF EFFORTS TO PREVENT, DETECT, AND TREAT NONCOMMUNICABLE DISEASES (NCDS), INCLUDING DIABETES AND CARDIOVASCULAR DISEASE, IN LOW-RESOURCE SETTINGS WORLDWIDE, WHERE THE BURDEN OF THESE DISEASES IS RISING DISPROPORTIONATELY. IN 2021, PATH CONTINUED TO SERVE AS THE SECRETARIAT OF THE COALITION FOR ACCESS TO NCD MEDICINES AND PRODUCTS. THIS GLOBAL, MULTISECTORAL COLLABORATION WORKS TO INCREASE ACCESS TO NCD MEDICINES AND HEALTH PRODUCTS IN LMICS. IN ADDITION TO GLOBAL ADVOCACY, THE COALITION LED THE DEVELOPMENT AND IMPLEMENTATION OF A FORECASTING PROGRAM FOR NCD MEDICINES AND PRODUCTS IN KENYA AND UGANDA. PATH IMPLEMENTED NCD PROJECTS IN GHANA, KENYA, AND VIETNAM TO BUILD STRONGER PHC SYSTEMS, SUPPLY CHAINS, AND DATA-DRIVEN DECISION-MAKING - ALL CRITICAL COMPONENTS OF HEALTH SYSTEM RESILIENCY. OUR EFFORTS IN GHANA INCLUDED SUPPLY CHAIN STRENGTHENING AND IMPLEMENTATION OF THE NCD NAVIGATOR - A FIRST-OF-ITS-KIND, LOCALLY MANAGED DIGITAL INFORMATION SYSTEM FOR NCD RESOURCE PLANNING AND ALLOCATION - IN 9 OF GHANA'S 16 REGIONS. IN PARTNERSHIP WITH THE GHANA HEALTH SERVICE, PATH'S HEALTHY HEART AFRICA PROJECT, WHICH FOCUSES ON HYPERTENSION MANAGEMENT AT THE COMMUNITY LEVEL, CONDUCTED MORE THAN 500,000 BLOOD PRESSURE SCREENINGS AND LINKED THOSE DIAGNOSED TO TREATMENT. IN SENEGAL, PATH ALSO LAUNCHED THE HEALTHY HEART AFRICA PROJECT, WHILE RWANDA AND TANZANIA PREPARED FOR IMPLEMENTATION. IN KENYA, PATH IMPLEMENTED A CUTTING-EDGE PROGRAM THAT ENABLES COMMUNITY AND HOUSEHOLD SCREENINGS FOR HYPERTENSION, REMOTE BLOOD PRESSURE AND BLOOD SUGAR MONITORING, TELEMEDICINE, COMMUNITY-BASED DRUG DELIVERY, AND ENHANCED DATA MANAGEMENT. WE TRANSITIONED OWNERSHIP OF THE NCD NAVIGATOR TO THE MOH BUT CONTINUED TO PROVIDE TECHNICAL ASSISTANCE. AS THE MOH SEEKS TO IMPROVE THE SUPPLY CHAIN IN PREPARATION FOR UNIVERSAL HEALTH COVERAGE, WE BEGAN IMPLEMENTING SEVERAL INNOVATIONS FOR NCDS, SUCH AS A STOCK TRACKER, AN ELECTRONIC MEDICAL RECORD MODULE, AND LAST-MILE DISTRIBUTION OF NCD MEDICINES AND SUPPLIES. PATH ALSO BEGAN IMPLEMENTING AN HIV/HYPERTENSION INTEGRATION PROJECT IN THREE FACILITIES IN WESTERN KENYA TO INCREASE ACCESS TO CARE. OUR FOCUS IN VIETNAM WAS ON A PHC MODEL THAT USES PUBLIC-PRIVATE PARTNERSHIPS, DIGITAL TOOLS, AND COMMUNITY HEALTH WORKERS TO SUPPORT SCREENINGS AND LINKAGES TO CARE. IN ADDITION, WE CONDUCTED A SUPPLY CHAIN ASSESSMENT TO DETERMINE THE AVAILABILITY AND AFFORDABILITY OF NCD MEDICINES AT THE PHC LEVEL. PATH ALSO LAUNCHED THE DIABETES CAREPAK IN KENYA AND VIETNAM, AN INNOVATIVE SOLUTION TO BUNDLE THE COMMODITIES NEEDED FOR SAFE ADMINISTRATION OF INSULIN AND OTHER DIABETES SELF-CARE PRODUCTS. EXPANSION INTO MALI, MOZAMBIQUE, TANZANIA, AND UGANDA WAS APPROVED TOWARD THE END OF THE YEAR. FINALLY, PATH LED AND CONTRIBUTED TO CONVENINGS TO RAISE AWARENESS OF NCDS AND ORCHESTRATE ACTION TO IMPROVE ACCESS TO NCD PREVENTION AND CARE.
FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE: SEXUAL AND REPRODUCTIVE HEALTH PATH'S WORK IN SEXUAL AND REPRODUCTIVE HEALTH (SRH) IS GUIDED BY THE PRINCIPLES OF CHOICE, EQUITY, AND DIGNITY FOR ALL PEOPLE AND GROUNDED IN AN UNDERSTANDING OF THE COMPLEX SOCIAL, BEHAVIORAL, AND GENDER DIMENSIONS OF SRH THROUGHOUT THE LIFE CYCLE. WE BUILD EVIDENCE AROUND TOOLS AND SERVICES THAT ARE CO-DESIGNED WITH AND FOR WOMEN AND GIRLS TO ADDRESS THEIR DIVERSE NEEDS AND CIRCUMSTANCES, REDUCE BARRIERS, AND EXPAND OPTIONS. PATH IS A LEADER IN THE SELF-CARE MOVEMENT, SUPPORTING INDIVIDUALS AND FAMILIES WHO CHOOSE TO MANAGE THEIR OWN HEALTH. IN SENEGAL, THE MOH, PATH, AND PARTNERS ARE ADVANCING POLICY THROUGH THE SELF-CARE PIONEERS, A COALITION OF CHAMPIONS LEADING THE DEVELOPMENT OF SENEGAL'S SELF-CARE GUIDELINES. THESE WILL BE AMONG THE FIRST NATIONAL SELF-CARE GUIDELINES IN THE WORLD, AND THE FIRST IN FRANCOPHONE AFRICA. WITH ASSISTANCE FROM PATH AND PARTNERS, COUNTRIES HAVE CONTINUED TO ACCELERATE SCALE-UP OF THE CONTRACEPTIVE INNOVATION, SELF-INJECTION WITH SUBCUTANEOUS DMPA (DMPA-SC). LED BY PATH IN PARTNERSHIP WITH JOHN SNOW, INC., THE DMPA-SC ACCESS COLLABORATIVE IN 2021 PROVIDED TECHNICAL ASSISTANCE TO 20 COUNTRIES AND COLLECTED DATA FROM 11 COUNTRIES SHOWING MORE THAN 315,000 CLIENT SELF-INJECTION VISITS. IN UGANDA, PATH AND THE MOH ARE IMPLEMENTING GROUNDBREAKING PERSON-CENTERED PROGRAMS TO DEMONSTRATE HOW SELF-INJECTION CAN BE OFFERED AT SCALE. FOR DECADES, PATH HAS BEEN AT THE FOREFRONT OF EVIDENCE-BASED STRATEGIES TO ADDRESS THE INEQUITABLE BURDEN OF CERVICAL CANCER IN LMICS, FROM HUMAN PAPILLOMAVIRUS (HPV) VACCINE RESEARCH AND DELIVERY TO CERVICAL CANCER SCREENING AND TREATMENT. GLOBALLY, PATH HELPED SHAPE STRATEGIES FOR LMICS AS PART OF WHO'S CALL FOR GLOBAL CERVICAL CANCER ELIMINATION, AND WE CONTINUE TO PURSUE OPPORTUNITIES FOR SECONDARY PREVENTION (I.E., EARLY DETECTION) INTERVENTIONS. IN PERU, PATH IMPLEMENTED A MODEL FOR EARLY DETECTION OF BREAST CANCER APPROPRIATE AND FEASIBLE FOR THESE SETTINGS. WE PARTNERED WITH THE MOH TO DESIGN AND IMPLEMENT A REAL-TIME DIGITAL PATIENT TRACKING SYSTEM FOR BREAST CANCER DETECTION. THROUGH THE USAID IMPROVING MARKET PARTNERSHIPS AND ACCESS TO COMMODITIES TOGETHER PROJECT IN MADAGASCAR, PATH AND PUBLIC- AND PRIVATE-SECTOR CHAMPIONS SUPPORTED THE GOVERNMENT TO DEVELOP A STRATEGY FOR A TOTAL MARKET APPROACH TO IMPROVE ACCESS TO HIGH-QUALITY HEALTH PRODUCTS FOR FAMILY PLANNING (FP), MATERNAL AND CHILD HEALTH, AND MALARIA. IN INDIA, PATH IMPLEMENTED SEVERAL SUPPLY CHAIN STRENGTHENING INITIATIVES TO HELP ENSURE AVAILABILITY OF FP PRODUCTS. WE PILOTED AN INFORMED PUSH MODEL TO REDUCE STOCKOUTS, INTRODUCED KITS FOR LAST-MILE FP AVAILABILITY, DESIGNED A SUPPLY CHAIN MANAGEMENT E-LEARNING COURSE, AND FACILITATED A PARTNERSHIP BETWEEN THE ODISHA STATE GOVERNMENT AND THE INDIA POST FOR FP DELIVERY. WE CONDUCTED A POLICY AND REGULATORY LANDSCAPE FOR PRIVATE-SECTOR FP DELIVERY AND CONTRIBUTED TO INDIA'S FP2030 DRAFT COMMITMENTS ON STRENGTHENING SUPPLY CHAINS. IN MYANMAR, PATH IS FULFILLING THE GROWING NEED FOR INFORMATION AND SERVICES TO ADDRESS GENDER-BASED VIOLENCE (GBV) AND SEXUAL AND REPRODUCTIVE HEALTH AND RIGHTS (SRHR) AMID THE CURRENT LOCAL POLITICAL SITUATION AND COVID-19 PANDEMIC. WITH FUNDING FROM WHO, WE INCREASED GBV AWARENESS IN THE PERI-URBAN YANGON MIGRANT COMMUNITY; SUPPORTED WOMEN IN CRISIS WITH FOOD, SHELTER, AND TRANSPORTATION; CONDUCTED A WELL-BEING WORKSHOP AND WEBINAR; AND FACILITATED A 16-DAY SRHR AND GBV ACTIVISM CAMPAIGN. PATH CONTINUED TO SERVE AS THE SECRETARIAT FOR THE REPRODUCTIVE HEALTH SUPPLIES COALITION, A GLOBAL PARTNERSHIP OF MORE THAN 540 PUBLIC AND PRIVATE ENTITIES AND NONGOVERNMENTAL ORGANIZATIONS WORKING TO EXPAND ACCESS TO CRITICAL SRH AND FP SUPPLIES AND SERVICES.
FORM 990, PART III, LINE 4B, DESCRIPTION OF PROGRAM SERVICE: PATH PUBLISHED SEVERAL ARTICLES ON THE ECONOMIC IMPACT OF RESPIRATORY SYNCYTIAL VIRUS (RSV) AND OTHER ACUTE RESPIRATORY INFECTIONS AMONG INFANTS IN LMICS, AND ON THE IMPORTANCE OF MATERNAL IMMUNIZATION AND THE STRENGTHENING OF RSV ASSAYS. ADDITIONALLY, PATH UPDATED OUR RSV VACCINE AND MONOCLONAL ANTIBODY SNAPSHOT, WHICH PROVIDES AN OVERVIEW OF THE INTERVENTION PRODUCT LANDSCAPE, AND OUR TRIAL TRACKER, WHICH PROVIDES INFORMATION ON RELATED CLINICAL TRIALS. DRUG DEVELOPMENT THROUGH OUR WORK ON DRUG DEVELOPMENT AND INTRODUCTION, PATH HELPS ENSURE THAT PEOPLE AROUND THE WORLD, ESPECIALLY CHILDREN IN LOW-RESOURCE SETTINGS, HAVE RELIABLE ACCESS TO LIFESAVING MEDICINES. OVER THE YEARS, OUR WORK HAS ADVANCED SOLUTIONS FOR A RANGE OF URGENT GLOBAL HEALTH CHALLENGES, INCLUDING ENTERIC AND DIARRHEAL DISEASES, NEGLECTED TROPICAL DISEASES, HIV/AIDS, AND MALARIA. DRAWING ON AN ENDURING COMMITMENT TO HEALTH EQUITY AND A UNIQUE PARTNERSHIP APPROACH THAT SPANS THE ACADEMIC, PRIVATE, NONPROFIT, AND GOVERNMENT SECTORS, OUR WORK OVERTURNS BARRIERS TO HEALTH AT EVERY STAGE OF DRUG DEVELOPMENT AND USE - FROM EARLY RESEARCH TO INTRODUCTION. IN 2021, WE CONTINUED DEVELOPING NEW THERAPEUTICS FOR CRYPTOSPORIDIUM, A DEADLY DIARRHEA-CAUSING PARASITE FOR WHICH NO HIGHLY EFFECTIVE TREATMENT IS AVAILABLE. WE DEMONSTRATED THAT OUR LEAD COMPOUND IS EFFECTIVE IN DAIRY CALVES, A KEY MODEL THAT MIRRORS HUMAN CLINICAL SYMPTOMS. WITH OUR MANUFACTURING PARTNER QUANSYS BIOSCIENCES, WE COMMERCIALLY LAUNCHED THE MICRONUTRIENT AND EED ASSESSMENT TOOL (MEEDAT), A NEW TOOL FOR ASSESSING ENVIRONMENTAL ENTERIC DYSFUNCTION (EED) - AN INTESTINAL DISORDER RESPONSIBLE FOR A SIGNIFICANT PORTION OF THE GROWTH STUNTING OF APPROXIMATELY 140 MILLION CHILDREN WORLDWIDE. MEEDAT WAS USED IN STUDIES OF CHILDREN IN ZAMBIA AND TANZANIA, WITH ADDITIONAL STUDIES PLANNED IN OTHER LOW-RESOURCE SETTINGS. PATH ALSO EXPLORED NEW USES AND PARTNERSHIPS FOR IOWH032, A DRUG CANDIDATE WE PREVIOUSLY DEVELOPED FOR TREATMENT OF CHOLERA, WHICH ALSO HAS POTENTIAL FOR TREATING OTHER DISEASES.
FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICE: THROUGH THE IDDS PROJECT, PATH SUPPORTED THE MINISTRY OF AGRICULTURE, ANIMAL INDUSTRIES AND FISHERIES (MAAIF) TO INSTRUCT THE FIRST-EVER ISO/IEC 17025:2017 (THE QUALITY STANDARD FOR OPERATION OF LABORATORIES) TRAINER OF TRAINERS COHORT IN THE COUNTRY AS PART OF A GLOBAL HEALTH SECURITY EFFORT TO IMPROVE DETECTION OF PRIORITY ZOONOTIC DISEASES. WORKING WITH RELEVANT NATIONAL STAKEHOLDERS, PATH DRAFTED AND OPERATIONALIZED A UGANDA STRATEGY FOR COORDINATED AND INTEGRATED SURVEILLANCE OF THESE DISEASES. PATH SUPPORTED THE NATIONAL ANIMAL DISEASES DIAGNOSTICS AND EPIDEMIOLOGY CENTER AND THE ANIMAL HEALTH NATIONAL REFERENCE LABORATORY WITHIN MAAIF TO IMPROVE DATA ENTRY, QUALITY, ANALYSIS, AND REPORTING. ALSO THROUGH IDDS, PATH REVITALIZED FACILITY- AND COMMUNITY-BASED SURVEILLANCE FOR COVID-19 IN EASTERN UGANDA. PATH ALSO SUPPORTED THE DEVELOPMENT OF STANDARD OPERATING PROCEDURES AND WASTE MANAGEMENT GUIDELINES FOR COVID-19 VACCINATION ROLLOUT AND PROVIDED REGULATORY SUPPORT TO THE MOH TO EXPEDITE COVID-19 VACCINE AUTHORIZATION AND SHIPMENT INTO THE COUNTRY. FURTHERMORE IN UGANDA, PATH SUPPORTED COUNTRYWIDE COLD CHAIN EQUIPMENT REPAIR AND MAINTENANCE WHEREBY MORE THAN 100 NONFUNCTIONAL COLD CHAIN DEVICES, SUCH AS VACCINE REFRIGERATORS, WERE REPAIRED. WE EXPANDED THE SCOPE OF THE COLD CHAIN INFORMATION SYSTEM TO INCLUDE COUNTRY-SPECIFIC REQUIREMENTS AND INVENTORY DATA FOR IMPROVED COLD CHAIN EQUIPMENT MANAGEMENT. THROUGH THE UNITAID HIV STAR III INITIATIVE, UGANDA HAS ACHIEVED SIGNIFICANT SCALE-UP IN HIV SELF-TESTING (HIVST) SERVICES. THE COUNTRY IS SET TO DISTRIBUTE 3.5 MILLION HIVST KITS ANNUALLY, MAKING IT THE LARGEST HIVST MARKET GLOBALLY. PATH DEVELOPED THE POST-MARKET SURVEILLANCE NATIONAL PLAN AND STANDARD OPERATING PROCEDURES FOR HIVST. PATH ALSO INTRODUCED TWO WHO-PREQUALIFIED BLOOD-BASED KITS INTO THE COUNTRY TO EXPAND CHOICE AND ACCESS. PATH INTEGRATED THE KITS INTO THE SUPPLY CHAIN AND OTHER SYSTEMS, LEADING TO THE GOVERNMENT'S REVIEW AND ADOPTION OF HIVST TRAINING MATERIALS FOR HEALTH CARE WORKERS AND DEVELOPMENT OF TRAINING MATERIALS FOR PEER HIVST DISTRIBUTORS. ZAMBIA IN PARTNERSHIP WITH THE ZAMBIA GOVERNMENT, PATH SUPPORTED HIGH-QUALITY, CUTTING-EDGE RESEARCH ON PRESSING HEALTH ISSUES, FROM COVID-19 TO MALARIA TO TB. FURTHERMORE, PATH IMPLEMENTED NEW DIGITAL HEALTH TOOLS AND APPROACHES ACROSS THE COUNTRY, FROM OUR PRIVATE-SECTOR PARTNERSHIP "VISUALIZE NO MALARIA" TO THE BETTER IMMUNIZATION DATA INITIATIVE. IN 2021, WE CONTINUED TO SUPPORT THE GOVERNMENT RESPONSE TO THE COVID-19 PANDEMIC. ONE NEW OPPORTUNITY WAS A BAYER-FUNDED PROJECT TO SUPPORT THE MOH ON KEY ASPECTS OF COVID-19 VACCINE ROLLOUT AND DISEASE SURVEILLANCE. ADDITIONALLY, PATH CONTINUED TO PROVIDE TECHNICAL SUPPORT TO THE MOH ON COVID-19 PROTECTIVE MEASURES. IN 2021, THE LIVING LABS PROJECT IN ZAMBIA ENGAGED FRONTLINE IMMUNIZATION HEALTH WORKERS TO IMPROVE VACCINE DELIVERY AND COVERAGE. THROUGH THIS PROJECT, THE WORKERS HELPED ADVISE ON LABELING FOR COVID-19 VACCINES AND HOW TO BEST ACCELERATE VACCINE DISTRIBUTION IN THEIR COMMUNITIES. THEIR FEEDBACK WILL IMPROVE VACCINATION COVERAGE FOR COVID-19 AND BEYOND. OUR WORK IN MALARIA IN ZAMBIA INCLUDED GROUNDBREAKING RESEARCH BY OUR LABORATORY TEAM BASED AT THE NATIONAL MALARIA ELIMINATION CENTER, EVALUATION OF NEW VECTOR-CONTROL TOOLS (SUCH AS THE ATTRACTIVE TARGETED SUGAR BAIT), AND TRAINING OF HEALTH WORKERS ON NEW MALARIA CONTROL GUIDELINES AND PROCEDURES, INCLUDING AT THE COMMUNITY LEVEL. PATH ALSO INCREASED THE NUMBER OF PEOPLE TESTED AND TREATED FOR TB IN ZAMBIA, EXPANDED TB CARE, AND CREATED STRATEGIES TO ADDRESS PEDIATRIC AND DRUG-RESISTANT TB, INCLUDING TRAINING HEALTH WORKERS ON NEW GUIDELINES AND INVESTING IN EFFECTIVE DIAGNOSTICS AT LABORATORIES ACROSS THE COUNTRY.
FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 WAS PREPARED BY AN OUTSIDE ACCOUNTING FIRM USING INFORMATION PROVIDED BY PATH ACCOUNTING SERVICES STAFF. PATH SENIOR MANAGEMENT REVIEWED THE DRAFT FORM. A COPY OF THE DRAFT WAS SENT TO THE BOARD OF DIRECTORS FOR COMMENT. AFTER THE COMMENT PERIOD, THE PRINCIPAL FINANCIAL OFFICER SIGNED THE FORM.
FORM 990, PART VI, SECTION B, LINE 12C PATH HAS POLICIES AND PROCEDURES TO ADDRESS CONFLICTS OF INTEREST. PATH MANAGEMENT AND ALL STAFF AT A DESIGNATED LEVEL OR HIGHER WITHIN THE ORGANIZATION MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. ALL FORMS ARE REVIEWED AND KEPT ON FILE. A CONFLICT MANAGEMENT PLAN IS DEVELOPED FOR ANY EMPLOYEE WITH A SIGNIFICANT ACTUAL OR PERCEIVED CONFLICT OF INTEREST. PATH ALSO HAS A WELL-DEFINED PROCEDURE FOR IDENTIFYING AND REPORTING ACTUAL AND POTENTIAL CONFLICTS OF INTEREST AMONG BOARD MEMBERS. NEW BOARD MEMBERS ARE ASKED TO COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM WITHIN 30 DAYS OF JOINING THE BOARD AND TO COMPLETE A NEW FORM ANNUALLY THEREAFTER. IN ADDITION, MEMBERS ARE REMINDED TO REPORT ANY NEW ISSUES THAT ARISE OUTSIDE OF THE ANNUAL DISCLOSURE PERIOD. THE DISCLOSURE FORMS ARE REVIEWED BY PATH'S GENERAL COUNSEL, AND IF ANY ACTUAL OR POTENTIAL CONFLICTS ARE IDENTIFIED, GENERAL COUNSEL MAKES A RECOMMENDATION TO THE CHAIR OF THE GOVERNANCE COMMITTEE AND THE CHAIR OF THE BOARD FOR A MANAGEMENT PLAN TO PROPERLY MANAGE ANY CONFLICTS. A FORMAL MANAGEMENT PLAN IS THEN AGREED UPON WITH THE BOARD MEMBER, AND THE ENTIRE BOARD OF DIRECTORS IS INFORMED AT THE NEXT REGULARLY SCHEDULED BOARD MEETING.
FORM 990, PART VI, SECTION B, LINE 15 THE BOARD'S EXECUTIVE COMPENSATION COMMITTEE ANNUALLY REVIEWS SALARIES AND BENEFITS FOR EXECUTIVE EMPLOYEE POSITIONS AND PROVIDES GUIDANCE TO THE PRESIDENT/CHIEF EXECUTIVE OFFICER (CEO) ON COMPENSATION DECISIONS FOR EXECUTIVE POSITIONS. THE COMPENSATION AND BENEFITS FOR PATH'S PRESIDENT/CEO ARE REVIEWED AND APPROVED BY THE ENTIRE BOARD OF DIRECTORS EACH YEAR. PATH ROUTINELY USES THE SERVICES OF EXTERNAL FIRMS TO ASSESS AND BENCHMARK EXECUTIVE COMPENSATION (PRESIDENT/CEO AND DIVISION CHIEFS). THE MOST RECENT MAJOR REVIEW WAS COMPLETED BY THE BOARD COMPENSATION COMMITTEE IN 2021. AT THE REQUEST OF THE BOARD, PATH ENGAGED FUTURE SENSE (A COMPENSATION, BENEFITS, AND HUMAN RESOURCES CONSULTING FIRM) TO REVIEW CURRENT AND PROPOSED BASE SALARIES OF PATH'S PRESIDENT/CEO AND DIVISION CHIEFS. FUTURE SENSE USED DATA FROM MULTIPLE SOURCES TO EVALUATE CURRENT AND PROPOSED BASE SALARIES FOR THESE POSITIONS. THE BOARD'S EXECUTIVE COMPENSATION COMMITTEE REVIEWED THE FUTURE SENSE REPORT AND APPROVED THE USE OF THE REPORT TO ESTABLISH A FRAMEWORK WITHIN WHICH THE PRESIDENT/CEO IS DELEGATED AUTHORITY TO ESTABLISH THE TOTAL COMPENSATION PACKAGES OF THE DIVISION CHIEFS. ADDITIONALLY, FUTURE SENSE REVIEWED THE PROPOSED TOTAL COMPENSATION AND BENEFITS PACKAGE FOR THE PRESIDENT/CEO POSITION AND OBTAINED A SIGNIFICANT NUMBER OF DATA POINTS TO ASCERTAIN ITS REASONABLENESS AND APPROPRIATENESS. THE BOARD APPROVED THE COMMITTEE'S RECOMMENDATION FOR THE PRESIDENT/CEO'S TOTAL COMPENSATION PACKAGE.
FORM 990, PART VI, SECTION C, LINE 19 PATH GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST; MOST DOCUMENTS ARE ALSO AVAILABLE ONLINE.
For Paperwork Reduction Act Notice, see the Instructions for Form 990 or 990-EZ.
Cat. No. 51056K
Schedule O (Form 990) 2021


Additional Data


Software ID:  
Software Version:  
SCHEDULE R
(Form 990)

Department of the Treasury
Internal Revenue Service
Related Organizations and Unrelated Partnerships
MediumBulletComplete if the organization answered "Yes" on Form 990, Part IV, line 33, 34, 35b, 36, or 37.
MediumBulletAttach to Form 990.
MediumBullet Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047
2021
Open to Public Inspection
Name of the organization
PATH
 
Employer identification number

91-1157127
Part I
Identification of Disregarded Entities. Complete if the organization answered "Yes" on Form 990, Part IV, line 33.
(a)
Name, address, and EIN (if applicable) of disregarded entity


(b)
Primary activity


(c)
Legal domicile (state
or foreign country)

(d)
Total income


(e)
End-of-year assets


(f)
Direct controlling
entity











Part II
Identification of Related Tax-Exempt Organizations. Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related tax-exempt organizations during the tax year.
(a)
Name, address, and EIN of related organization


(b)
Primary activity


(c)
Legal domicile (state
or foreign country)

(d)
Exempt Code section


(e)
Public charity status
(if section 501(c)(3))

(f)
Direct controlling
entity

(g)
Section 512(b)(13) controlled entity?
Yes No
(1)FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND
207 ROUTE DE FERNEY 1218 LE GRAND-S
GENEVA    
SZ
EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH SZ 501(C)(3)   PATH
 
Yes
 
(2)PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH -KENYA
ACS PLAZA 4TH FL LENANA RD PO BOX
NAIROBI    
KE
EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH KE 501(C)(3)   PATH
 
Yes
 










For Paperwork Reduction Act Notice, see the Instructions for Form 990.
Cat. No. 50135Y
Schedule R (Form 990) 2021
Schedule R (Form 990) 2021
Page 2
Part III
Identification of Related Organizations Taxable as a Partnership. Complete if the organization answered "Yes" on Form 990, Part IV, line 34, because it had one or more related organizations treated as a partnership during the tax year.
(a)
Name, address, and EIN of
related organization



(b)
Primary activity




(c)
Legal
domicile
(state or foreign
country)


(d)
Direct controlling
entity



(e)
Predominant income(related, unrelated, excluded from tax under sections 512-514)

(f)
Share of total income




(g)
Share of end-of-year
assets



(h)
Disproprtionate allocations?




(i)
Code V-UBI
amount in box 20 of
Schedule K-1
(Form 1065)
(j)
General or
managing
partner?



(k)
Percentage
ownership


Yes No Yes No












Part IV
Identification of Related Organizations Taxable as a Corporation or Trust. Complete if the organization answered "Yes" on Form 990, Part IV, line 34 because it had one or more related organizations treated as a corporation or trust during the tax year.
(a)
Name, address, and EIN of
related organization
(b)
Primary activity
(c)
Legal
domicile
(state or foreign
country)
(d)
Direct controlling
entity
(e)
Type of entity
(C corp, S corp,
or trust)
(f)
Share of total income
(g)
Share of end-of-year
assets
(h)
Percentage
ownership
(i)
Section 512(b)(13) controlled entity?
Yes No












Schedule R (Form 990) 2021
Schedule R (Form 990) 2021
Page 3
Part V
Transactions With Related Organizations. Complete if the organization answered "Yes" on Form 990, Part IV, line 34, 35b, or 36.
Note. Complete line 1 if any entity is listed in Parts II, III, or IV of this schedule.
Yes
No
1 During the tax year, did the orgranization engage in any of the following transactions with one or more related organizations listed in Parts II-IV?
a Receipt of (i) interest, (ii) annuities, (iii) royalties, or (iv) rent from a controlled entity .....................
1a
 
No
b Gift, grant, or capital contribution to related organization(s) ............................
1b
Yes
 
c Gift, grant, or capital contribution from related organization(s) ............................
1c
Yes
 
d Loans or loan guarantees to or for related organization(s) ............................
1d
 
No
e Loans or loan guarantees by related organization(s) ............................
1e
 
No
f Dividends from related organization(s) ............................
1f
 
No
g Sale of assets to related organization(s) ............................
1g
 
No
h Purchase of assets from related organization(s) ............................
1h
 
No
i Exchange of assets with related organization(s) ............................
1i
 
No
j Lease of facilities, equipment, or other assets to related organization(s) .......................
1j
 
No
k Lease of facilities, equipment, or other assets from related organization(s) ......................
1k
 
No
l Performance of services or membership or fundraising solicitations for related organization(s) .....................
1l
 
No
m Performance of services or membership or fundraising solicitations by related organization(s) .................
1m
 
No
n Sharing of facilities, equipment, mailing lists, or other assets with related organization(s) ...................
1n
 
No
o Sharing of paid employees with related organization(s) ............................
1o
 
No
p Reimbursement paid to related organization(s) for expenses ............................
1p
 
No
q Reimbursement paid by related organization(s) for expenses ............................
1q
 
No
r Other transfer of cash or property to related organization(s) ............................
1r
 
No
s Other transfer of cash or property from related organization(s) ............................
1s
 
No
2
If the answer to any of the above is "Yes," see the instructions for information on who must complete this line, including covered relationships and transaction thresholds.
(a)
Name of related organization
(b)
Transaction
type (a-s)
(c)
Amount involved
(d)
Method of determining amount involved
(1) PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH-KENYA

C 2,279,943 FMV
(2) FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND

B 5,789,794 FMV




Schedule R (Form 990) 2021
Schedule R (Form 990) 2021
Page 4
Part VI
Unrelated Organizations Taxable as a Partnership. Complete if the organization answered "Yes" on Form 990, Part IV, line 37.
Provide the following information for each entity taxed as a partnership through which the organization conducted more than five percent of its activities (measured by total assets or gross revenue) that was not a related organization. See instructions regarding exclusion for certain investment partnerships.
(a)
Name, address, and EIN of entity
(b)
Primary activity
(c)
Legal domicile
(state or foreign
country)
(d)
Predominant income (related, unrelated, excluded from tax under sections 512-514)

(e)
Are all partners
section
501(c)(3)
organizations?
(f)
Share of total income




(g)
Share of
end-of-year
assets
(h)
Disproprtionate allocations?
(i)
Code V-UBI
amount in box 20
of Schedule K-1
(Form 1065)
(j)
General or
managing
partner?
(k)
Percentage
ownership


Yes No Yes No Yes No






























Schedule R (Form 990) 2021
Schedule R (Form 990) 2021
Page 5
Part VII
Supplemental Information
Provide additional information for responses to questions on Schedule R. See instructions.
Return Reference Explanation
Schedule R (Form 990) 2021

Additional Data


Software ID:  
Software Version: